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Abstract 
This study investigated how gastrointestinal and skin bacterial infections were 
affected by differential expression of connexin (Cx) 26 and a disintegrin and 
metalloprotease (ADAM) 17 in vitro. 
Cx26 is a component of gap junctions, which facilitate the transfer of small 
molecules between two cells. Recessive mutations in Cx26 cause non 
syndromic hearing loss (NSHL), and in certain populations, specific mutations 
account for the majority of Cx26 related NSHL. Their common occurrence 
suggests that they may provide a heterozygous, protective advantage to 
carriers. In this study adherence by the attaching and effacing pathogen 
Enteropathogenic Escherichia coli (EPEC) was significantly reduced in cells 
expressing mutant Cx26 compared to wild type Cx26. Furthermore, EPEC 
adherence and invasion of an alternative enteric pathogen, Shigella flexneri 
were reduced following treatment with Cx26 short-interfering-RNA in intestinal 
cells. These findings suggest that the loss of functional Cx26 expression 
improves protection against enteric bacteria.  
ADAM17 releases substrates including tumour necrosis factor alpha and 
ligands of the epidermal growth factor receptor and therefore is involved in the 
induction of immune responses and maintenance of the epidermal barrier. This 
study demonstrated that ADAM17 provides protection during Staphylococcus 
aureus infection of keratinocytes. Subsequently the protective effects of 
ADAM17 mediated protection were explored. Secretion of the proinflammatory 
cytokines Interleukins 6 and 8 correlated with ADAM17 activity. Additionally 
gene expression profiling was performed which identified the IL-17 signalling 
pathway, which is known to be important during S. aureus infection, as a 
potential downstream target of ADAM17. 
In summary, based on these findings, Cx26 and ADAM17 may represent 
potential therapeutic targets for gastrointestinal and skin bacterial pathogens. 
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GJ Gap junction 
GJB Gap junction protein beta 
GJB2 Gap junction protein beta 2 (encoding Cx26) 
GJIC Gap junction intracellular communication 
gp130 Glycoprotein 130 
GPCR G Protein coupled receptor  
GrlA Global regulator of locus of enterocyte effacement activator 
GrlR Global repressor of locus of enterocyte effacement repressor 
GTP Guanosine triphosphate  
GTPase Guanosine triphosphate phosphohydrolase 
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H (his) Histidine (amino acid) 
H2O Water 
H2O2 Hydrogen peroxide 
H2SO4 Sulphuric acid 
hBD Human beta defensin 
HB-EGF Heparin-binding EGF-like growth factor 
HID Hystrix-like icthyosis deafness 
HLY Human lysozyme promoter 
HPV Human papiloma virus 
HRP Horseradish peroxidase 
I Ionomycin 
ICAM1 Intracellular adhesion molecule 1 
IDP Inner denser plaque 
IEC Intestinal epithelial cell 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
IL6-R Interleukin 6 receptor 
ins Insertion 
IP3 Inositol trisphosphate 
Ipa Invasion plasmid antigen 
Ipg Invasion plasmid gene 
iRhom Inactive rhomboid protein 
ITGB1 Integrin, beta 1 
Ix Innexin 
IκBα Inhibitor of nuclear factor kappa B alpha  
JNK Jun N-terminal protein kinase 
K Potassium 
K (Lys) Lysine (amino acid) 
kB Kilobase 
kDa Kilodalton 
KID Keratitis-icthyosis deafness 
L (Leu) Leucine 
L. monocytogenes Listeria monocytogenes 
LB Luria Bertani 
LEE Locus of enterocyte effacement 
ler Locus of enterocyte effacement encoded regulator 
LFA1 Lymphocyte function-associated antigen 1 
LOF Loss of function 
LPS Lipopolysaccharide 
M Molar 
M (Met) Methionine (amino acid) 
M cell Microfold cell 
MA Milliamp 
MAPK Mitogen activated protein kinase 
MFI Mean fluorescent intensity 
Mg Miligram 
MgCl2 Magnesium chloride 
MLC Myosin light chain 
mg Miligram 
ml Millilitre 
mM Millimolar or milimetre 
MMP Matrix metalloprotease 
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MOI Multiplicity of infection 
mRNA Messenger ribonucleic acid 
MS Multiple sclerosis 
MSCRAMM Microbial surface components recognising adhesive matrix molecules 
MV Millivolt 
Mxi Membrane excretion protein 
N (Asn) Asparginine (amino acid) 
Na Sodium 
NaN3 Sodium azide 
NF-ĸB  Nuclear factor kappa B 
Ng Nanogram 
NHE Sodium hydrogen exchanger 
NK Natural killer 
nM Nanomolar or nanometre 
NOD Nucleotide-binding oligomerisation-domain-containing 
NSHL Non syndromic hearing loss 
NT N terminal 
NTP Non-targeting pool 
O2 Oxygen 
ODP Outer denser plaque 
P Protein reference sequence 
P (Pro) Proline 
P. falciparum Plamsodium falciparium 
PAMP Pathogen associated molecular pattern 
Panx Pannexin 
PAT Putative anion transporter 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
pg Picogram 
PGN Peptidoglycan 
Pixel Picture element 
PKC Protein Kinase C 
PMA Phorbol-12-myristate-13-acetate 
PPK Palmoplantar keratoderma 
PPR Pattern recognition receptor 
PVL Panton-Valentine leukocidin 
Q (Gln) Glutamine (amino acid) 
qRT-PCR Quantitative reverse transcriptase polymerase chain reaction 
R (Arg) Arginine (amino acid) 
RE Relative expression 
RGB Red green blue 
RHBDF2 Rhomboid 5 homolog 2 (Drosophila) (encoding iRhom2) 
RNA Ribonucleic acid 
RNase Ribonuclease 
RPM Revolutions per minute 
RT-PCR Reverse transcriptase polymerase chain reaction 
S (Ser) Serine (amino acid) 
S. aureus Staphylococcal aureus 
S. boydii Shigella boydii 
S. dysenteriae Shigella dysenteriae 
S. flexneri Shigella flexneri 
S. sonnei Shigella sonnei 
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S. typhi Salmonella typhi 
sarA Staphylococcal accessory regulator 
SCIN Staphylococcal complement inhibitor 
SDS Sodium-dodecyl-sulphate  
SEM Standard error of the mean 
SGLT Sodium dependent glucose transporter 
SH Src Homology 
sIL-6R Soluble interleukin 6 receptor 
siRNA Small interfering RNA 
SNP Single nucleotide polymorphism 
Spa Surface presentation antigen (Shigella) or Staphylococcal Protein A 
(S. aureus) 
SSC-A Side scatter 
SVMP Snake venom metalloprotease 
T Thymine (nucleic acid) 
T (Thr) Threonine (amino acid) 
TACE Tumour necrosis factor alpha converting enzyme 
TBE Tris borate EDTA 
TBS Tris buffered saline 
TCR T cell receptor 
TE Tris-EDTA buffer 
TER Transepithelial resistance 
TGF Transforming growth factor 
TGM Transglutaminase 
Th T helper  
TIMP Tissue inhibitor of matrix metalloprotease 
Tir Translocated intimin receptor 
TJ Tight junction 
TLR Toll like receptor 
TM Transmembrane 
TNFR Tumour necrosis factor alpha receptor  
TNFα Tumour necrosis factor alpha 
TOC Tylosis with oesophageal cancer 
TRAPS Tumour necrosis factor receptor associated periodic syndrome 
TWL Transepithelial water loss 
U/ml Units/millilitre 
UV Ultraviolet 
V Volts 
V/v Volume/volume 
V (Val) Valine (amino acid) 
-ve Negative 
Vir Virulence protein 
VS Vohwinkel syndrome 
W (Trp) Tryptophan (amino acid) 
W/v Weight/volume 
WASP Wiskott-Aldrich-syndrome protein 
WAVE Wiskott-Aldrich-veprolin-homologous 
WT Wild type 
X Any amino acid residue 
Y (Tyr) Tyrosine (amino acid) 
Y. enterocolitica Yersinia enterocolitica 
Zn Zinc 
ZO Zona occludens 
µg Microgram 
22 
 
µl Microlitre 
µM Micromolar or micrometre 
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1.1 Effect of Connexin (Cx) 26 expression on gastrointestinal 
bacterial infection  
1.1.1 Gap junction intercellular communication (GJIC) 
In multicellular organisms, intercellular communication is mediated by gap 
junctions (GJ) and is required to maintain cellular homeostasis and to 
orchestrate responses to extracellular stimuli2. Before GJ proteins were 
identified, the structure of GJs was discovered using electron microscopy and 
X-ray diffraction. A GJ plaque consists of hundreds of tightly clustered individual 
channels which connect two cells by spanning the cell membranes and the 
space between the cells3,4 (figure 1.1.1). GJs permit the sharing of small 
molecules including ions (e.g. Ca2+), metabolites (e.g. adenosine triphosphate 
(ATP)), nutrients (e.g. glucose) and second messengers (e.g. inositol 
trisphosphate (IP3))5, whilst restricting the passage of molecules exceeding 
1kDa in size, for example nucleic acids and proteins6. By facilitating electrical 
and metabolic coupling between cells7, gap junction intercellular communication 
(GJIC) is important for processes including cell growth and development8. For 
example, GJs expressed in periventricular precursor cells in the developing 
brain play a role in Ca2+ signalling, which regulates the proliferation of neural 
cells9. 
 
 
 
 
 
 
 
 
(Image modified from http://www.landesbioscience.com/curie/chapter/852/) 
Cell 2 
Gap junction 
Cell 1 
Hemichannel 
(connexon) 
Connexin subunit 
Figure 1.1.1: Structure of a gap junction. Six Cx subunits oligomerise and form a Cx 
hemichannel. At the cell surface hemichannels from adjacent cells dock end to end. This 
forms a GJ channel, which spans the cell membranes and intracellular space thereby 
connecting two cells. Small molecules are shared between cells via GJs facilitating 
intercellular communication. 
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1.1.2 GJ proteins 
Three families of GJ proteins have been described which are connexins (Cxs), 
innexins (Ixs) and pannexins (Panxs).  In vertebrates most GJs are formed from 
Cxs, and the first Cx was cloned in 198610. To date 21 Cx genes have been 
described in humans and 20 in mice11. Cx genes have been allocated to α, β, γ, 
δ and ε subgroups based on their structure and sequence homology12. The 
genomic structure of the majority of Cx genes consists of two exons, the first of 
which is non-coding and the second which contains the entire coding region of 
the gene13.  Cx proteins are named according to their molecular mass, for 
example Cx26 is approximately 26kDa7. In invertebrates GJ form from Ixs, 
which are proteins specific to invertebrates, and which are unrelated to Cxs8,14. 
Although both groups of proteins share a similar topological structure, their 
primary amino acid sequences are only 16% homologous to each other15. 
Invertebrate GJ proteins were termed Ixs, which was a name given to describe 
a group of proteins that were invertebrate analogs of Cx proteins16.  More 
recently three PANX genes were cloned in humans, and as they were homologs 
of Ixs, Ixs were subsequently reclassified with their vertebrate homologs in the 
Panxs family14. 
1.1.3 Cx expression in human tissue 
With the exception of erythrocytes, mature sperm cells and skeletal muscle, Cxs 
are expressed by all tissue types7. Cx43 is the most widely expressed Cx and 
localises to at least 35 different cell types including astrocytes, keratinocytes 
and cardiomyocytes17. Commonly two or more Cx proteins are coexpressed by 
cells and tissues. For example keratinocytes express Cx26, Cx30, Cx30.3, 
Cx31.1 and Cx43, and  Cx26 is coexpressed with Cx32 in hepatocytes17.  
1.1.4 Cx protein structure 
Cx proteins consist of four transmembrane (TM) alpha helices, two extracellular 
loops, a cytoplasmic loop, a cytoplasmic amino (N) terminus and a cytoplasmic 
carboxyl (C) terminus9 (figure 1.1.2). The extracellular loops harbour three 
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conserved cysteine residues, which form disulphide bonds connecting the two 
extracellular loops. The cysteine residues are required for the formation of 
functional GJ channels and if they are mutated, the ability of Cxs to form  
functional GJs is compromised9.  
(Image modified from18) 
While the transmembrane domains and extracellular loops are conserved 
among different Cx proteins, the length and sequence of the cytoplasmic 
terminus and cytoplasmic loop of different Cx proteins varies. Cx50 has a long 
cytoplasmic terminus whereas Cx26 has a short cytoplasmic terminus19.  The 
variation in the sequence of the cytoplasmic terminus and the cytoplasmic loop 
of different Cx proteins confers specific properties to GJ channels formed by 
different Cx proteins, including voltage and pH dependency7,19. For example, 
Cx26 and Cx43 channels are closed at positive and negative voltages 
respectively on the cytoplasmic side of the GJ7. Decreasing the intracellular pH 
also tends to reduce junctional conductance, and Cxs exhibit different 
sensitivities to pH, for instance Cx50 is more sensitive than Cx32 to a fall in 
pH20. Sensitivity to voltage and pH changes thus likely affects GJ permeability 
to small molecules.   
Figure 1.1.2: Cx protein structure. Cx proteins consist of 4 transmembrane domains (m1-
m4), 2 extracellular loos (el1 and 2), one cytoplasmic loop (cl), a cytoplasmic amino 
terminus (NH2) and a cytoplasmic carboxyl terminus (HOOC).  
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1.1.5 GJ assembly  
1.1.5.1 Cx protein synthesis  
Cx proteins have a short half-life of a few hours meaning that they are 
continuously biosynthesised and degraded17. Consequently the level of Cx 
protein expression and GJIC can rapidly be upregulated or downregulated to 
accommodate changes in physiological conditions17.  After gene transcription, 
with the exception of Cx26 which may be inserted into the endoplasmic 
reticulum (ER) membrane both post- and co-translationally21, Cx proteins are 
co-translationally incorporated into the ER membrane17.  
1.1.5.2 Cx hemichannel formation 
Six individual Cx subunits oligomerise to form a hemichannel (connexon)2,17. 
While this occurs predominantly in the ER2,17 some Cxs including Cx43 and 
Cx46 oligomerise in the trans-Golgi network22,23. The hemichannel formed can 
be either homomeric, when the Cxs in the hemichannel are the same, or 
heteromeric, when the Cxs in the channel are different9,17.  
1.1.5.3 Cx hemichannel trafficking to the cell surface, GJ assembly and 
degradation 
After exiting the ER, most Cxs pass through the Golgi apparatus and then traffic 
to the cell surface2,17. However, the incorporation of Cx26 into functional GJs is 
relatively unaffected by disruption of the Golgi apparatus, demonstrating that 
Cx26 can traffic to the cell surface via a Golgi independent pathway24.  Upon 
exiting the Golgi apparatus, hemichannels are packaged into transport vesicles. 
These are loaded onto microtubules and undergo anterograde transport to the 
cell surface via plus ended motor proteins, for example kinesins 17,25,26.  After 
insertion into the plasma membrane, Cx hemichannels from adjacent cells dock 
end to end, which is guided by the adherens junction components N- and E-
cadherin. This forms a GJ channel which connects the cytoplasms of the two 
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cells. GJ channels can be either homotypic, composed of two identical 
hemichannels, or heterotypic, composed of two different hemichannels (figure 
1.1.3). Homotypic and heterotypic GJ channels are composed of either 
homomeric or heteromeric hemichannels. Tens to thousands of these individual 
GJ channels subsequently cluster together and form a GJ plaque9. The 
combination of Cx proteins which interact with each other is different in different 
tissue types and this affects the permeability of GJs to specific molecules9,17. 
For example, although the transfer of cAMP and cGMP is equally efficient 
through homomeric channels formed by Cx32, cGMP passes more efficiently 
through heteromeric hemichannels composed of Cx32 and Cx2627. 
 
  
 
 
 
 
 
 
 
 
(Image modified from http://herkules.oulu.fi/isbn9514259351/html/i245454.html) 
 
Hemichannel clustering at the cell surface is a continually active, dynamic 
process7,17. Pulse chased experiments using tetracysteine-tagged Cx43 
revealed that hemichannels continually traffic to the cell surface28. Newly 
formed GJ channels localise to the outer margin of the GJ, and as they mature 
they migrate into the centre of the GJ plaque28. Older GJ channels are removed 
from the plaque by endocytosis, and certainly for Cx43, this step is initiated by 
ubiquitination. Cx43 endocytosis may then result from the internalisation of 
uncoupled hemichannels, or the internalisation of whole GJs into double-
Figure 1.1.3: GJ channels. GJ channels form from the end to end docking of two Cx 
hemichannels from adjacent cells. Homotypic GJ channels are composed of two identical 
hemichannels. Each hemichannel may be homomeric (composed of the same Cx) or 
heteromeric (composed of different Cxs). Heterotypic GJ channels are composed of two 
different hemichannels. Each hemichannel of a heterotypic GJ channel may be homomeric 
or heteromeric.  GJ are composed of clusters of tens to thousands of GJ channels. 
 
Homomeric 
Homotypic 
Heteromeric 
Homotypic 
Homomeric
Heterotypic 
Heteromeric 
Heterotypic 
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membrane vesicles termed ‘annular junctions’. Following internalisation, 
degradation has subsequently been shown to occur in the lysosome or 
proteasome, or by the process of autophagy7,17,19. The life cycle of Cx proteins 
is shown in figure 1.1.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Image from Smyth, J. W. and Shaw R. M. The Gap Junction Life Cycle. Heart Rhythm. 9, 151-
153 (2012).)  
1.1.6 GJ regulation 
The cytoplasmic loop and cytoplasmic terminus of Cx proteins are sites subject 
to post-translational modifications which serve to regulate GJs. GJ opening and 
permeability are regulated by various factors including the intracellular 
concentration of Ca2+, voltage, pH and phosphorylation7. Phosphorylation of 
serine, threonine and tyrosine residues located in the cytoplasmic terminus can 
Figure 1.1.4: Life cycle of Cx proteins. Upon exiting the Golgi apparatus Cx hemichannels 
are packaged into transport vesicles. These are loaded onto microtubules for their transport 
to the cell surface via plus-ended motor proteins, e.g. kinesins. After insertion into the 
plasma membrane at the intercalated disc, Cx hemichannels from adjacent cells dock end 
to end forming a GJ channel, which is guided by adherens junction components. Unpaired 
Cx hemichannels are endocytosed and whole GJs can be internalised into double 
membrane ‘annular junction’ vesicles. Cx hemichannels and GJs may then be degraded in 
the lysosome or proteasome, or by the autophagy process.  
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alter the unitary conductance, mean open time, or voltage and pH sensitivity of 
GJ channels, thereby modifying the sharing of ions and small molecules 
between cells7. With the exception of Cx2629, all other known Cxs can be 
phosphorylated30. 
1.1.7 Cx phosphorylation 
Cx phosphorylation is thought to be important at various stages during the 
lifecycle of Cx proteins. For example, phosphorylation of the C-terminus of Cx43 
by Protein Kinase A increases its incorporation into the plasma membrane31, 
while phosphorylation by casein kinase regulates the assembly of Cx43 
hemichannels into GJ plaques32. Conversely epidermal growth factor (EGF) 
signalling induces Cx43 phosphorylation via the mitogen activated protein 
kinase (MAPK) pathway, which accelerates the internalisation and subsequent 
degradation of Cx4333. In many tumours, EGF signalling is enhanced, and the 
authors suggested that it could lead to enhanced Cx degradation, which in turn 
could account for the reduction in GJIC which occurs in some tumour types33. 
1.1.8 Unpaired Cx hemichannels  
In addition to forming GJs, Cx hemichannels also exist as isolated channels at 
the cell surface. This was first observed when individual Xenopus oocytes 
injected with Cx46 mRNA displayed conductance at low concentrations of 
extracellular Ca2+ and incorporated fluorescent dyes from the extracellular 
medium34. Treating cells with GJ blockers including heptanol and octanol 
reduced dye uptake by 50%35. Unpaired Cx hemichannels were subsequently 
discovered in astrocytes36 and ventricular myocytes37. Subsequently other Cx 
proteins including Cx26, Cx4538 and Cx5039 were shown to form functional 
unpaired Cx hemichannels40. 
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1.1.8.1 Unpaired Cx hemichannel function 
In a resting cell Cx hemichannels are closed, but certain stimuli trigger their 
opening41. These include a decrease in the concentration of extracellular Ca2+ 
to below the physiological concentration, mechanical membrane stress, 
membrane depolarisation, ischemia, metabolic inhibition, changes in pH and 
phosphorylation41.  Open hemichannels permit the exchange of molecules 
between the intracellular and extracellular environment, thereby facilitating 
paracrine signalling2. ATP was the first molecule shown to be released by Cx 
hemichannels41. More recently Cx hemichannels have been shown to release 
other molecules including glutamate by astrocytes42 and prostaglandins by 
osteoclasts43.  
In humans Ca2+ plays important roles in numerous physiological processes 
including fertilisation, programmed cell death, neurotransmitter release and 
muscle contraction44. Ca2+ signalling is facilitated by Cx hemichannels which 
propagate Ca2+ waves to neighbouring cells2. In response to changes in the 
cytoplasmic concentration of Ca2+, Cx hemichannels open leading to the 
release of ATP from the cell2. ATP binds to purinergic receptor 2Y, which is a 
G-protein-coupled-receptor (GPCR) on neighbouring cells, activating 
phospholipase C2. This leads to the formation of inositiol trisphosphate,  
triggering the  release of Ca2+ from ER stores, and the opening of new Cx 
hemichannels, which in turn transmits the Ca2+ wave to surrounding cells2.  
1.1.9 Experimental approaches used to study GJs and unpaired 
hemichannels 
Many functional assays performed in vitro have been used to study the activity 
of GJs14.  
1.1.9.1 Cx protein labelling with fluorescent tags 
Over-expression of proteins labelled with fluorescent tags, for example green 
fluorescent protein (GFP) or mCherry fluorescent protein, enables their 
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behaviour and function to be visualised in transfected cells. This technique has 
been used to investigate differences between the localisation of wild type and 
mutant Cx proteins2.  
1.1.9.2. Dye transfer assays 
Dye transfer assays (figure 1.1.5) have been used to measure whether a dye 
can pass between cells via GJs, or between the intracellular and extracellular 
environment via unpaired Cx hemichannels. Using dyes with different molecular 
sizes provides an indication of the size of molecules which can pass through 
specific hemichannels. This technique has been used to study the 
permeabilities of specific GJs and unpaired hemichannels formed from different 
Cx proteins, and to assess how the passage of small molecules is affected by 
specific Cx mutations45. 
  
 
 
 
 
 
 
 
(Image modified from46)  
1.1.9.3 Dual clamp voltage technique 
The dual clamp voltage technique (figure 1.1.6) is used to measure 
electrophysical coupling between cells. Xenopus oocytes which have been 
injected with Cx DNA or RNA are commonly used in this assay. The dual 
voltage clamp technique measures the flow of ions between cells/oocytes which 
is termed the transjunctional voltage47. Each cell/oocyte is clamped individually 
 a 
a b 
Figure 1.1.5: Dye transfer assay. Lucifer yellow dye is injected into the cells marked with 
an asterisk. Lucifer yellow binds to DNA labelling the nuclei of cells. If the injected cell forms 
GJs with neighbouring cells, dye will be transferred from the injected cell. a is an example of 
a cell which is not coupled to many other cells, whilst b shows a cell which has formed GJs 
with multiple adjacent cells.  
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and has a recording electrode and a current injecting electrode inserted into it48. 
The voltage within the second cell/oocyte is measured, while the current is 
varied in the first cell/oocyte but kept constant in the second cell/oocyte48. As 
the current is kept constant in the second cell/oocyte, any variation in the 
voltage in the second cell/oocyte results from current passing from the first 
cell/oocyte into the second cell/oocyte via GJs48. This technique can be used to 
compare the transjunctional voltage between WT and Cx mutants thereby 
determining any effect which the mutant may have on the GJ channel function. 
 
1.1.9.4 Cx hemichannel blockers 
Using chemicals to block hemichannel activity permits the study of GJs and 
unpaired hemichannels. However many of the chemicals available are not 
specific to Cx channels and also target other membrane channels41. For 
example, whilst  aliphatic alcohols such as heptanol and octanol disrupt the 
plasma membrane compressing Cx channels, they also compress other 
membrane channels41. Other chemicals, for example 18α-glycyrrhetinic acid 
may be more specific to Cx hemichannels49. It has been suggested that 18α-
glycyrrhetinic acid can bind directly to Cx proteins and induce hemichannel 
Figure 1.1.6: Dual clamp voltage technique 
Oocyte 1 Oocyte 2
Current injecting electrodge
Recording electrode
Oocyte 1: 
varied 
current
Oocyte 2: 
constant 
current
Any change in voltage in oocyte 2 results from current passing  from 
oocyte 1 (red arrows)  to oocyte 2.
34 
 
closure. Additionally it has also been shown to interfere with the incorporation of 
Cx hemichannels into GJ plaques49.  
1.1.9.5 Cx mimetic peptides 
Cx mimetic peptides are short amino acid sequences corresponding to part of 
the sequence contained by the Cx protein. For example, the mimetic peptide 
Gap 26 is identical to a sequence on extracellular loop 1, while Gap 27 is 
identical to a sequence on extracellular loop 2 of Cx4341. They have been 
designed to specifically inhibit Cx channels and have facilitated the study of GJs 
and unpaired hemichannels41. Incubating cells with Cx mimetic peptides for 10-
30 minutes inhibits unpaired hemichannels, whereas GJ inhibition requires an 
incubation of one hour minimum41. The hypotheses are that Cx mimetic 
peptides might inhibit Cx function by preventing the incorporation of Cx 
hemichannels into GJ channels, by damaging the structure of existing GJ 
channels or by becoming incorporated inside GJ channels 41.   
1.1.9.6 Mouse models 
Mouse models in which specific Cx genes are knocked out, or in which specific 
Cx mutations are expressed have been used to study the functions of WT Cx 
proteins and the mechanisms of disease associated with specific Cx mutations. 
However it is important to remember that differences exist between humans and 
mice.  For example, creating a mouse with a double knockout out of WT Cx26 
led to embryonic lethality approximately 11 days post coitum, which the authors 
suggested was due to an inability to grow properly resulting from the defective 
uptake of glucose50. However in humans the loss of both Cx26 alleles only 
causes deafness, thus suggesting that Cx proteins may have different functions 
between the two species2.  
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1.1.10 Mutations in Cx26 
Cx26 mutations cause disease in a tissue specific fashion2. Recessive 
mutations in Cx26 cause non syndromic hearing loss (NSHL) in which only 
hearing is affected. Some dominant mutations in Cx26 solely cause NSHL, 
whereas others are linked to syndromic diseases. In addition to deafness, 
patients also present with cutaneous involvement. Mutations causing NSHL 
span the entire Cx26 coding region, but those that cause syndromic disease 
tend to be concentrated within the N-terminus and extracellular loop 151. Many 
Cx26 NSHL mutations are small insertions or deletions, or nonsense mutations 
where an amino acid is substituted with a stop codon. Cx26 syndromic 
mutations result from a single missense mutation, which results in the 
substitution of a different amino acid, and production of full length, mutated 
Cx2651.  
1.1.11 Structure of the ear and deafness 
The mammalian ear is composed of the outer, middle and inner ear (figure 
1.1.7).  Sound waves are collected by the pinna and then channelled down the 
auditory canal of the outer ear onto the tympanic membrane (ear drum). The 
middle ear contains three ossicles (bones) which conduct vibrations of the 
tympanic membrane to the cochlear located within the inner ear52. The cochlear 
comprises three fluid filled tubular compartments: the scala media which 
contains endolymph and the scala tympani and scala vestibule which contain 
perilymph52-54. Endolymph is highly concentrated with K+ and has an electrical 
potential of +80 mV53,54. Vibrations of the ossicles causes endolymphatic K+ to 
enter the hair cells of the organ of Corti and leads to their depolarisation53,54. K+ 
then circulates to the perilymph before returning to the endolymph53,54. Nerve 
impulses are subsequently transmitted to the brain via the cochlear nerve for 
interpretation.  
Two types of hearing impairment exist. Conductive hearing loss occurs when 
abnormalities of the outer ear, tympanic membrane or ossicles prevent sound 
travelling to the inner ear. Sensorineural hearing loss manifests itself when the 
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inner ear or components of the brain involved in sound interpretation are 
dysfunctional.  
(Image modified from 
http://www.d.umn.edu/~jfitzake/Lectures/UndergradPharmacy/SensoryPhysiology/Audition/Coc
hleaStructure.html) 
1.1.11.1 Cx expression in the ear 
Several Cx proteins, including Cx26, Cx30, Cx31 and Cx32 have been detected 
within the epithelia and connective tissue of the rodent cochlea demonstrating a 
requirement for Cx mediated GJIC in hearing53. Mutations in various Cxs 
including Cx26, Cx30 and Cx31 cause deafness53. The expression of other 
Figure 1.1.7: Structure of the ear and movement of K+ in response to sound  
Outer ear 
Inner ear 
Middle ear 
Sound vibrations captured by 
pinna are channelled down the 
ear canal onto the ear drum. 
Vibrations of the ear drum are 
conducted by the three 
ossicles to the cochlear.  
In response to sound endolymphatic K+ 
in the scala media enters the hair cells 
of the Organ of Corti (red arrow), 
circulates to the perilymph in the scala 
vestibuli and scala tympani (blue 
arrows) and then returns to the 
endolymph in the scala media (green 
arrows). 
a 
b 
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functional Cx proteins is not sufficient to prevent the development of deafness 
resulting from mutations. This suggests that all the Cx proteins expressed in the 
ear are required for hearing, with each having specific, slightly different 
functions within the ear.  
It has been proposed that GJs present in the cochlear mediate K+ recycling to 
ensure that the high concentration of K+ required for transmitting the auditory 
signal is maintained in the endolymph2. GJs may also be important for the 
maintenance of cells within the organ of Corti.  Conditionally knocking out Cx26 
in cochlear epithelial tissue of mice results in the death of epithelial support cells 
at postnatal day 14, which subsequently extends to hair cells55, thus 
demonstrating that Cx26 mediated GJIC is required for the survival of cells 
within the cochlear. 
1.1.12 Structure of the skin 
The skin forms a protective barrier between the body and the external 
environment, which provides protection against invading pathogens and 
prevents excessive water and solute loss56. The skin also functions to regulate 
body temperature, acts as a sensory organ and as a storage organ for lipids 
and water. 
The skin is composed of three main layers, the epidermis, dermis and 
hypodermis (figure 1.1.8). The epidermis is the outermost layer of the skin and 
will be discussed in detail in section 1.1.12.1. The dermis lies below the 
epidermis. The epidermis and dermis are separated by the basement 
membrane, which primarily functions to connect the two layers. The hypodermis 
is the deepest layer of the skin and is found beneath the dermis. 
The dermis consists of connective tissue57. It has an extracellular matrix (ECM) 
composed of collagen and elastin  fibres which are synthesised by fibroblasts57. 
The structure of the ECM provides the skin with structural support, extensibility 
(ability to be stretched) and elasticity (ability to return to its original form). The 
dermis contains mechanoreceptors which are sensitive to touch and heat, hair 
follicles, sebaceous (sweat) glands, lymphatic vessels and blood vessels. The 
blood vessels function to transport nutrients to and remove waste products from 
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cells within the epidermis and the dermis. The dermis can be divided into two 
layers, with the papillary layer being more superficial to the reticular layer57. It 
contains dermal papillae which are finger-like projections which extend into the 
epidermis to provide improved strength to the connection between the 
epidermis and the dermis57. The deeper reticular layer is usually much thicker 
than the papillary layer and contains the majority of the elastin and collagen 
fibres 57.  
The hypodermis contains nerves, blood vessels and adipocytes which store 
fat58, thus meaning that the hypodermis acts as an energy reserve and an 
insulating layer. The hypodermis also functions to connect the skin to the 
underlying bone and muscle58. 
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(Images taken from http://www.webmd.com/skin-problems-and-treatments/picture-of-the-skin 
(a) and 
http://www.standardofcare.com/mwiki/index.php?title=Epidermis&redirect=no&printable=yes (b)) 
1.1.12.1 Epidermis 
The epidermis is a stratified epithelium, which means that it is two or more cells 
thick59. This is in contrast to simple epithelia, such as intestinal epithelium, 
which is only one cell thick59.  95% of the cells in the epidermis are 
keratinocytes. In addition to acting as first line defence and forming a barrier 
Figure 1.1.8: Structure of the skin and localisation of Cx proteins in the epidermis.  
Cx30, Cx30.3, Cx31, Cx43 
Cx43 
Cx26 (palmoplantar, vaginal 
and buccal epithelium) 
a 
b 
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preventing pathogens from entering the body, keratinocytes also play an 
important role in the stimulation of immune responses. They express pattern 
recognition receptors including toll-like receptors (TLRs) and nucleotide-binding 
oligomerisation domain (NOD) receptors which recognise conserved sequences 
expressed by pathogens, leading to the production of proinflammatory and 
chemotactic signals. Keratinocytes also secrete peptides including cathelicidins 
and defensins which display antimicrobial activity towards invading pathogens, 
in turn contributing towards their elimination. 
The epidermis is formed and continuously regenerated by terminally 
differentiating keratinocytes by the process of cornification (also termed terminal 
differentiation or keratinisation)60. It is composed of five layers which will be 
discussed below.  
The basal layer (Stratum basale) is the deepest layer of the epidermis (figure 
1.1.8) and the only layer to contain proliferating cells, which give rise to 
keratinocytes60. Keratinocytes are anchored to the basement membrane by 
hemidesmosomes. Basal keratinocytes express the structural components 
keratin 5 and keratin 14, which  assemble into keratin intermediate filaments60. 
Intermediate filaments, along with microtubules composed of tubulin, and 
microfilaments composed of actin form the cytoskeleton of epithelial cells60. The 
basal layer of the epidermis also contains melanocytes which produce melanin 
pigment which confers resistance to UV light, and Merkel cells which are 
involved in light touch sensation60. 
The spinous layer (Stratum spinosum) of the epidermis is above the basal layer 
(figure 1.1.8). Keratinocytes which have lost their mitotic potential migrate from 
the basal layer into the spinous layer and are connected to each other by 
desmosomes60.  Desmosomes are intracellular junctions which link cell surface 
adhesion proteins to the actin cytoskeleton, and which connect neighbouring 
cells to each other. The structure of a desmosome is shown in figure 1.1.9. 
Desmosomes contain desmoglein and desmocollin, which are transmembrane 
proteins belonging to the cadherin family of proteins61. In humans three 
desmocollins and four desmogleins have been described61. The interactions 
between the extracellular domains of desmoglein and desmocollin connect two 
keratinocytes61. The cytoplasmic side of the desmosome consists of an outer 
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denser plaque (ODP) and an inner denser plaque (IDP) spanned by the 
desmoplakin protein61. At the ODP the cytoplasmic domains of desmocollin and 
desmoglein attach to desmoplakin via plakoglobin and plakophillin, while at the 
IDP desmoplakin attaches to the keratin intermediate filaments of the 
keratinocyte61. 
(Image modified from62) 
 
In the spinous layer of the epidermis keratinocytes begin to differentiate and 
express keratin 1 and keratin 10 which replace the expression of keratin 5 and 
keratin 1460. The spinous layer also contains Langerhan cells, which are a 
component of the immune system that function as antigen presenting cells60. 
They continuously monitor the environment for danger signals, and when 
activated they migrate to the regional lymph nodes and present antigen to T 
cells, which in turn stimulates the adaptive immune response63. 
The granular layer (Stratum granulosum) of the epidermis is above the spinous 
layer (figure 1.1.8). Keratinocytes migrate from the spinous layer upwards to the 
granular layer60. Within the granular  layer  the cornified envelope (CE) protein 
fillagrin is produced following cleavage of its precursor pro-fillagrin60. Fillagrin 
Figure 1.1.9: Structure of a desmosome. Keratinocytes are connected by interactions 
between desmoglein (Dsg) and desmocollin (Dsc). At the cytoplasmic face the outer denser 
plaque (ODP) and the inner denser plaque (IDP) are spanned by desmoplakin (DP). At the 
ODP DP attaches to Dsg and Dsc via plakoglobin (PG) and plakophillin (PP). At the IDP DP 
attaches to keratin intermediate filaments (IF) of the cell cytoskeleton.  
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forms aggregates with tightly packed keratin filaments and leads to their 
flattening60.   
The transitional layer (Stratum lucidium) is located above the granular layer 
(figure 1.1.8). This layer is normally absent from thin epithelium, and is usually 
only present in thick epithelium, including the palms and soles. 
The CE (Stratum corneum) is the outer layer of the epidermis (figure 1.1.8) and 
is the product of the cornification process which produces dead corneocytes 
from terminally differentiated keratinocytes60. When keratinocytes are 
permeabilised by Ca2+, trans-glutaminases are activated which mediate the 
cross linking of CE proteins including loricrin, involucrin and small proline-rich 
proteins. CE proteins are synthesised and deposited under the plasma 
membrane in the granular layer60. As keratinocytes migrate upwards from the 
granular layer, lipids are released from their lamellar bodies, which are cross 
linked onto the preassembled CE proteins by transglutaminases60. Also during 
the cornification process, organelles within the keratinocytes including the 
nucleus are destroyed60. The cornified layer is continuously renewed by cells 
migrating up through the inner layers and subsequently being sloughed off the 
top of the epidermis by desquamation60. 
1.1.12.2 Cx expression in the skin 
In human and rodent epithelia, GJs exist in the basal, spinous and granular 
layers, but not the cornified layers2 (figure 1.1.8). Cx expression within the 
epidermis undergoes spatial and temporal regulation19 which leads to a distinct 
expression pattern of specific Cx proteins at different layers within the 
epidermis2. For example, whereas Cx43 expression is present throughout the 
suprabasal epidermal layers of interfollicular skin19, albeit with highest 
expression being detected in the granular layer64,65; Cx30.3 and Cx31 
expression appears to be restricted specifically to the granular layer66. It has 
thus been suggested that Cx proteins are differentially expressed because they 
might be required for specific stages of keratinocyte differentiation2.  Cx26 is 
only detected in the sweat glands and hair follicles of the normal interfollicular 
epidermis66, but is expressed by normal vaginal and buccal epithelium67. Cx26 
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expression has also been found in the basal and granular layers of 
palmoplantar epithelium67, and within damaged and diseased epithelium66. 
Thus Cx26 may have a role during keratinocyte differentiation in normal vaginal 
and buccal epithelium, within hyperproliferative epithelium and during wound 
healing.  
1.1.12.3 Cx26 expression and wound healing 
Various studies have suggested a requirement for Cx26 expression during 
wound healing. A hypothesis is that Cx26 may facilitate keratinocyte 
proliferation, differentiation and migration into the wound site2,68. The exact 
localisation of Cx26 expression within the epidermis has shown some variation 
depending on the species used in the wound healing studies68. For example, 
Cx26 is upregulated behind the leading edge of the wound in both rats69 and 
mice70,  but increased Cx26 expression in the leading edge of the wound only 
occurs in mice70,69. Moreover tape stripping of human skin also results in the 
upregulation of Cx26 expression throughout the epidermis67. Interestingly 
deregulated Cx26 expression has been shown to be detrimental for wound 
healing resolution68. For example, in mice persistent expression of Cx26 in the 
epidermis results in hyperproliferation of keratinocytes and prevents wound 
remodelling71. Furthermore in humans, psoriasis is associated with keratinocyte 
hyperproliferation, and upregulated Cx26 expression has been observed in 
psoriatic lesions compared to normal skin72. Taken together these findings 
suggest that the early stages of wound healing require Cx26, but the process 
may be compromised by abnormal expression of Cx26 during the later stages68.  
1.1.13 Mechanism of Cx26 mutations in human disease 
Although the mechanisms by which Cx26 mutations cause disease are poorly 
understood, analysis of different Cx26 mutants in vitro has identified four 
possible ways Cx26 mutations might affect the function of GJs.   
Some Cx26 mutations, particularly many of those associated with NSHL are 
loss of function (LOF) mutations which prevent the formation of functional GJs 
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at the cell surface. Consequently these mutations may lead to a disruption in K+ 
recycling2, and the death of cells within the cochlear which could lead to 
deafness. Mutants may not traffic correctly to the cell surface, or if they 
successfully reach the cell surface, may not be incorporated into the appropriate  
homotypic/heterotypic GJ required for normal function in healthy tissue2. Many 
Cx26 NSHL mutations including the most frequent recessive c.35delG mutation, 
lead to a premature termination of protein translation73. The c.35delG mutation 
leads to the deletion of a guanine at position 35, resulting in the introduction of a 
stop codon after residue 1374. The early termination of protein translation 
truncates the Cx26 protein, and when HeLa cells are transfected with the 
c.35delG mutant in vitro, GJ do not form75.   
Some mutations mistraffic and may accumulate in the cytoplasm or organelles2. 
For example, immunofluorescence revealed that the p.R143W NSHL mutation 
accumulates in the cytoplasm of transfected HeLa cells rather than trafficking to 
the GJ45. Accumulation of Cx26 mutations has also been observed in the Golgi 
apparatus, for example in the trans-Golgi network by the p.D66H mutant76. 
Other mutations may act in a dominant negative fashion affecting the function of 
WT Cx262. For example, coexpression of the p.R75W mutation with WT Cx26 
in Xenopus oocytes, suppresses the electrical activity of WT Cx2677. 
Furthermore such mutations may affect the function of a different Cx protein 
expressed within the cell. For example, expression of certain Cx26 mutations 
which cause skin disease in Xenopus oocytes, suppresses the activity of 
coexpressed WT Cx4378. Moreover, the Cx26-D66H mouse which mimics 
Vohwinkel syndrome (VS), in which p.D66H is expressed in the suprabasal 
epidermal layers, exhibits defective transport of WT Cx26 and Cx30 to the cell 
surface79. When mutant Cx proteins act in a dominant negative fashion, the type 
of hemichannel which can form GJs may be altered. This potentially alters the 
specific properties of the GJ including its permeability, which could influence 
GJIC between cells and possibly contribute to the development of disease19. 
Many of the dominant Cx26 mutations associated with palmoplantar 
keratoderma (PPK) with deafness, Bart-Pumphrey syndrome (BPS) and VS are 
thought to act in a dominant negative fashion51. 
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Other mutations, particularly those associated with Keratitis–ichthyosis 
deafness (KID) syndrome and Hystrix-like ichthyosis deafness (HID) syndrome 
may traffic to the cell surface but induce aberrant hemichannel activity51,19. For 
example, expression of the p.A40V mutation in Xenopus oocytes results in the 
production of membrane currents which are absent in oocytes expressing WT 
Cx2680. Such activity of unpaired hemichannels could result in the deregulated 
release of molecules into the extracellular environment, which could induce cell 
death and alter the behaviour of neighbouring cells2,19.   
1.1.14 Mutations in Cx26 linked to NSHL 
Approximately one in one thousand individuals is affected with deafness at birth 
or in early childhood81. Hereditary NSHL is classified as autosomal dominant, 
(DFNA – Deafness, Autosomal Dominant), autosomal recessive (DFNB – 
Deafness, Neurosensory Autosomal Recessive) or X-linked (DFNX – Deafness, 
X Linked) and more than 100 genetic loci have been linked to deafness81. 80% 
of hereditary NSHL cases arise from recessive mutations82 and between 30-
60% of these cases are attributed to mutations in Cx2683. Dominant mutations 
in Cx26 have also been linked to NSHL73.  
1.1.14.1 Recessive mutations in Cx26 linked to NSHL 
DFNB NSHL was first linked to a locus on chromosome 13q11, which was 
termed DFNB1 by homozygosity mapping in two consanguineous Tunisian 
families84. Subsequently a locus identified in a French family affected by 
dominant deafness, which was termed DFNA3, was linked to the same region 
of the chromosome, 13q1285. The GJB2 gene localises to this area of the 
chromosome, which led to the hypothesis that mutations in Cx26 were 
responsible for both deafness forms81. Screening the GJB2 gene in three 
consanguineous Pakistani families affected by recessive deafness identified the 
two nonsense mutations p.W24X and p.W77X86. In a separate study the size of 
the DNB1 locus was reduced and found to include the GJB2 gene, and 
subsequently, screening GJB2 identified the most frequent recessive c.35delG 
mutation74.  This mutation leads to the deletion of a guanine at position 35, 
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which results in the introduction of a stop codon after residue 1374. The early 
termination of protein translation truncates the Cx26 protein, and not 
surprisingly, when HeLa cells are transfected with the c.35delG mutant in vitro, 
GJs do not form75. The p.W24X, p.W77X and c.35delG mutations were some of 
the first recessive Cx26 mutations linked to NSHL. 
GJB2 was also screened in a family with palmoplantar keratoderma (PPK) and 
deafness86. Although none of the mutations showed linkage to PPK, the p.M34T 
mutation was identified in individuals with deafness and originally reported as a 
dominant mutation86. However, further analysis of the family showed that 
deafness only manifest in individuals when a dominant Cx26 mutant, p.D66H 
was also present87. Other studies reported that the p.M34T mutation was 
present in individuals with normal hearing, and consequently p.M34T was 
reclassified as a recessive Cx26 NSHL mutation88.  
To date, more than ninety recessive Cx26 NSHL mutations have been identified 
and the full list can be found on the Connexin-deafness homepage 
(http://davinci.crg.es/deafness). The Cx26 NSHL mutations most relevant to the 
background and experiments for this work are detailed in table 1.1.1 and their 
location within the Cx26 protein in shown in figure 1.1.9 a. 
Table 1.1.1: Recessive mutations in Cx26 associated with NSHL 
TM= transmembrane domain, EL=extracellular loop, NT=N terminal, fx=framshift 
 
Nucleotide 
change 
Amino acid Protein 
domain 
Ref 
c.71G>A p.W24X TM1 86 
c.231G>A p.W77X TM2 86 
c.101T>C p.M34T TM1 88 
c.35delG p.G12fx NT 74 
c.427C>T p.R143W TM3 89 
c.235delC p.L78fx TM2 90 
c.167delT p.L81fx EL2 74 
1.1.14.2 Dominant mutations in Cx26 linked to NSHL 
The first mutation in Cx26 linked to the DFNA3 locus (dominant NSHL) was 
p.W44C91. Although the p.R75W mutation was linked to PPK and deafness in 
an Egyptian family,  it was also identified in a control subject with no skin 
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disease77. This suggested that the p.R75W mutation could solely cause 
dominant NSHL hearing loss, without necessarily causing syndromic disease. 
The dominant mutations in Cx26 associated with NSHL discovered  to date82 
are listed in table 1.1.2 and their location within the Cx26 protein in shown in 
figure 1.1.9 b.  
 
Table 1.1.2: Dominant mutations in Cx26 associated with NSHL 
EL=extracellular loop, TM= transmembrane domain 
 
Nucleotide 
change 
Amino acid Protein 
domain 
Ref 
c.131G>C p.W44S EL1 82 
c.132G>C p.W44C EL1 91 
c.223C>T p.R75W EL1 77 
c.428G>A p.R143Q TM3 92 
c.487A>C p.M163L EL2 93 
c.534G>A p.D179W EL2 94 
c.551G>A p.R184Q EL2 95 
c.605G>T p.C202F TM4 96 
c.125delAGG p.del42E EL1 78 
1.1.15 Syndromic diseases associated with Cx26 mutations 
Syndromic diseases are caused by dominant Cx26 mutations. In addition to 
deafness such mutations also cause ectodermal dysfunction and skin 
disorders51. Diseases include Vohwinkel syndrome (VS), Bart-Pumphrey 
syndrome (BPS), Palmoplantar keratoderma (PPK) with deafness, Keratitis–
ichthyosis deafness (KID) syndrome and Hystrix-like ichthyosis deafness (HID) 
syndrome.  The symptoms of these diseases are described in table 1.1.3, the 
Cx26 mutations listed in table 1.1.4 and the location of the mutations within the 
Cx26 protein are shown in figure 1.1.9 c.  
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Table 1.1.3: Symptoms of syndromic diseases caused by dominant mutations in Cx26 
 
Disease Symptoms 
VS 51 • Sensorineural deafness 
• Palmoplantar hyperkeratosis (thickening of the stratum corneum of the 
palms and soles) 
• Pseudoainhum (constrictions of the circumference of the fingers and 
toes) 
• Pseudoainhum can lead to autoamputation (spontaneous detachment) 
of the fingers and toes 
BPS 51 • Palmoplantar hyperkeratosis 
• Sensorineural deafness  
• Hyperkeratosis of the metacarpophalangeal and interphalangeal joints 
of the hand, termed as knuckle pads 
• Leukonychia (whitening, thickening and crumbling of the nails)  
PPK with 
deafness 
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• Palmoplantar hyperkeratosis 
• Sensorineural hearing loss, a form less severe than results from other 
syndromic Cx26 mutations  
KID 
syndrome 
51
 
• Mild to severe sensorineural hearing loss 
• Loss of eyebrows and eyelashes 
• Mild to severe keratitis (inflammation of the cornea)  
• Keratitis may eventually lead to blindness 
• Skin lesions may be present all over the body of patients and are 
usually accompanied by ichthyosis (scaling of the skin) 
• Skin lesions and ichthyosis lead to an increased susceptibility to 
bacterial, viral and fungal infections. 
• Increased probability of developing carcinomas 
HID like 
syndrome 
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• Excluding keratosis, HID syndrome presents with similar symptoms to 
KID syndrome 
• Skin of HID syndrome patients is characterised by the presence of 
spiky hyperkeratotic masses with a cobblestone-like appearance all 
over the body 
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Table 1.1.4: Dominant mutations in Cx26 associated with syndromic diseases  
 
VS=Vohwinkel syndrome, BPS=Bart Pumphrey syndrome, PPK=palmoplantar 
keratoderma, KID=keratitis-ichthyosis-deafness syndrome, HID=hystrix-like-ichthyosis-
deafness syndrome EL=extracellular loop, CL=cytoplasmic loop, CT=C terminus, NT= N 
terminus 
 
Disease Nucleotide change Amino acid Protein 
domain 
 
Ref 
VS c.175G>A p.G59S EL1 97 
c.196G>C p. D66H C EL1 98 
c.389G>T p.G130V CL 99 
BPS c.162C>A p.N54K EL1 100 
c.175G>A p.G59S EL1 101 
 
PPK with 
deafness 
c.160A>C p.N54H EL1 102 
c.176C>G p.G59A EL1 103 
c.175G>C p.G59R EL1 104 
c.219A>G p.H73R EL1 105 
c.224G>A p.R75Q EL1 106 
c.389G>T p.G130V CL 107 
c.458C>T p.S183F EL2 108 
c.223C>T p.R75W EL1 77 
c.125delAGG p.del42E EL1 78 
KID syndrome c.34G>C p.G12R CT 109 
c.40A>C p.N14Y NT 110 
c.50C>T p.S17F CT 109 
c.119C>T p.A40V EL1 80 
c.134G>A p.G45E EL1 111 
c.148G>A p.D50N EL1 109 
c.148G>T p.D50Y EL1 112 
HID like  
syndrome 
c.148G>T p.D50Y EL1 113 
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Figure 1.1.9: Location of 
mutations in Cx26 
protein. Recessive (a) 
and dominant (b) 
mutations associated with 
NSHL. Dominant 
mutations associated with 
syndromic disease (c). 
el=extracellular loop, 
m=transmembrane 
domain, cl=cytoplasmic 
loop, COOH=C terminus, 
NH2=N terminus, 
fx=framsehift 
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The same mutation within Cx26 can give rise to different diseases. For example 
the p.G59S mutation is associated with VS97 and BPS101, while the p.D50Y 
mutation is linked to KID112 and HID-like113 syndromes. This demonstrates that 
some of the symptoms associated with specific disease differ, but there is  also 
overlap in the clinical presentation of the diseases51. The emerging view is that 
there are two broad groups of diseases associated with syndromic Cx26 
mutations, the VS-BPS-PPK group and the KID-HID group51.  
1.1.16 Potential heterozygote advantage linked to recessive NSHL Cx26 
mutations 
With a few exceptions most of the recessive Cx26 NSHL mutations described 
are only found in a few individuals82. However specific Cx26 NSHL mutations 
are more prevalent in certain geographic locations or ethnic groups. For 
example, the c.35delG mutation is responsible for 20% of childhood hereditary 
hearing loss in European descendants114 with carrier frequencies ranging from 
1/35 in southern Europe to 1/79 in central and northern Europe115. The 
c.235delC mutation has a carrier frequency of 2% in Japanese populations, and 
of 70 mutant GJB2 alleles screened in deaf Japanese individuals, 10 were 
c.235delC116. In Ghana the p.R143W mutation is the most prevalent recessive 
Cx26 NSHL mutation, and of 121 mutant GJB2 alleles screened in unrelated 
deaf individuals, 110 were p.R143W95. Additionally the p.167delT mutation has 
been reported to have a carrier frequency of 4% in Ashkenazi Jews117.  
It has been hypothesised that high carrier frequencies of specific Cx26 NSHL 
mutations exist because they confer a heterozygote advantage to carriers45,118-
120
. Heterozygous advantage exists when a heterozygous individual who carries 
one wild type copy and one mutated copy of a gene, has an advantage over a 
homozygous individual who carries two wild type copies of a gene. For 
example, sickle cell anaemia is a recessively inherited condition where red 
blood cells develop abnormally. In Africa the occurrence of individuals who are 
heterozygous for the sickle gene (AS) is relatively common, and it has been 
shown that these individuals are better protected from death with Plasmodium 
falciparum malaria121. The red bloods cells of healthy individuals are disc-
shaped and flow easily in the bloodstream, whereas those of sickle cell patients 
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are crescent shaped and block the flow of blood. When sickle cell anaemia 
patients are exposed to low O2 conditions, their red blood cells undergo sickling 
and removal by phagocytosis. AS heterozygotes produce normal and abnormal 
haemoglobin which means that some of their red blood cells will also undergo 
sickling. Invasion of red blood cells by P. falciparum causes decreases in the 
intracellular pH and O2 concentration121. This causes the red blood cells to 
sickle, which in turn leads to their phagocytosis and removal from the blood 
stream121. This occurs preferentially in AS heterozygotes compared to healthy 
individuals, meaning they have a reduced number of parasites circulating within 
the bloodstream121.   
Another example of heterozygous advantage is where cystic fibrosis patients 
who carry a mutated copy of the cystic fibrosis transmembrane conductance 
regulator gene (CFTR) have improved protection against infection with Vibrio 
cholerae, the causative agent of cholera122. The cholera toxin induces cAMP 
mediated Cl- secretion via CFTR channels from enterocytes into the intestinal 
lumen, which in turn acts to drive Na+ and water movement out of the cell122. 
Individuals heterozygous for the CFTR gene have reduced diarrhoea production 
compared to healthy individuals. CFTR heterozygotes also have improved 
protection against Salmonella typhi, the causative agent of typhoid123. S. typhi 
utilises the CFTR protein to translocate into intestinal epithelial cells, meaning 
that bacterial uptake is significantly reduced into cells expressing CFTR mutants 
compared to WT CFTR123.  
The examples described above represent instances of when having one wild 
type and one mutated copy of a gene may be more beneficial than two wild type 
copies. Carrying the mutation confers a protective advantage by reducing 
susceptibility to infection. If carrying a Cx26 NSHL mutation conferred a 
heterozygote advantage, it could account for the high carrier frequencies of 
specific Cx26 NSHL mutations within certain geographic locations or ethnic 
groups45,118-120.  
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1.1.16.1 Recessive NSHL Cx26 mutations linked to epidermal thickness  
Interestingly, although Cx26 NSHL mutations do not cause skin disease, 
expression of the p.143W and c.35delG mutations is linked to a thicker 
epidermis (figure 1.1.10). Measurements of the epidermal thickness of skin 
sections taken from biopsies of heterozygote carriers of the p.R143W allele and 
p.R143W Cx26 homozygotes, revealed that the epidermis was significantly 
thicker compared to WT Cx26 homozygotes120. When the epidermal thickness 
of carriers of the c.35delG allele was measured by sonography and compared 
to WT Cx26 homozygotes it was found to be twice as thick118.  The epidermis of 
organotypic cultures grown with keratinocytes was also significantly thicker 
when the pR143W mutation was expressed4.  Organotypic models of the skin 
provide a three-dimensional model in which the skin can be studied in vitro. 
They mimic more accurately what happens during keratinocyte growth and 
differentiation in vivo than cell monolayers. The technique involves growing 
keratinocytes on de-epidermalised dermis (DED) until they form an epidermis. 
The thicker epidermis associated with p.143W expression did not result from 
increased cell proliferation, since there was no difference in expression of the 
proliferation marker Ki67 in organotypic cultures expressing p.R143W or WT 
Cx2645. Staining for the epidermal differentiation marker Keratin 14 was 
restricted to the basal layer of organotypic cultures expressing WT Cx26, but 
was detected in both the basal and suprabasal epidermal layers in organotypic 
cultures expressing p.R143W45. The authors suggested this was indicative of 
keratinocytes undergoing an extended terminal differentiation program which in 
turn may produce a thicker epidermis45. The thicker epidermis that is associated 
with heterozygote carriers of the p.R143W allele could also result from 
increased cell viability as keratinocytes transfected with p.R143W exhibited 
significantly reduced cell death compared to keratinocytes expressing WT 
Cx26119. It has been suggested that a thicker epidermis could be beneficial to 
carriers, if it acts as a more robust barrier, which in turn provides improved 
barrier against infection and trauma118,120. 
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(Images obtained from118,120) 
1.1.17 Cx protein expression linked to gastrointestinal bacterial infection  
Recent evidence has indicated a role for intercellular communication mediated 
by Cx26 during Shigella flexneri infection, the causative agent of bacillary 
dysentery. Cx43 has also been implicated in mice during infection with the 
attaching and effacing pathogen Citrobacter rodentium.  C. rodentium is the in 
vivo model used to study human Enteropathogenic Escherichia coli (EPEC) and 
Enterohemorrhagic Escherichia coli (EHEC) infection. Shigella and EPEC will 
be discussed in detail in sections 1.1.18-22.  
1.1.18 Shigella 
The gastrointestinal pathogens Shigella and EPEC are gram negative bacteria 
belonging to the family Enterobacteriaceae. Shigella is the causative agent of 
bacillary dysentery or shigellosis. Shigellosis presents with symptoms ranging 
from watery diarrhoea to dysentery. Dysentery is diarrhoea which contains 
a 
Figure 1.1.10: Epidermal thickness of p.R143W and c.35delG heterozygotes. 
Measurements of biopsies taken from WT Cx26 homozygotes, heterozygous carriers of the 
p.R143W allele and p.R143W Cx26 homozygotes (a) and epidermal thickness of WT Cx26 
homozygotes and heterozygous carriers of the c.35delG allele (b). Heterozygous carriers of 
p.R143W and c.35delG have a si\gnificantly thicker epidermis than WT Cx26 homozygotes. 
 
b  Epidermal thickness (mm) 
 
 
wt/wt wt/c.35delG 
Females 0.38 0.81 
Males 0.42 0.93 
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blood and mucus within the faeces, and is accompanied by fever and 
abdominal cramps124. Complications may arise from shigellosis which can lead 
to death, particularly in toddlers and young children124. These include 
hypoglycaemia (when the concentration of blood glucose has fallen below 70 
mg/dlL125),  bacteraemia (viable bacteria are present within the circulating 
blood) and septicaemia  (an infection caused by bacteraemia). Severe 
dehydration results from fever and diarrhoea and can lead to problems124 
including hypovolemia (a decreased volume of circulating blood), haemolytic 
uraemic syndrome (haemolytic anaemia (anaemia resulting from the destruction 
of red blood cells) and uraemia (accumulation of urea in the blood))  and toxic 
megacolon (dilation of the colon leading to its obstruction126).  
Four species of Shigella have been identified which are S. flexneri, S. sonnei, S. 
dysenteriae and S. boydii. With the exception of S. sonnei, the other three 
serogroups are further subcategorised into specific serotypes. This 
classification is based on the carbohydrate composition of the O-antigenic 
polysaccharide chain of the Lipopolysaccharide (LPS) surface antigen124.  
Shigella is a highly invasive bacterium, and as few as ten to one hundred 
bacteria are sufficient to establish disease in humans127. Shigellosis therefore 
represents an important issue for public health. Although Shigellosis occurs 
worldwide, it is significantly more prevalent in developing countries. Of an 
estimated 164.7 million annual cases of Shigellosis, only 1.5 million cases were 
observed in developed countries, while 163.2 million cases, with 1.1 million 
deaths, were identified in developing countries128. Shigellosis in developing 
countries tends to be associated with infection with S. flexneri and S. 
dysenteriae, while S. sonnei is responsible for many cases in developed 
countries. Whereas shigellosis endemics tend to be caused by S. flexneri and 
S. sonnei, shigellosis epidemics and pandemics are usually associated with S. 
dysenteriae type I124. Shigellosis is associated with poor hygiene and can be 
transmitted directly by the faecal-oral route, where bacteria in the faeces of an 
infected individual are ingested by a non-infected individual, or indirectly 
through the ingestion of contaminated food or water124.  Shigellosis thus affects 
individuals who exhibit poor levels of hygiene, and therefore is most 
predominant in young children. 69% of shigellosis cases and 61% of deaths 
associated with shigellosis occur in children under the age of five years old128.  
56 
 
1.1.19 Enteropathogenic Escherichia coli (EPEC) 
Escherichica coli (E. coli) is the most abundant non-pathogenic organism of the 
mammalian colon microflora129 and represents the most common cause of 
diarrhoea worldwide130. Certain strains of E. coli have acquired virulence factors 
making them pathogenic129,131 such as Enteropathogenic  E .coli (EPEC) and 
Enterohemorrhagic E. coli (EHEC), which are human pathogens belonging to 
the attaching and effacing lesion forming family of bacteria.  EHEC produces 
Shiga toxins which enable the bacteria to cause haemorrhagic colitis which can 
progress to haemolytic uraemic syndrome132. EPEC induces watery diarrhoea, 
which may be accompanied by low grade fever, nausea and vomiting, and is 
also a major cause of acute gastroenteritis (inflammation of the gastrointestinal 
tract). EPEC can be divided into typical and atypical strains, which will be 
discussed in section 1.1.22.1. Typical EPEC is a leading cause of diarrheal 
disease and dehydration associated deaths in infants aged between six months 
and two years of ages in developing countries, where it is associated with a 
mortality rate of 10-40%131,133. Atypical EPEC is more common than typical 
EPEC in developed countries, and causes disease in a broader age group134. 
EPEC can be transmitted by the faecal-oral route or through contact with an 
infected individual.  
Shigella and EPEC infections are treated with oral rehydration in combination 
with antibiotics. Although antibiotic courses have proved useful for the treatment 
of many cases of diarrhoea, one of the major problems is the emergence of 
multiple antibiotic resistance124,130. Current therapies are not sufficient to 
eradicate the problems associated with gastrointestinal pathogens, and as 
diarrhoea represents a leading cause of death in developing countries, there is 
an urgent need to find new treatments for gastrointestinal bacterial infection. 
1.1.20 Type III secretion system 
The ability of Shigella and EPEC to establish an infection is mediated by a type 
III secretion system, which is inserted into the host cell plasma membrane135. It 
is used to deliver bacterial proteins, which are termed effectors, from the 
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cytoplasm of the bacteria into the host cell cytoplasm, where they can 
manipulate host cell functions and contribute to the establishment of disease135. 
1.1.20.1 Shigella secretion apparatus 
The genes encoding components of the Shigella secretion apparatus localise to 
a 31 kb region, termed the entry region, of a 213 kb virulence plasmid124,136. The 
entry plasmid contains the genes which encode the structural components of 
the secretion apparatus, mxi (membrane excretion proteins) and spa (surface 
presentation antigens) genes; genes which encode proteins secreted by the 
apparatus including ipa (invasion plasmid antigens) A, B, C and D, ipg (invasion 
plasmid gene) B1 and IcsB; chaperones including ipgA, IpgC, IpgE and Spa 15; 
and transcriptional activators Vir (virulence protein) B and MxiE124,136. 
Chaperone proteins bind to specific effectors in the bacterial cytoplasm before 
they are secreted124. For example, the chaperone protein encoded by IpgE 
binds to IpgD136. When IpgE is mutated, the amount of IpgD protein found in 
whole IpgE mutant cell extracts is significantly decreased, demonstrating that 
IpgE is required for the production and stability of IpgD137. Additional virulence 
factors are also encoded by genes outside the entry region of the virulence 
plasmid124. 
In order for secreted proteins to pass from the cytoplasm of the bacteria into the 
host cell cytoplasm, they must pass through three membranes, the outer and 
inner membranes of the bacteria and the host cell membrane (figure 1.1.11).  
The base of the secretion apparatus is anchored in the cytoplasm of the 
bacteria135.  It consists of protein ring structures spanning the inner (MxiG) and 
outer (MxiD) bacterial membranes, which are connected to each other by 
MxiJ138. A 60 nm needle formed from MxiH138 is attached to the base of the 
secretion apparatus, and projects from the surface of the bacterial cell into the 
extracellular milieu139.  Prior to contact with the host cell, IpaB and IpaD are 
assembled in a complex at the tip of the needle, where they have been 
proposed to have roles in recognising host cell components140. Upon contact of 
IpaB with the host cell membrane, IpaB is inserted into the membrane and 
undergoes a conformational change140. This signal is transduced through IpaD, 
which results in the activation of the secretion apparatus140. This leads to the 
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secretion of IpaC, which now localises to the tip of the needle complex, and also 
inserts into the host cell membrane140. The complex formed by IpaB and IpaC is 
a translocation pore, through which secreted proteins which have been 
transported down the needle complex can be delivered into the host cell 
membrane141. In order for effectors to be secreted, the secretion apparatus 
must be energised, which is achieved through the hydrolysis of ATP molecules 
into ADP molecules by the cytoplasmic ATPase Spa47135.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Image modified from142) 
Figure 1.1.11: Structure of type III secretion system of Shigella.  The base of the 
secretion system apparatus consists of MxiM and MxiG protein rings spanning the outer and 
inner membranes connected to each other by MxiJ.  A needle composed of MxiH is 
connected to the base of the secretion apparatus and projects into the extracellular milieu. 
Effector proteins are delivered into the host cell through the translocator, which is composed 
of IpaB and IpaC. The cytoplasmic ATPase Spa47 energises the secretion apparatus.  
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1.1.20.2 EPEC secretion apparatus 
The genes encoding the EPEC secretion apparatus localise to the 
chromosomal locus of enterocyte effacement (LEE)143,144. The base of the 
secretion apparatus consists of E. coli secretion (Esc) C rings spanning the 
outer bacterial membrane, connected to rings composed of EscR, EscS EscT, 
EscU and EscV spanning the inner bacterial membrane, by means of EscJ 
(figure 1.1.12). The needle complex, which is composed of EscF, forms a 
projection channel, and is directly connected to the E. coli secreted protein 
(Esp) A filamentous extension.  The filamentous extension is unique to the 
secretion apparatus found in EPEC138. EspA is also connected to the EspB/D 
translocator complex138. The LEE also contains the E. coli attaching and 
effacing (eae) gene, which encodes the bacterial outer membrane protein 
Intimin; and secreted effector proteins including the translocated intimin 
receptor (Tir), Map, EspB, EspF, EspG, EspH and EspZ 138,145. Similarly to 
Shigella, EPEC encodes chaperone proteins which ensure efficient secretion of 
secreted proteins138. For example, Chaperone of E. coli secretion (Ces) F 
chaperones EspF146 and CesAB chaperones EspA and EspB147. Up to 20 or 30 
other effectors also exist which are encoded by genes outside of the LEE. 
1.1.20.3 Secretion system gene expression regulation 
The expression of secretion system genes is tightly regulated to ensure that 
proteins are expressed in sufficient quantities at the appropriate time point 
during infection. It also means that gene expression can be adjusted by the 
bacteria to accommodate changes within their environment. Gene expression is 
regulated by temperature in Shigella where the mxi, spa and ipa genes are 
transcribed at 37°C, but not at 30°C148.  Their transcription is also regulated by 
the transcriptional activators VirB and VirF148. So if Shigella is growing in culture 
at 37°C, transcription of genes which are under the control of VirB and VirF 
occurs. Contact with epithelial cells leads to increased activation of the 
secretion apparatus148. This leads to increased transcription of genes encoding 
effector proteins. The transcription of these genes is regulated by the 
transcriptional activator MxiE148.  Gene expression in EPEC is also regulated by 
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temperature, and is activate and inactive at 37ºC and 28ºC respectively149. 
Gene expression is influenced by nutrient availability, with EPEC undergoing 
localised adherence to intestinal epithelial cells (IEC) more efficiently in the 
presence of extracellular glucose than galactose150. The LEE-encoded regulator 
(ler) is a key regulator of EPEC virulence factors including the Esp proteins, 
Intimin and Tir151.  Ler transcription is activated by the global regulator of LEE 
activator (GrlA) and repressed by the global regulator of LEE repressor 
(GrlR)129,138. Ler expression is also activated by quorum sensing152. Bacteria 
constitutively secrete signalling molecules termed autoinducers152. They have 
receptors for these signalling molecules, so they can detect other bacteria 
within the local environment, and respond by inducing the transcription of 
specific genes152.  Thus tight regulation of gene expression in Shigella and 
EPEC helps to establish a successful infection. 
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(Image modified from138) 
 
A major difference between Shigella and EPEC is how they cause disease. 
Shigella is an intracellular pathogen which invades colonic epithelial cells. 
EPEC is an extracellular pathogen which colonises the surface of the intestinal 
epithelium. EPEC forms attaching and effacing lesions which allow it to adhere 
Figure 1.1.12: Structure of type III secretion system of EPEC.  Protein rings composed 
of EscC span the outer bacterial membrane and EscR, S, T, U and V span the inner 
bacterial membrane. The rings are connected to each other by EscJ. The needle complex 
is composed of EscF and is connected to the EspA filamentous extension, which is unique 
to the EPEC secretion system. The translocator is composed of EspD/B. The cytoplasmic 
ATPase EscN energises the secretion apparatus. 
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intimately to IECs. Shigella and EPEC infections will be discussed in detail in 
sections 1.1.21 and 1.1.22. 
1.1.21 Shigella infection 
1.1.21.1 Macrophage apoptosis and the inflammatory response during 
Shigella infection 
1.1.21.1.1 Mucosal immune response 
 
To understand how Shigella invades the colonic epithelium, a description of the 
mucosal immune system is required. Immune responses are induced in the 
Peyer’s Patches (figure 1.1.13)153.  Peyer’s Patches contain central B cell 
follicles, which are surrounded by areas of T cells153. The subepithelial dome 
contains antigen presenting cells (APCs) including macrophages and dendritic 
cells153. It is superficial to the lymphoid follicles of Peyer’s patches and lies 
below the follicular associated epithelium, which contains specialised epithelial 
microfold (M) cells153. M cells transfer antigen from the intestinal lumen by 
transcytosis to APCs within the subepithelium dome153. In turn APCs migrate to 
the lymphoid follicles and interact with naïve lymphocytes153. Once lymphocytes 
have been primed, they leave the Peyer’s patches via draining nodes and 
migrate into the mesenteric lymph node153. From here they travel through the 
thoratic duct into the bloodstream before migrating to the lamina propria153. The 
lamina propria is the site of effector immune responses in the mucosal immune 
system and comprises immune cells including T and B lymphocytes, 
macrophages, dendritic cells, neutrophils and mast cells153.  
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(Image modified from153) 
 
1.1.21.1.2 Macrophage apoptosis and inflammatory response 
 
Shigella uses M cells to cross the epithelial barrier by transcytosis into the 
subepithethial dome124, where the bacteria invade resident macrophages (figure 
1.1.14)154. Shigella lyses the phagocytic vacuole in which they were internalised 
in, enabling them to escape into the macrophage cytoplasm, where they 
replicate before triggering macrophage apoptosis154. Macrophage cell death 
results from inflammasome mediated activation of Caspase 1. Inflammasome 
activity can be stimulated by lipopolysaccharide (LPS), which is released as the 
bacteria escape from the phagocytic vacuole154, and by the effector IpaB71. The 
production of interleukin (IL) 1β contributes to inflammation within the intestine, 
and leads to immune cell recruitment into the tissue. This is important because 
it damages the epithelial surface, which allows more bacteria to cross the 
Figure 1.1.13: Mucosal immune system. Immune responses are induced in the Peyer’s 
patches (PP). M cells transfer luminal antigen to antigen presenting cells (APCs) such as 
macrophages and dendritic cells in the subepithelial dome. APCs migrate into the 
lymphoid follicle which consists of a central B cell area surrounded by T cell areas, where 
they interact with naïve lymphocytes. Once primed, lymphocytes exit the PP and migrate 
into the mesenteric lymph node before entering the bloodstream via the thoratic duct. 
They then migrate to the lamina propria (LP) which is the site of effector immune 
responses. The LP contains immune cells including T and B cells, macrophages, dendritic 
cells, neutrophils and mast cells.   
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intestinal barrier and gain access to the basolateral pole of epithelial cells, to 
disseminate to neighbouring cells and in turn spread throughout the tissue. 
Shigella invasion into enterocytes will be discussed in section 1.1.21. Epithelial 
cells infected with Shigella are an importance source of IL-8, and because of its 
role in neutrophil recruitment into the intestine, IL-8 also has a pivotal role 
during Shigella infection. The persistence of Shigella within the intestine 
activates the innate immune system through the release of bacterial products 
including LPS and peptidoglycan (PGN), which are pathogen-associated 
molecular patterns (PAMPs). PAMPs are patterns conserved among a specific 
group of pathogens, which are recognised by pattern recognition receptors 
(PRRs). PPRs may be expressed at the cell surface, for example toll-like-
receptor (TLR) 4, which is activated by LPS155, or they may be found 
intracellularly, such as nucleotide-binding oligomerisation-domain-containing 
protein 1 (NOD1), which recognises PGN156. This triggers signalling cascades 
involving nuclear factor (NF)-ĸB, and MAPKs including extracellular-signal-
regulated kinase (ERK) and p38, which serve to induce transcription of genes 
including cytokines, chemokines and adhesion molecules, which are involved in 
the immune response157. NF-ĸB is a transcription factor which directly induces 
inflammatory gene transcription. Its activity relies on its translocation to the 
nucleus, which occurs when its inhibitor, inhibitor of NF-κB alpha (IκBα) 
undergoes phosphorylation, and subsequent polyubiquitination and 
proteosomal degradation157. ERK and p38 MAP kinase signalling induces gene 
transcription by histone H3 phosphorylation, which permits transcription factors 
to gain access to chromatin157. Bacterial and inflammatory response 
dissemination throughout the intestine results in oedema (abnormal fluid volume 
between cells, and the production of a mucopurulent discharge (fluid containing 
mucus and pus), followed by the formation of abscesses and mucosal 
haemorrhaging, and thus accounts for the symptoms associated with 
Shigella124. 
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(Image from http://edoc.hu-berlin.de/dissertationen/averhoff-petra-2006-05-
24/HTML/chapter1.html.) 
1.1.21.2 Shigella invasion into enterocytes 
Following release from dying macrophages Shigella invades IECs. This relies 
on the production of effectors which target the host cell actin machinery.  The 
Figure 1.1.14: Inflammatory responses during Shigella infection.  
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regulation of actin by the host cell (section 1.1.22.2.1) and its modification by 
Shigella effectors (section 1.1.22.2.2) will be discussed. 
 
1.1.21.2.1 Actin dynamics within the host cell 
 
The regulated assembly, turnover and spatial organisation of actin filaments is 
responsible for many processes which enable cells to change shape, to migrate 
and to extend membrane protrusions (e.g. filopodia)158. In cells actin exists in 
two forms, globular actin (G-actin) which can undergo polymerisation into actin 
filaments (F actin). F actin is polarised and comprises a fast growing, barbed, 
plus end and a slow growing, pointed, minus end158,159. Actin filaments are 
orientated such that the barbed end faces the plasma membrane of the cell, 
whilst the pointed end is at the rear of the cell158. Actin turnover is coupled with 
ATP hydrolysis158,159. Actin filaments undergo treadmilling in which the filament 
remains roughly the same length158,159. Whilst actin monomer subunits are 
added to the barbed end, they are also lost from the pointed end. Actin 
assembly and turnover is regulated by many actin binding proteins.  For 
example, actin-depolymerising-factor ADF/cofilin family members promote actin 
depolymerisation160 and also sever pre-existing actin filaments161. This results in 
an increase in the concentration of G-actin within the cell, which can be 
incorporated into the actin filament at the barbed end. Capping proteins bind to 
the end of actin filaments. This regulates the length of the actin filament by 
preventing the association and dissociation of actin monomer subunits162,163. 
Capping barbed ends also regulates filament growth direction, since G-actin 
subunits are guided to the small number of uncapped barbed ends that are 
available for subsequent actin polymerisation158. Multiple proteins including 
CapZ capping protein bind to barbed end filaments, whilst members of the 
tropomodulin protein family cap pointed end filaments162,163. The effect of 
capping actin filaments is balanced by the generation of new filaments 158. The 
actin-related-protein (Arp) 2/3 complex is activated by members of the Wiskott-
Aldrich-syndrome protein (WASP) and WASP family verprolin-homologous 
(WAVE) families of proteins, and plays an important role in the branching and 
nucleation of actin filaments164,165. WASP and WAVE proteins initiate new actin 
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filament polymerisation by bringing together actin monomers within the Arp2/3 
complex. They also bind to existing actin filaments and stimulate the formation 
of additional new filaments. Two models have been proposed to explain how 
the Arp2/3 complex promotes branching: one which proposes that branching 
occurs at the barbed end of growing filaments; and the other which proposes 
that branching may occur at the side of existing filaments166.  
The RhoA GTPases RhoA, Rac and Cdc42 are master regulators of actin 
dynamics, whose downstream targets include the actin regulatory proteins 
discussed in the previous paragraph158. They are a subfamily within the Ras 
superfamily of small guanosine triphosphate phosphohydrolases (GTPases)167, 
and are active and inactive when they are bound by GTP and GDP 
respectively168. They are regulated by three classes of proteins168. Guanine 
nucleotide exchange factors (GEFs) stimulate guanosine triphosphate (GTP) 
binding, and GTPase activating proteins (GAPs) trigger GTP hydrolysis to 
guanosine diphosphate (GDP)168. Additionally, the RhoA GTPases are inhibited 
by guanine nucleotide dissociation inhibitors (GDIs), which sequester them in a 
GDP bound state168. Once RhoA GTPases are activated in their GTP bound 
state, they can activate actin regulatory protein downstream targets, whose 
activities have been discussed above. Thus activated Rho GTPases regulate 
the assembly, spatial arrangement and turnover of actin filaments. They also 
represent the main target of Shigella effectors for invasion into cells.  
 
1.1.21.2.2 Invasion of Shigella into IECs and spread from cell to cell 
 
Shigella invasion into IECs requires the formation of filopodia and membrane 
ruffles, which are actin rich membrane protrusions that form phagocytic cups 
enclosing the bacteria169. A role for a number of effectors has been 
demonstrated in invasion through their activation of Rho GTPases. For 
example, IpaC activates Rac and Cdc42, which stimulates the activity of the 
Arp2/3 complex, and leads to the branching of new actin filaments170,192. IpgB1 
also activates Rac, which may occur directly if IpgB1 has intrinsic GEF activity 
for Rac170, or indirectly if it recruits the Rac GEF DOCK 180171. IpgD also acts to 
enhance actin polymerisation. IpgD possesses phosphatidylinositol 
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phosphatase activity, converting phosphatidylinositol 4,5-bisphosphate into 
phosphatidylinositol 5-monophosphate, and has been proposed to promote 
detachment of the actin cytoskeleton from the plasma membrane, which may 
favour actin polymerisation at the site of invasion172. In order for bacterial 
invasion into the enterocyte to take place, the phagocytic cup must close173. 
This has been proposed to occur by an inhibition of actin polymerisation, 
resulting from an interaction between IpaA, and vinculin169,174. IpaA binds to the 
cytoskeletal protein vinculin, and this interaction has been suggested to cause 
vinculin to act as a capping protein, binding to barbed end filaments and 
attenuating their growth175,176.  
Following uptake into IECs, Shigella lyse the vacuole they were internalised in, 
and escape into the cytoplasm where they become covered with F-actin. The 
outer surface membrane protein VirG, is asymmetrically distributed over the 
surface of the bacterium, and accumulates at one pole154. VirG recruits host cell 
components including N-WASP and the Arp2/3 complex142. Activation of the 
Arp2/3 complex by N-WASP, causes actin nucleation at one pole of the 
bacterium. This leads to the formation of an actin tail which propels the 
bacterium through the cytoplasm142. When the bacteria reach the plasma 
membrane, they trigger actin protrusions into neighbouring cells, which 
subsequently endocytose the bacteria.  As this enables Shigella to disseminate 
through the tissue without being exposed to the extracellular environment, the 
bacteria evade the host immune response142.  VirA also facilitates bacterial 
movement within the cytoplasm. Shigella movement is perturbed by 
microtubules, which are composed of α- and β- tubulin154.  As VirA degrades α-
tubulin, this creates a tunnel in the microtubule network through which the 
bacteria can move smoothly177. In summary, the bacteria hijack the host cell 
machinery which regulates the assembly and turnover of actin. As this is pivotal 
for their invasion into epithelial cells and spread throughout the intestine, it is an 
absolute requirement for setting up a successful infection.  
1.1.22 EPEC infection 
During EPEC infection a variety of mechanisms act in combination to induce 
diarrhoea development. These mechanisms include the formation of attaching 
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and effacing lesions, the disruption of the epithelial barrier and the modification 
of ion and water transport and will be discussed in the following sections. 
1.1.22.1 Attaching and effacing lesion formation: intimate adherence to 
IECs 
As previously mentioned, EPEC is a non-invasive extracellular bacterium, which 
colonises the surface of the intestinal mucosa by forming attaching and effacing 
lesions on the surface of IECs131.  EPEC can be divided into typical and atypical 
strains. Both strains produce the chromosomal locus of enterocyte effacement 
(LEE), which encodes the type III secretion apparatus and has been described 
in section 1.1.20.2. A key difference between typical EPEC and atypical EPEC 
is the production of a ~95 kb plasmid termed EPEC adherence factor (EAF) 
plasmid. Typical EPEC express the EAF plasmid and undergo localised 
adherence to IECs143,178, and this will be discussed in the next paragraph. 
Atypical EPEC do not produce the EAF plasmid and therefore do not undergo 
localised adherence to IECs. 
For typical EPEC, the initial step  in attaching and effacing lesion formation  
occurs when the bacteria undergo localised adherence to IECs, where tight 
clusters of bacteria bind and form micro-colonies on the cell surface143. This 
requires the production of type IV fimbriae produced by EPEC, which are known 
as bundle forming pili (BFP), and which are encoded by the EAF plasmid143,178.  
BFP are proteinaceous fibrillar organelles, which extend out of the surface of 
the bacterium, facilitating the adhesion of the bacterium to the host cell and the 
recruitment of additional bacteria into micro-colonies on the cell143,178.  
Following localised adherence, the bacteria induce actin pedestal formation 
beneath them, allowing them to adhere intimately to the enterocyte. They inject 
their own receptor, Translocated Intimin Receptor (Tir) into the host cell 
membrane via the type III secretion system138,179. Binding of Tir to the bacterial 
outer membrane protein Intimin, mediates intimate adherence to IECs131. Actin 
pedestal formation requires the activation of the Arp2/3 complex by N-WASP, 
which leads to actin polymerisation and cytoskeleton rearrangements. EPEC 
and the closely related bacteria, EHEC activate N-WASP in different ways. 
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EPEC Tir is phosphorylated on the Y474 tyrosine residue and recruits the host 
cell adaptor protein Nck, which in turn recruits and activates N-WASP138. On the 
other hand, instead of Nck, EHEC utilises its effector EspFu, which binds 
directly to and activates N-WASP138. EPEC Tir also recruits cytoskeletal 
proteins including α-actinin, ezrin and myosin light chain to the site of pedestal 
formation131. Such proteins may provide a direct link between the bacterium and 
the host cell cytoskeleton180,181. Thus EPEC and EHEC induce cytoskeleton 
rearrangements and actin pedestal formation so that they can adhere tightly to 
the IEC (illustrated in figure 1.1.15). This leads to the formation of the attaching 
and effacing lesions on the intestinal surface, which is the hallmark of EPEC 
and EHEC infections.  
  
 
 
 
 
 
 
 
 
 
 
 
 
(Image obtained from Dr. Olivier Marchès) 
 
  
Figure 1.1.15: Attaching and effacing lesion formation. Transmission Electron 
Microscopy of the ileal loop of rabbits infected with WT EPEC (a) and mutant EPEC, 
∆escN (b). WT EPEC adheres intimately to the microvilli brush border, which leads to the 
formation of attaching and effacing lesions (red arrows) and causes the destruction of the 
microvilli. EPEC ∆escN is unable to form attaching and effacing lesions on cells because it 
is deficient in type III secretion and unable to deliver effectors into the host cell. 
 
a 
b 
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1.1.22.2 Disruption of the epithelial barrier 
1.1.22.2.1 Epithelial barrier structure 
 
The intestinal epithelium separates the intestinal lumen and subepithelial 
tissue131. By acting as a physical, ion and size selective barrier, the passage of 
molecules between the two environments is tightly regulated182. Apical 
junctional complexes, which include tight junctions (TJ) and adherens junctions 
(AJ) (figure 1.1.16), provide adhesive contacts between neighbouring cells, and 
therefore function to maintain the intestinal barrier131,182. TJs maintain IEC 
polarity by preventing the lateral diffusion of membrane proteins between apical 
and basal surfaces183. TJs also prevent ions and solutes from passing between 
adjacent cells, meaning that they must enter cells by diffusion or active 
transport183. AJs are thought to initiate and stabilise cell: cell adhesion by 
connecting the actin cytoskeletons of neighbouring cells183.  
Localised clustering of transmembrane proteins including occludin, claudins and 
junctional adhesion molecules is necessary for their incorporation into TJs and 
is mediated through binding to the C-terminus of cytoplasmic zona occludens 
(ZO) proteins. The N-terminus of ZO proteins is anchored to the actin filaments 
and the myosin light chain (MLC) of the perijunctional actomyosin ring, which 
regulates TJ permeability131,182,184. AJs lie directly below TJs, and form from 
interactions of nectins and cadherins (transmembrane proteins) with afadins 
and catenins (cytoplasmic proteins). With regard to cadherin and catenin 
interactions, while  β-catenin and p120 catenin bind directly to the cadherin, α- 
catenin binds via β-catenin182.  AJs are closely connected to the actin 
cytoskeleton, through the direct binding of afadin and catenin protein family 
members to actin182.   
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(Image modified from185) 
 
1.1.22.2.2 Epithelial barrier modification by EPEC 
 
During EPEC infection both the structure and function of TJs are manipulated. 
One mechanism which regulates the permeability of TJs is phosphorylation of 
the myosin light chain (MLC) of the actomyosin ring by myosin light chain 
kinase. EPEC has been shown to induce MLC phosphorylation in IECs186.  This 
stimulates the contraction of the actomyosin ring, which causes an increase in 
paracellular permeability and a decrease in transepithelial resistance (TER), 
indicating that the integrity of the barrier is compromised131,187. EPEC can 
directly modify the localisation of TJ proteins. For example, claudin-1 has been 
redistributed from TJs in EPEC infected IECs188 and in C. rodentium infected 
mice189. Both EspF and Map have been shown to induce occludin redistribution 
during EPEC infection of IECs190. Phosphorylation is required for occludin 
Figure 1.1.16: Apical junctional complex structure. Tight junctions (TJ) form from 
interactions of claudins, occludin and junctional adhesion molecules (transmembrane 
proteins) with zona occludens (cytoplasmic proteins). Adherens junctions (AJ) form from 
interactions of nectins and cadherins (transmembrane proteins) with afadins and catenins 
(cytoplasmic proteins). TJs and AJs are connected to the actomysoin ring via their 
cytoplasmic proteins.  
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localisation to the TJ, and during EPEC infection, occludin is translocated from 
the TJ to the cytosol, which coincides with its dephosphorylation187. Mice with 
an EspF mutation infected with C. rodentium, highlight the importance of barrier 
modification during attaching and effacing bacterial infection in vivo191. Although 
the bacteria are able to adhere intimately to the epithelium, they do not disrupt 
TJs, and this leads to reduced water movement into the intestinal lumen 
compared to wild type mice191.  In addition, EPEC has been shown to target AJs 
in an EspB dependent manner192. When EspB bound to α-catenin within a 
complex of E-cadherin/β-catenin/α-catenin, it induced a conformational change 
in the structure of α-catenin, leading its dissociation from the AJ192. Thus by 
targeting TJ and AJ proteins, EPEC manipulates the structure of the junction. 
This compromises the integrity of the intestinal epithelial barrier, which is 
confirmed by a decrease in TER and an increase in paracellular permeability.  
Compromising the intestinal barrier may facilitate bacterial penetration through 
the intestinal epithelium192.  
1.1.22.3 Modification of water and ion transport 
1.1.22.3.1 Water and ion transport 
 
The transport of water, electrolytes and solutes in the intestine is tightly 
regulated to maximise their absorption.  Various transporter proteins including 
Na+ dependent glucose transporter (SGLT) 1, Na+/H+ exchanger isoforms 2 and 
3 (NHE2/NHE3), and Cl-/HCO3- exchangers, down regulated in adenoma (DRA) 
and putative anion transporter (PAT) 1 mediate the absorption of water and 
solutes across the intestinal epithelium131.  For example, amino acids and sugar 
absorption is coupled to Na+ transport by SGLT-1193. As nutrients are absorbed 
by IECs, the osmolarity of the intestinal lumen decreases194. Osmosis is defined 
as the movement of water from a region of low solute concentration to a region 
of high solute concentration. Thus the reabsorption of nutrients also drives the 
reabsorption of water across the intestinal epithelium194. On the other hand, 
water is also secreted from IECs into the intestinal lumen193. Cl- secretion from 
IECs is mediated by the opening of the cystic fibrosis transmembrane conductor 
regulator channel193. The exit of Cl- from the cell drives the movement of Na+ 
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into the intestinal lumen193, thereby increasing the luminal electrolyte 
concentration, and creating an osmotic gradient which causes water to move 
into the lumen.  Water absorption through cellular membranes is also mediated 
by aquaporin channels expressed in colonic epithelial cells131. Thus various 
transporter proteins and channels act in combination to ensure maximum 
reabsorption of water and nutrients across the intestinal epithelium. 
 
1.1.22.3.2 Modification of water and ion transport by EPEC 
 
EPEC modifies host cell electrolyte reabsorption. For example, EspF targets 
NHE3 to reduce Na+ uptake195. EspG and EspG2 destroy the microtubule 
network to prevent DRA trafficking from intracellular compartments to the apical 
membrane of  IECs, leading to reduce Cl- uptake196. Moreover, the cooperative 
action of EspF, Map, Tir, and Intimin reduced the activity of the SGLT-1 co-
transporter197. By reducing nutrient and electrolyte reabsorption across the 
intestinal epithelium, EPEC also reduces water reabsorption across the 
epithelial barrier. Additionally, EPEC directly reduces water reabsorption by 
manipulating aquaporin expression. For example, in C. rodentium infected mice, 
EspF and EspG mediated AQP2 and AQP3 redistribution from the apical and 
lateral membranes to the cytosol in colonocytes198. The authors suggested that 
this may contribute to diarrhoea production, and consistently, AQP2 and AQP3 
returned to their normal localisation when the mice recovered from infection198. 
Thus by targeting transporter proteins and aquaporin channels, EPEC reduces 
solute and water reabsorption across the epithelial barrier. The resulting 
increase in luminal water contributes to the development of diarrhoea131.   
1.1.22.4 Diarrhoea development in EPEC 
In summary, the formation of attaching and effacing lesions, epithelial barrier 
disruption and modification of water and ion transport act in combination to 
mediate diarrhoea development. The formation of attaching and effacing lesions 
on the epithelial surface leads to the shortening and destruction of intestinal 
microvilli131,180. Microvilli increase the absorptive area of the intestine so by 
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destroying them, EPEC reduces the area over which nutrient and water 
reabsorption across the epithelial barrier can occur131,180. The disruption of the 
epithelial barrier causes water to move between epithelial cells into the lumen, 
and concurrently, water reabsorption is also reduced because EPEC targets 
various transporter proteins and channels. The net effect is to increase the 
volume of water in the intestinal lumen. As diarrhoea production occurs before 
attaching and effacing lesion formation is complete, this suggests that the other 
mechanisms probably contribute to the initial onset of diarrhoea204,221.  
1.1.23 Cx hemichannels and gastrointestinal bacterial infection 
Cx26 is expressed within the human colon199. Unpaired Cx26 hemichannels 
have been linked to infection with S. flexneri. S. flexneri induces transient peaks 
in the intercellular concentration of Ca2+,  which opens Cx26 hemichannels and 
in turn releases ATP into the extracellular medium200. Prior to invasion into cells, 
Shigella are captured by filopodial extensions200. ATP signalling stimulates the 
retrograde flow of filopodial actin, in a process dependent on ERK1/2 
activation200. This in turn causes the filopodia to retract bringing the bacteria into 
contact with the cell body where invasion takes place200.  Thus by opening Cx26 
hemichannels, S. flexneri induces signalling cascades which result in their 
internalisation into IECs. Subsequently HeLa cells transfected with p.R143W 
were shown to be significantly less susceptible to invasion with S. flexneri than 
HeLa cells expressing WT Cx2645. This in vitro data suggests that WT Cx26 
expression facilitates cellular invasion, whereas carrying the p.R143W mutation 
may provide improved protection against infection with S. flexneri. These results 
support the heterozygous advantage hypothesis. In vivo data demonstrate that 
heterozygote carriers of the c.35delG and p.R143W mutations have a thicker 
epidermis. One of the principal functions of the skin is to form a defensive 
barrier against invading pathogens. Similar protective properties of the skin also 
exist in the gut epithelium, so plausibly, the epidermis of the gut epithelium of 
Cx26 heterozygotes may also be thicker than normal individuals. This in turn 
could provide carriers of Cx26 NSHL mutations with improved protection 
against infection with enteric bacteria. This may be most beneficial in 
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developing countries where infection with gastrointestinal pathogens including 
S. flexneri is greatest.  
Unpaired Cx43 hemichannels have been linked to Citrobacter rodentium201 and 
Yersinia enterocolitica202 infections.  During C. rodentium infection, unpaired 
Cx43 hemichannels are detected at the apical plasma membrane of mouse 
colonocytes, which have been suggested to facilitate water secretion into the 
intestinal lumen, and in turn contribute to diarrhoea development201. 
Furthermore, diarrhoea production was significantly reduced in mice carrying a 
heterozygous mutation in Cx43201. Y. enterocolitica can be ingested by both 
phagocytic and non-phagocytic cells, including IECs and endothelial cells202. 
Following internalisation, Y. enterocolitica invades the intestinal epithelium and 
proliferates in underlying lymphoid tissue202. Y. enterocolitica invasion into Cx43 
transfected HeLa cells was significantly reduced by treatment with a 
hemichannel blocker, thus indicating a role for Cx43 hemichannels during Y. 
enterocolitica infection202. Y. enterocolitica induced tyrosine phosphorylation of 
Cx43202. Cx phosphorylation regulates GJ function, for example by modifying 
GJ opening, which could favour bacterial uptake202.  These results further 
support a hypothesis that a loss of functional Cx expression reduces infection 
with gastrointestinal bacteria 
1.1.24 Aims and hypotheses (Results chapters 3 and 4) 
As described in sections 1.1.16 and 1.1.22, high carrier frequencies of specific 
Cx26 NSHL mutations exist in certain geographic locations, and these have 
been suggested to confer a heterozygous advantage, namely that carriers have 
a thicker epidermis and may be better protected from infection with 
gastrointestinal bacteria.  The aim of this project was to investigate how 
infection with gastrointestinal bacteria was affected by Cx26 expression in vitro 
using S. flexneri and EPEC as models of infection. EPEC adhesion and S. 
flexneri invasion were quantified in cells expressing a Cx26 NSHL mutation, and 
in intestinal cells that had been treated with siRNA to Cx26 (chapter 4).   It was 
hypothesised that a loss of functional Cx26 expression would reduce infection 
by both pathogens. Methods were developed to quantify EPEC infection using 
an automated system (chapter 3). This aimed to quantify infection within a large 
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population of cells without any bias. An automated system would be more 
accurate than quantifying infection by manual counting, because humans may 
make mistakes over the number of cells which have been counted, or may be 
biased with regards to which cells to include in the analysis.  
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1.2 Effect of a disintegrin and metalloprotease (ADAM) 17 
expression on cutaneous bacterial skin infection  
1.2.1 Ectodomain shedding 
Various membrane bound precursor proteins including cytokines, growth factors 
and receptors undergo regulated cleavage by specific enzymes from the 
surface of cells in a process termed ectodomain shedding203, which is illustrated 
in figure 1.2.1. This results in the release of the soluble extracellular domains 
from the membrane bound portions of the proteins, which can participate in 
autocrine, juxtacrine or paracrine signalling, and which are important in a wide 
range of biological processes. Specific proteins can be activated, inhibited and 
functionally altered by proteolytic cleavage, meaning that ectodomain shedding 
provides a mechanism to regulate specific proteins. The majority of ectodomain 
shedding is mediated by proteins which belong to the membrane bound ‘a 
disintegrin and metalloprotease’ (ADAM) family of proteins204.  ADAM17 was 
the first ADAM protein to be implicated in ectodomain shedding, because it was 
identified as the tumour necrosis factor alpha (TNFα) converting enzyme 
(TACE) 203,205,206. TNFα is synthesised as a 26 kDa membrane bound precursor 
protein, and this undergoes proteolysis by ADAM17/TACE releasing a soluble, 
secreted 17 kDa biologically active protein into the bloodstream.  
(Image taken from http://walchecklab.umn.edu/research-interests/ectodomain-shedding) 
Figure 1.2.1: Principle of ectodomain shedding. Membrane bound precursor proteins 
undergo cleavage from the cell surface by proteases, e.g. ADAM17, to release a soluble, 
mature extracellular portion of the protein. 
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1.2.2 Structure of ADAM proteins 
ADAM proteins are members of the metzincin super-family of metalloproteases. 
They are characterised by the possession of a catalytic Zn2+ in their active site, 
and their members also include the serralysin, the astacin and the adamalysin 
families of proteins207. ADAM proteins are multi-domain proteins, composed of a 
prodomain, a metalloprotease domain, a disintegrin domain, a cysteine-rich 
domain, a single transmembrane domain and a cytoplasmic tail. The cysteine-
rich domain of many ADAMs also contain an epidermal growth factor (EGF)-like 
repeat208. The structure of ADAM proteins is shown in figure 1.2.2. 
 
 
 
 
 
 
 
 
 
 
 
(Image adapted from 209) 
1.2.2.1 Metalloprotease domain 
X-ray crystallographic studies have revealed that the catalytic part of the 
metalloprotease domain of ADAM proteins consists of a globular structure with 
an active cleft located between two subdomains210,211.  The active cleft contains 
a highly conserved Zn2+ binding motif, HEXXHXXGXXH, in which a catalytically 
active Zn2+ is bound by three histidines, a catalytic glutamate residue, and a 
Figure 1.2.2: ADAM protein structure. ADAM proteins are multi-domain proteins 
consisting of a prodomain, metalloprotease domain, disintegrin domain, cysteine-rich 
domain, transmembrane domain and a cytoplasmic tail. The cysteine rich domain of many 
ADAM proteins also contains an epidermal growth factor (EGF)-like repeat. ADAM proteins 
are synthesised as precursor proteins, which undergo maturation following prodomain 
removal. 
 
Metalloprotease 
Disintegrin 
Transmembrane 
Prodomain 
Cysteine-rich/ EGF 
like repeat 
Cytoplasmic tail 
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downstream methionine turn which loops around to face the HEXXHXXGXXH 
motif212.  The specificity of substrates cleaved by the ADAM protein is 
determined by the structure of the active site.  
1.2.2.2 N terminal signal sequence and prodomain 
ADAMs are synthesised as proproteins in the rough ER. The N terminus of 
ADAMs contains a signal sequence, which directs the protein from the ER to its 
site of maturation in the Golgi apparatus210,211. The prodomain of ADAMs also 
localises to the N terminus of the protein, and functions to maintain the catalytic 
part of the metalloprotease domain in an inactive state. This is achieved by a 
cysteine switch mechanism, in which a conserved cysteine residue within the 
prodomain binds to the catalytic Zn2+ in the metalloprotease domain, blocking 
the active site213. Removal of the prodomain from ADAMs occurs by proprotein 
convertase mediated cleavage, e.g. by furin at  a conserved Rx(R/K)R motif214. 
This results in the removal of the cysteine from the catalytic Zn2+, which makes 
the active site accessible, and leads to the activation of the ADAM protein.  
1.2.2.3 Disintegrin domain 
The disintegrin domain of ADAMs was named because of its similarity to the 
disintegrin domain of metalloprotease proteins found in snake venom (SVMPs), 
which function to inhibit blood clotting215. SVMPs target integrins, which are cell 
surface receptors composed of an α and β chain, that mediate the attachment 
of cells to other surrounding cells, or to the extracellular matrix (ECM). Integrins 
expressed on the surface of activated platelets bind to ligands including 
fibrinogen, by means of an arginine-glycine-aspartic acid (RGD) motif. The 
disintegrin domain of SVMPs also contains an RGD motif, which enables 
SVMPs to bind to integrins expressed on the platelet surface, blocking the 
interaction between fibrinogen and integrins. This leads to an inhibition of 
platelet aggregation and blood clotting at the wound site210. The disintegrin 
domain of human ADAM15 contains an RGD motif, which is recognised by the 
α5β3 and α5β1 integrins, and which facilitates ADAM15 binding216. The 
disintegrin domain of most ADAM proteins does not contain an RGD motif. 
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However, all ADAMs excluding ADAM10 and ADAM17, can interact with 
members of the α4/α9 integrin subfamily through an aspartic acid located in 
their disintegrin domains210,217.  
ADAM17 has recently been shown to interact with α5β1 integrin218.  Although 
the precise amino acid sequence which mediates this interaction is unknown, 
binding was localised to the disintegrin and cysteine-rich domains of ADAM17. 
Whereas cells expressing either full length WT ADAM17, or a construct 
containing the disintegrin and cysteine-rich domains of ADAM17, adhered to 
α5β1 integrin coated beads, cells expressing a construct missing the disintegrin 
and cysteine-rich domains did not. This is an example of how the interaction of 
proteins with the disintegrin domain of an ADAM is supported by its cysteine 
rich-domain210. It has been suggested that the interaction of ADAM proteins with 
integrins may influence events including cell adhesion and migration, and 
consistently, colocalisation of ADAM17 and α5β1 integrin has been observed at 
membrane ruffles and focal adhesions218.  
1.2.2.4 Cytoplasmic tail 
The length and sequence of the cytoplasmic tail varies between ADAM 
proteins210. ADAMs can interact with specific intracellular proteins by means of 
conserved sequences expressed within the cytoplasmic tail. The most common 
sequences are proline-rich PXXP motifs, which facilitate interactions with Src 
Homology (SH) 3 domain containing-proteins. Such interactions function to 
regulate the trafficking, maturation and metalloprotease activity of the ADAM 
protein. Phosphorylation of specific serine, threonine and tyrosine residues 
within the cytoplasmic tail also serves to regulate the ADAM protein. For 
example, ERK-mediated phosphorylation of residue Thr735 of pro-ADAM17, 
results in its trafficking from the ER to the cell surface219 .  
1.2.3 ADAM protein discovery 
In mammals the first ADAM proteins identified were the human sperm protein 
fertilin components ADAM1 (fertilin-α) and ADAM2 (fertilin-β)220. The disintegrin 
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domains of ADAM1 and ADAM2 are left exposed because the ADAMs are 
cleaved after their metalloprotease domains221. Consequently they facilitate the 
binding of the sperm to the egg through their interaction with integrins 
expressed by the zona pelluicida, a specialised ECM which surrounds the 
developing oocyte. Subsequently, 25 ADAM genes have been identified in 
humans, of which 4 are pseudogenes220. Pseudogenes are genomic DNA 
sequences similar to normal genes, but which are non-functional, for example 
they are non-protein coding sequences. Of the 21 ADAM proteins encoded in 
humans, 13 are catalytically active, while the remaining 8 lack critical feature(s) 
in the active site of the metalloprotease domain220. ADAM1 is catalytically 
active, and ADAM2 is catalytically inactive, but knocking out either gene in mice 
results in male infertility, arising from defects in sperm migration and 
adhesion222,223. Thus both catalytically active and inactive ADAM proteins are 
required during development220. In humans a significant number of ADAM 
proteins are expressed in the testis, of which ADAM20, 21 and 30 are 
catalytically active, whilst ADAM2, 7, 18 and 29 are catalytically inactive220. The 
expression of specific ADAM proteins in the testis thus establishes a role for 
them in sperm function and spermatogenesis. However, it is not often possible 
to directly translate how ADAM proteins participate in fertility in rodents, into 
what occurs in humans, because some of the rodent testis-specific ADAM 
genes are only expressed as pseudogenes in humans. Of the remaining human 
ADAM genes which are catalytically active, ADAM8 and 28 are restricted to 
haematopoietic cells, whilst ADAM9, 10, 12, 15, 17, 19 and 33 exhibit 
expression throughout somatic tissue220.  The widespread expression of both 
catalytically active and inactive ADAMs thus means they play a role in a large 
number of cellular and biological events in humans and other species. 
1.2.4 ADAM protein regulation 
As ADAM proteins are involved in a wide range of cellular processes including 
ectodomain shedding, cell migration, cell adhesion and cell signalling, they play 
important roles in development and cellular homeostasis. ADAM protein activity 
is dysregulated in many diseases including cancers, inflammatory diseases 
(e.g. rheumatoid arthritis and multiple sclerosis) cardiovascular diseases (e.g. 
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atherosclerosis), asthma and Alzheimer’s220, so it is important to understand 
how ADAM proteins are regulated. ADAM protein activity is both constitutive, 
and can be induced through natural and experimental stimuli. ADAM17 
mediated substrate shedding can be stimulated by treatment of cells with 
phorbol esters including phorbol-12-myristate-13-acetate (PMA), in a process 
dependent on Protein kinase C (PKC) signalling209. ADAM17 activity can also 
be affected by intracellular signalling pathways, for example the ERK/MAPK 
pathway203. Tissue inhibitors of matrix metalloproteases (TIMPs) are expressed 
within cells which bind to active matrix metalloproteases (MMPs) and inhibit 
their proteolytic activity220. Although the specificity of TIMPs for MMPs is broad, 
it is a lot more restricted for ADAMs. For example, while ADAM10 can be 
inhibited by TIMP-1 and TIMP-3, TIMPs have no effect on ADAM8 and 9220. In 
addition as already mentioned, the cytoplasmic tail of ADAM proteins contains 
specific phosphorylation and proline rich motifs, which can also regulate the 
activity of the ADAM protein.  
1.2.5 ADAM17 and inflammation 
The immune response is associated with elevated levels of proinflammatory 
cytokines including TNFα, interleukin (IL) 1β and IL-6, which induce the 
transcription of proinflammatory effector molecules including cell adhesion 
molecules and chemokines involved in leukocyte recruitment209,224. ADAM17 
mediated cleavage of TNFα thus makes it an important stimulator of immune 
responses. ADAM17 expression is  elevated in inflammatory conditions 
including rheumatoid arthritis, Crohn’s disease, pulmonary inflammation and 
multiple sclerosis225. ADAM17 activity also enhances IL-6 signalling, which 
contributes to inflammation. IL-6 signalling is transduced via the glycoprotein 
(gp) 130 signalling molecule. gp130 may be expressed on the surface of some 
cells from which the IL-6 receptor (IL-6R) is absent. When ADAM17 cleaves the 
IL-6R, a soluble form (sIL-6R) is released into the circulation, which binds to IL-
6, and in turn this complex interacts with gp130226.  IL-6 signalling can therefore 
occur in cells where the membrane bound IL-6R is absent227. Interestingly, 
ADAM17 also displays anti-inflammatory activity in the immune system. 
ADAM17 cleaves the membrane bound TNFα receptors, TNFR1 and TNFR2, 
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releasing soluble forms into the circulation.  This acts to downregulate TNFα 
signalling by reducing the amount of TNFα which can bind to membrane 
associated TNFRs in two ways224. It leads to a decrease in the number of cell 
surface TNFRs, and the soluble receptors released by ADAM17 bind 
antagonistically to soluble TNFα. The importance of regulating TNFα signalling 
is demonstrated in patients with TNF receptor associated periodic syndrome 
(TRAPS)228. A mutation within the cleavage site of TNFR1 prevents ADAM17 
mediated cleavage of the receptor, and consequently, the control of 
inflammation in patients is perturbed leading to inflammatory skin lesions and 
recurrent periods of high fevers228. In summary, the activities of ADAM17 are 
both pro- and anti-inflammatory within the immune system. ADAM17 plays a 
key role in the induction of immune responses, but also acts to control 
inflammation and prevent excessive inflammatory responses.   
1.2.6 ADAM17 mediated regulation of epidermal growth factor receptor 
(EGFR) signalling 
1.2.6.1 EGFR signalling 
Signalling by ligands of the epidermal growth factor (EGF) family is involved in 
numerous cellular processes including proliferation, differentiation, motility, 
adhesion and death. The EGFR is a member of a family of receptor tyrosine 
kinases, whose other members compromise erythroblastic leukaemia viral 
oncogene homologs (ErbB) 2, 3 and 4229. Ligand binding to its receptor 
promotes homo- and hetro- dimerisation. This stimulates the cytoplasmic kinase 
activity, which triggers autophosphorylation on specific tyrosine residues within 
the cytoplasmic tail. Various intracellular signalling proteins are recruited to 
phosphorylated tyrosine residues, which subsequently activate downstream 
signalling cascades including the MAPK and phosphatidylinositol 3-kinase-
activated Protein kinase B pathways. Ectodomain shedding of the EGF family of 
ligands is required for paracrine signalling. ADAM10 and ADAM17 are key 
upstream regulators of EGFR signalling. ADAM10 sheds EGF and betacellulin, 
whereas transforming growth factor alpha (TGFα), epiregulin, amphiregulin and 
heparin-binding EGF-like growth factor (HB-EGF) are released by ADAM17230. 
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Different members of the EGF family bind to different receptors of the ErbB 
family. EGF, amphiregulin and TGF-α bind solely to the EGFR, while 
betacellulin, HB-EGF and epiregulin bind to the EGFR and ErbB4. Finally, some 
neuregulins bind solely to ErbB4, while other neuregulins bind to both ErbB3 
and ErbB4231. 
Since ErbB signalling is involved in many biological processes, it follows that 
dysregulated signalling may be linked to disease. Insufficient ErbB signalling 
has been associated with neurodegenerative conditions including multiple 
sclerosis (MS)232. MS results from damage to glial and Schwann cell derived 
myelin sheaths that enclose neurons, which compromises the transmission of 
electrical impulses within the central nervous system (CNS).  Mice with glial 
cells expressing a dominant negative ErbB receptor exhibit delayed myelination 
onset, which leads to thinner myelin fibre production233. This demonstrates that 
an appropriate level of ErbB signalling is required for the correct functioning of 
the CNS, and to prevent the development of neurodegenerative conditions. On 
the other hand, excessive ErbB signalling has been associated with many 
cancer types including lung, breast and colon carcinomas232,234. Excessive 
signalling leads to the uncontrolled proliferation of tumour cells, and can result 
from gene amplifications, which usually enhance subsequent ErbB protein 
translation, or mutations which permit ErbB receptor activation independently of 
ligand binding234. In summary, the ErbB signalling network has key roles in 
many different cellular processes, but must be tightly regulated to prevent the 
development of disease.  
1.2.6.2 ADAM17-/- mice 
As ADAM17 is an upstream regulator of EGFR signalling, ADAM17-/- mice are 
nearly phenotypically identical to mice lacking certain EGFR ligands. Both types 
of mice exhibit perinatal lethality and display developmental defects203. For 
example, similarly to TGFα-/- mice, ADAM17-/- mice have defects in epithelial 
structure, maturation and morphogenesis, including the inability to undergo 
eyelid fusion235. Both amphiregulin-/- mice and ADAM17-/- mice exhibit defective 
branching of the mammary glands236 . Moreover, heart development is defective 
in HB-EGF-/- mice and ADAM17-/- mice, and is characterised by enlarged and 
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misshapen heart valves237. These observations demonstrate the absolute 
requirement for ADAM17 mediated shedding of EGFR ligands during 
developmental processes.  
1.2.6.3 ADAM17 mediated regulation of EGFR signalling in epidermal 
barrier function 
ADAM17 mediated regulation of EGFR signalling is required for epidermal 
barrier maintenance238. As discussed previously in section 1.1.16, the epidermal 
barrier is generated and maintained by the cornification process60. 
Keratinocytes which detach from the basal layer of the epidermis are committed 
to terminal differentiation, and migrate through the suprabasal layers to the 
surface of the epidermis where they form the cornified layer. The cornification 
process is initiated by the formation of the cornified envelope, in which its 
structural components are crosslinked by transglutaminases to form an 
insoluble protein network. Mice harbouring a conditional knock out of ADAM17 
in keratinocytes (ADAM17-/-) have dysregulated expression of keratinocyte 
differentiation markers238. For example, the expression of involucrin and 
transglutaminase 3, which are required to initiate cornification, was 
decreased238. The defect in terminal differentiation and cornified layer formation 
in ADAM17-/- mice resulted in a defective epidermal barrier, which led to 
increased transepidermal water loss and inflammatory cell infiltrates238. 
ADAM17 mediated shedding of EGFR ligands promotes keratinocyte terminal 
differentiation and stimulates transglutaminase activity, thereby facilitating the 
cornification process, which is required to maintain the epidermal barrier238. 
ADAM17 expression also prevents the development of chronic dermatitis in WT 
mice, which occurs in ADAM17-/- mice because of its role in barrier 
maintenance238. Therefore, targeting ADAM17 mediated regulation of the EGFR 
signalling pathway could represent a potential target for treatment of epidermal 
barrier defects.  
The use of therapeutics targeting the ADAM17-EGFR signalling pathway for 
epidermal barrier defects however, must be considered carefully. Loss of 
functional ADAM17 expression results in the development of chronic dermatitis 
in mice238, and led to the formation of pustular skin lesions in a patient suffering 
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from a neonatal onset inflammatory skin and bowel syndrome239. However, 
elevated ADAM17 mRNA expression has been associated with psoriatic skin 
lesions225. The skin barrier is also compromised in psoriasis, a condition which 
is associated with dysregulated inflammation, keratinocyte hyperproliferation 
and abnormal keratinocyte terminal differentiation225. Stimulating ADAM17 
activity could improve the epidermal barrier function resulting from reduced 
ADAM17 expression, by promoting keratinocyte terminal differentiation and 
cornification. However, inhibiting ADAM17 activity was also beneficial in a 
murine model of psoriasis240. Inhibiting metalloprotease activity led to reduced 
inflammation and decreased abnormal keratinocyte proliferation and 
differentiation, presumably as a result of impaired proinflammatory cytokine and 
EGFR ligand shedding240. ADAM10 represents a second ADAM protein, which 
could also be carefully targeted for epidermal barrier defects. Adherens 
junctions (AJ) participate in the maintenance of the epidermal barrier. The AJ 
component E-cadherin is shed by ADAM10, which influences cell adhesion and 
migration in vitro241. Keratinocytes exhibit impaired cell adhesion in eczematous 
dermatitis, which may result from increased ADAM10 mediated shedding of E-
cadherin242. Thus, depending on the requirements for specific conditions, ADAM 
proteins could be targeted to either increase or decrease their activity as a 
means to improve epidermal barrier function. 
1.2.6.4 ADAM17 mediated regulation of EGFR signalling in intestinal 
barrier function 
A study by Chalaris et al243 highlights the importance of EGFR signalling to 
maintain the intestinal barrier. The authors created mice in which ADAM17 was 
conditionally knocked out in all tissues. In mice, colitis can be induced by 
treating them with dextran sodium sulphate (DSS). When ADAM17-/- mice were 
treated with DSS, they exhibited significantly worsened intestinal inflammation 
and ulceration compared to WT mice243. The impaired shedding of EGFR 
ligands in ADAM17-/- mice led to an inhibition of intestinal epithelial cell (IEC) 
proliferation following DSS treatment. However, under normal conditions, the 
proliferation of colonic tissue in ADAM17-/- mice was not significantly different to 
WT mice243. Thus ADAM17 mediated regulation of EGFR signalling would 
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appear to be required, not for the basal level of IEC proliferation, but rather for 
the regeneration of IECs in response to injury or inflammation. IEC regeneration 
is essential for maintenance of the intestinal barrier243.  
1.2.7 ADAM17 loss of function mutation in humans 
Using high through-put sequencing technology, our group identified the first loss 
of function (LOF) mutation in ADAM17 as the cause of a recessively inherited 
neonatal onset inflammatory skin and bowel disease in a Lebanese family239. Of 
the three children who were born to consanguineous unaffected parents, one 
child was unaffected, whilst two suffered from the syndrome. The syndrome 
presented with neonatal onset chronic diarrhoea and lesions of the skin. The 
skin lesions were perioral and perianal erythema (redness of the skin due to 
inflammation) with fissures (breaks and tears of the skins), a generalised 
pustular (pus filled, blister like lesions) rash which developed into psoriaform 
erythroderma and recurrent infections with Staphylococcal aureus (S. aureus). 
In addition, the children also presented with short or broken hair, wiry and 
disorganised eyebrows and eyelashes, and thickened nails with had repeated 
pseudomonas and candida infections. The cutaneous phenotype of the affected 
boy is illustrated in figure 1.2.3 
 
 
 
 
 
 
 
 
(Images taken from239) 
 
Figure 1.2.3: Cutaneous phenotype of boy with ADAM17 LOF mutation. Facial 
erythema (reddening), short hair and wiry disorganised eyebrows (A), widespread pustular 
rash (B) and thickened nails (C) 
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Homozygosity mapping using single nucleotide polymorphism (SNP) arrays, 
which enable detection of single nucleotide variations within the DNA sequence, 
was performed on the parents and siblings of the family239. Analysis of the SNP 
data detected segregation to long stretches of SNP homozygosity on 
chromosomes 2, 5 and 21. Sequencing of exons within this region subsequently 
revealed a 4 base pair deletion in exon 5 of ADAM17 (c.603-606delCAGA) on 
chromosome 2. The mutation introduces a premature stop codon truncating the 
ADAM17 protein. The resulting protein contains only the signal sequence and 
prodomain, and lacks the metalloprotease, disintegrin, transmembrane and 
cytoplasmic domains. When peripheral blood mononuclear cells (PBMCs) were 
stimulated with the bacterial cell wall component lipopolysaccharide (LPS), with 
PMA, or by T cell activation using an anti-cluster-of-differentiation (CD) 3 or 28 
antibody, TNFα secretion was not detected. This was consistent with a loss of 
functional ADAM17 expression by the patient. ADAM17-/- mice die perinatally. 
Although the affected girl died at 12 years of age from Parvovirus-B19-
associated myocarditis, despite repeated skin infections, the affected boy has 
survived until adulthood and now lives a normal life. This highlights the potential 
differences in function and requirements of ADAM proteins between humans 
and mice.  
1.2.8 Tylosis with oesophageal cancer 
Tylosis with oesophageal cancer (TOC) is a rare condition which is inherited in 
an autosomal dominant manner. To date five pedigrees have been reported 
from the UK244, USA245, Germany246, Spain247 and Finland248. TOC is 
characterised by non-epidermolytic palmoplantar keratoderma (thickening of the 
skin on the palms and soles), oral leukoplakia (white keratotic patches on the 
mucous membranes of the oral cavity, e.g. the tongue) and follicular 
hyperkeratosis. The clinical presentation of TOC is illustrated in figure 1.2.4. 
While the risk of developing oesophageal cancer is increased by up to 95% by 
the age of 65 in TOC patients, the incidence of other malignancies is not 
affected. Linkage and haplotype analysis has allowed researchers to map the 
TOC locus to a region on chromosome 17q25c249-251. Our group has recently 
identified mutations in the RHBDF2 gene as the cause of TOC. RHBDF2 
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encodes the inactive Rhomboid 2 (iRhom2) protein. We identified three 
missense mutations in exon 6 of iRhom2: c.557T>C (p.Ile186Thr) in the UK and 
USA pedigrees; and c.566C>T (p.Pro189Leu) in the German pedigree252. An 
additional mutation,  c.562 G > A (p.Pro189Leu) was identified in the Finnish 
pedigree  in a separate study248.  
 
 
 
 
 
 
 
 
 
(Images taken from252) 
1.2.9 iRhom2 
iRhom2 is a member of the rhomboid family of seven transmembrane spanning 
intramembrane serine proteases. The active site of rhomboid proteins is 
contained within the transmembrane domain of rhomboids which cleave 
substrates within, or immediately adjacent to, their transmembrane domain253. 
The Rhomboid gene was first identified in Drosophila for its role in development, 
where it was named after an embryonic mutant phenotype, which resulted in the 
formation of a rhomboid shaped head254. Rhomboids were subsequently 
discovered to control developmental processes in Drosophila through regulation 
of the EGFR signalling pathway. In Drosophila, rhomboids cleave membrane 
bound members of the EGF ligand family, analogous to their cleavage by 
specific ADAM proteins in mammals.  
A recent study has identified three subgroups of eukaryotic Rhomboid proteins, 
including the catalytically active proteases, and a group of inactive rhomboid-
like proteins (iRhoms)255. iRhoms closely resemble rhomboids, but they lack 
Figure 1.2.4: Clinical presentation of tylosis with oesophageal cancer (TOC). 
Palmoplantar keratoderma (thickening of skin on palms and soles (A) and oral leukoplakia 
(white patches on mucous membranes of the oral cavity (B). 
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catalytic residues.  Specific members of the iRhom group are missing different 
catalytic residues. For example, some members lack either the histidine or 
serine or both residues. iRhom2 misses the catalytic serine721 residue252.  All 
iRhom family members have an additional proline residue in the first x position 
of the rhomboid catalytic GxSx motif, which is absent in active proteases255. 
Although the function of the proline residue is unknown, because of its close 
proximity to the catalytic serine, it is believed to inhibit the proteolytic activity of 
the protein253. Compared to active rhomboid proteases, iRhoms also have an 
extended cytoplasmic N-terminal domain, and a conserved ‘iRhom homology’ 
loop domain between the first two transmembrane domains (figure 1.2.5). The 
‘iRhom homology’ domain contains 16 cysteine residues which have been 
proposed to form disulphide bridges; this could be important to maintain the 
stability of the folded protein253,255.  
  
 
 
 
 
 
 
 
 
(Image modified from256) 
 
Figure 1.2.5: Structure of iRhom proteins. iRhoms lack one or both of the catalytic 
serine and histidine residues and have an additional proline inserted into the catalytic 
motif. iRhoms also have an extended cytoplasmic N-terminus and an iRhom homology 
domain. 
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1.2.9.1 Function of iRhom2  
Whereas the EGFR signalling pathway is activated by active rhomboid 
proteases, iRhom has recently been shown to inhibit  EGFR signalling in 
Drosophila, a function which is also shared by mammalian iRhom proteins257. 
iRhom localises to the ER where it can bind to EGF ligand family members, 
promoting their destabilisation and targeting them for endoplasmic reticulum 
associated degradation (ERAD) (figure 1.2.6). ERAD is a system which targets 
misfolded proteins of the ER for degradation, and consequently this represents 
one way in which iRhom2 can regulate the availability of EGF ligand family 
members which can be shed by ADAM17.  
The analysis of iRhom2-/- mice in two separate studies has revealed that 
iRhom2 functions to regulate the localisation and subsequent ability of ADAM17 
to interact with its substrates. In the first study, it was observed that iRhom2 is 
required to function as a cargo receptor, binding to pro-ADAM17 at its site of 
synthesis in the ER, and mediating its transport to its site of activation within the 
Golgi apparatus (figure 1.2.6)256. TNFα secretion following LPS stimulation was 
completely reduced in macrophages from iRhom2-/- mice compared to 
macrophages from WT mice, because mature ADAM17 failed to traffic to the 
cell surface256. In the second study, TNFα shedding was also impaired in 
iRhom2-/- mice, and they were more susceptible to infection with Listeria 
monocytogenes than WT mice258. WT mice were better able to control the 
replication of bacteria, such that the bacteria titres recovered from organs of 
iRhom2-/- mice were significantly greater than those recovered from WT mice258.  
These two studies thus highlight that iRhom2 plays a role in the regulation of 
the ADAM17 dependent immune response. The iRhom2 mediated transport of 
pro-ADAM17 from the ER represents a crucial step required for the activation 
and maturation of ADAM17. In the absence of iRhom2, ADAM17 fails to traffic 
to the cell surface, which has consequences for protection during bacterial 
infection.  
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S. aureus is an important pathogen associated with skin disease and as already 
mentioned in section 1.2.7, the ADAM17 deficient patient suffered from 
repeated Staphylococcal infections. S. aureus will therefore be discussed in 
detail in sections 1.2.10-15. 
1.2.10 S. aureus 
S. aureus causes a wide spectrum of diseases including localised skin disease 
(e.g. wound infection and impetigo), toxinoses (e.g. toxic shock syndrome and 
scalded shock syndrome) and systemic diseases (e.g. pneumonia, bacteraemia 
and endocarditis)260,261. It is the most common cause of skin and soft tissue 
infections262 and additionally, it exists as a component of the flora in 
approximately 30% of healthy individuals who are asymptomatically colonised. 
In such individuals, whilst the bacteria persist without causing infection, they 
have an increased risk of developing a subsequent infection261. Other risk 
factors for S. aureus infections include those whose skin barrier function is 
compromised, and those who are immunocompromised, for example individuals 
who suffer from AIDS or an immune deficiency261. Strains of S. aureus including 
Methicillin-resistant S. aureus (MRSA) are associated with both community-
acquired and hospital-acquired infections261. S. aureus is usually transmitted 
directly by skin-to-skin contact with a colonised or infected individual 261.  
Figure 1.2.6: Functions of iRhom2 in the ER. iRhom2 regulates EGF signalling by binding 
to ligands of the EGF family and targeting them for ER associated degradation (ERAD). 
Concurrently, iRhom2 regulates ADAM17 maturation and traffics pro-ADAM17 from its site 
of synthesis in the ER to the Golgi apparatus ,where it undergoes further processing 
required for its maturation. 
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1.2.11 S. aureus adherence factors and colonisation 
S. aureus is primarily an extracellular pathogen. Colonisation with S. aureus is 
initiated when bacteria adhere to plasma or components of the ECM260. 
Adhesion is mediated by surface adhesins of the microbial surface components 
recognising adhesive matrix molecules (MSCRAMMs) family of proteins263,264. 
MSCRAMMs harbour an amino-terminal signal sequence, targeting them for 
transport via the Sec dependent secretion system across the inner membrane, 
periplasm, and outer membrane to the bacterial surface263. Ligand binding 
domains of MSCRAMMs localise to the N-terminus of the protein263. The C-
terminus of MSCRAMMs contains a conserved LPXTG cell wall sorting signal 
motif263,264, which undergoes cleavage between the threonine and glycine 
residues. The threonine is then anchored to the bacterial cell wall peptidoglycan 
(PGN) by a sortase263,264. Since PGN is directly linked to the ligand binding 
domains of the MSCRAMMs, bacteria are able to adhere to host cells. 
MSCRAMMs include fibronectin-binding-proteins (Fnbp) A and B which bind to 
fibronectin (ECM), clumping factor A and B which bind to fibrinogen (plasma), 
and collagen binding protein which binds to collagen (ECM)263.  
1.2.12 Cellular invasion by S. aureus 
Although S. aureus is primarily considered an extracellular pathogen, it can 
invade a variety of cell types. These may be professional phagocytes including 
neutrophils, monocytes and macrophages, and non-professional phagocytes 
including endothelial and epithelial cells and fibroblasts260,265. Cellular invasion 
is mediated by some MSCRAMMs including FnbpA and B. FnbpA and B 
interact with the host cell α5β1 integrin receptor264. Following ligand binding, 
integrin clustering initiates signalling cascades, to activate RhoA, Rac and 
Cdc42 (Rho GTPases)266. This leads to rearrangement of the host cell actin 
cytoskeleton, triggering bacterial uptake264. Cellular invasion enables the 
bacteria to escape the host cell immune response264, and consequently, S. 
aureus which has invaded macrophages can persist in the phagocytic vacuole 
for 3-4 days, before escaping to the cytoplasm and triggering cell lysis267. Thus 
the bacteria can replicate without being eliminated, which contributes to the 
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establishment of disease. Cellular invasion may also contribute to the 
development of systemic disease264. 
1.2.13 Cutaneous immune response to S. aureus 
In addition to forming a protective barrier against invading pathogens, the skin 
also initiates immune responses against S. aureus. Many immune cells reside 
within the skin including Langerhans cells which persist in the epidermis, and 
macrophages, dendritic cells, natural killer (NK) cells and T and B cells which 
persist in the dermis268. During S. aureus infection, neutrophils are the first cells 
recruited to the site of infection from the bloodstream269. Initially bacterial 
components including PGN and lipoteichoic acid are recognised by pattern 
recognition receptors including TLR2 on the cell surface, and NOD2 within the 
cytoplasm of a variety of cell types including keratinocytes, Langerhans cells, 
monocytes and dendritic cells270. This leads to the production of 
proinflammatory cytokines, including TNFα, IL-6 and IL-1β270. Subsequently, the 
expression of adhesion molecules required for leukocyte migration is 
upregulated including L-selectin and lymphocyte function-associated antigen 1 
(LFA1) on the surface of neutrophils, and E-selectin and intracellular adhesion 
molecule 1 (ICAM1) on the endothelium262,271. The initial interaction between 
the neutrophils and the endothelium is weak, meaning that neutrophils roll along 
the endothelium262,271. However, when the endothelium becomes activated, 
neutrophils adhere firmly262,271. Then they migrate across the endothelium by 
the process of diapedesis and enter the underlying tissue262,271. Additionally, 
neutrophil recruitment requires the expression of chemokines including 
chemokine (C-X-C motif) ligand (CXCL) 5 and IL-8, which are upregulated in 
response to bacterial recognition262,271. Chemokines activate receptors 
expressed on the leukocyte surface, which directs leukocyte migration to the 
infection site262,271.  
At the site of infection, neutrophils use several mechanisms to kill bacteria. 
Bacteria are internalised into neutrophil phagosomes. They are coated with 
opsonins including antibodies produced by B cells and components of the 
complement cascade (e.g. C3b).  Opsonised bacteria are recognised by Fc 
receptors (recognises the constant, Fc portion of the antibody) and complement 
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receptors expressed on the neutrophil surface262. Within the phagosome 
bacteria may be killed directly, for example by the respiratory burst, which 
generates reactive oxygen species, including O2- and H2O2262,269. Antimicrobial 
peptides including cathelicidin and defensins may act to inhibit bacterial growth, 
or may lyse bacterial membranes to directly kill them. Furthermore, proteinases 
including Cathepsin D and elastase reside in the phagosome and help kill 
bacteria by degrading bacterial proteins and components262. Neutrophils kill 
bacteria which have not been internalised. They release antimicrobial peptides 
and proteases from secretory vesicles by degranulation262,269. Neutrophils also 
release neutrophil extracellular traps, which are chromatin fibre projections that 
are coated with antimicrobial peptides,  which trap and kill invading bacteria272. 
The complement cascade also plays an important role in killing bacteria. When 
host antibody binds to antigen expressed on the surface of bacteria, it can 
activate the classical pathway of the complement system, which leads to the 
killing of the bacteria by two methods265. As mentioned previously, opsonins 
including C3b are generated, which enhance subsequent phagocytosis273. 
Alternatively, the components C5b, C6, C7, C8 and C9 interact with each other 
and form the membrane attack complex, which forms pores in the bacterial 
membrane resulting in its lysis273 
With regards to the T cell response, traditionally mouse models have suggested 
that T helper (Th) 1 cells provide protection during S. aureus infection, because 
they secrete proinflammatory cytokines which recruit neutrophils to the site of 
infection262,274,275. More recently it has emerged that Th17 cells also play a role 
during S. aureus infection262. Together with NK cells and γδ T cells, Th17 cells 
produce IL-17. This causes neutrophil recruitment through the production of 
chemokines including CXCL1, CXCL2, CXCL5, and IL-8276. IL-17 signalling 
drives ganulopoiesis factor expression, e.g. colony stimulating factors (CSF) 2 
and 3, which are required for the production and maintenance of neutrophil 
populations276.  Finally, antimicrobial peptides including cathelicidin and human 
beta defensins (hBD) 2 and 3 are produced in response to IL-17 signalling262.  
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1.2.14 Immune response evasion by S. aureus 
Multiple mechanisms exist, which enable S. aureus to evade the host immune 
response. For example, the expression of Staphylococcal Protein A (SpA) on 
the surface of the bacteria inhibits phagocytosis. SpA is composed of five 
domains (A-E), each of which can bind to Fcγ on the surface of phagocytes 
altering its conformation. This prevents the recognition of bacteria opsonised  
with IgG, thus inhibiting their subsequent uptake260. S. aureus produces factors 
which inhibit the complement system. The complement cascade is initiated 
when the C1q component binds to antibody-antigen complexes. SpA binds to 
C1q, which in turn inhibits the induction of the cascade265,277. The 
staphylococcal complement inhibitor (SCIN) acts downstream within the 
complement cascade to inhibit the C3 convertase, thereby preventing the 
accumulation of the C3b opsonin on the surface of the bacterium278.  
Additionally, components produced by the complement cascade, for example 
C5a also function as chemoattractants and mediate the recruitment of 
leukocytes to the site of infection. Their activity can also be inhibited by proteins 
NK 
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Figure 1.2.7: IL-17 signalling pathway. IL-17 produced by cells in the skin including 
natural killer (NK cells), Th17 cells and γδ T cells leads to the production of antimicrobial, 
granulopoiesis and chemotactic factors.  
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expressed by S. aureus, for example chemotaxis inhibitory protein of  S. 
aureus (CHIPS), which binds to the C5a receptor, and in turn inhibits its 
activation by C5a 279. S. aureus injects cytolytic toxins including the α- and β-
haemolysins and Panton-Valentine leukocidin (PVL) into the host cell plasma 
membrane to trigger its lysis260. Monomer subunits delivered into the cell initially 
bind to the plasma membrane and oligomerise to form a β barrel pore, which 
facilitates the influx and efflux of small molecules and ions260. This leads to 
changes in ionic gradients, and an increase in osmotic pressure, which in turn 
causes  water to enter the cell, triggering its subsequent swelling and 
rupturing260.  Cytolytic toxins display cytotoxicity towards specific cells types. 
While α-haemolysin lyses platelets, erythrocytes and monocytes, PVL is 
particularly cytotoxic towards myeloid cells265. Additionally, β-haemolysin has 
been observed to lyse erythrocytes, monocytes, neutrophils and 
lymphocytes265.  
The production of the superantigens toxic shock syndrome toxin-1 and the 
staphylococcal enterotoxins can have detrimental effects on T cell 
signalling260,265. T cell receptors (TCR) expressed on the surface of T cells 
recognise specific peptides bound to major histocompatibility molecules on the 
surface of antigen presenting cells280. However, TCRs can also be activated 
non-specifically by bacterial and viral protein superantigens. This leads to a 
massive inflammatory response, where up to 1 in 5 T cells may be activated, 
compared to approximately 1 in 10,000 T cells activated during a normal 
antigen presentation281. Superantigen mediated activation of T cells is 
characterised by non-specific T cell clonal expansion and massive T cell 
derived pro-inflammatory cytokine release. This is followed by the deletion or 
anergy of responding T cells, which leads to the substantial loss of the T cell 
repertoire280. Moreover, the uncoordinated release of proinflammatory cytokines 
can be detrimental to the host and can lead to multi-organ failure and 
subsequent death282. Additionally, SpA has also been shown to act as a 
superantigen for B cells260,265,283. By non-specifically interacting with IgM, Spa 
induced the polyclonal expansion of non-specific B cells and subsequent 
depletion of the B cell pool 284. 
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1.2.15 Regulation of virulence factors 
The importance of gene expression regulation has already been discussed for 
S. flexneri and EPEC in section 1.1.20.3. In S. aureus gene expression is under 
the control of several global regulatory systems including the accessory gene 
regulator (agr) system and the staphylococcal accessory regulator (sarA)260,265. 
Virulence factor expression is controlled in response to stimuli including cell 
density, nutrient availability, and environmental cues such as temperature, pH 
and osmolarity260,265,285. The production of specific virulence factors is controlled 
in a temporal manner, which means that specific virulence factors are 
expressed at the appropriate time point during infection, and in quantities which 
are sufficient for their survival within the host depending on the conditions of the 
local environment260,265,285. For example, the co-ordinated actions of the 
regulatory systems ensures that surface proteins including adhesins are 
expressed during the early stages of infection, whilst secreted proteins are 
upregulated during the later stages of infection260.  The control of gene 
regulation is pivotal for S. aureus to establish a successful infection.  
1.2.16 Aims and hypotheses (Results chapter 5) 
As described in section 1.2.7, loss of functional ADAM17 leads to recurrent 
Staphylococcal infections in a patient suffering from an inflammatory skin and 
bowel syndrome239, suggesting that ADAM17 acts to provide protection during 
bacterial infection. It has recently been shown that iRhom2 is required for 
ADAM17 maturation and consequently plays a role in the regulation of the 
ADAM17 dependent immune response256; iRhom2-/- mice are more susceptible 
than WT mice to infection with L. monocytogenes (section 1.2.9)258.  The skin 
condition TOC is caused by mutations in RHBDF2 (section 1.2.8), which make 
iRhom2 overactive and therefore, TOC mutations are predicted to increase 
ADAM17 activity. The aim of this project was to consider how bacterial infection 
was affected by ADAM17 activity, using S. aureus which is a relevant pathogen 
to skin disease as an in vitro model of infection. Attempts made to immortalise 
keratinocytes from the ADAM17 deficient patient were unsuccessful, so to 
mimic loss of functional ADAM17 expression in vitro, keratinocyte cell lines 
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were treated with siRNA against ADAM17. Infection was then compared in 
untreated keratinocytes and keratinocytes treated with ADAM17 siRNA. 
Knocking down ADAM17 was predicted to increase S. aureus adhesion and 
invasion. The effect of increased ADAM17 activity on infection was then 
investigated by comparing infection in control and TOC keratinocytes. It was 
predicted that ADAM17 would provide protection, with TOC keratinocytes 
exhibiting reduced infection compared to control keratinocytes. Assuming that 
the results obtained suggest that functional ADAM17 reduced infection, the way 
in which ADAM17 acts will subsequently be explored.  
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2.1 Cell Culture 
2.1.1. Cell lines 
Caco-2 and HT-29 cells are human intestinal epithelial cell lines derived from a 
colorectal adenocarcinoma. The cell lines are obtained from two different 
patients. HT-29 cells and Caco-2 cells are derived from well differentiated and 
moderately differentiated adenocarcinomas respectively. Caco-2 cells 
spontaneously express differentiation markers and form polarised monolayers 
with microvilli and tight junctions upon reaching confluence286. HT-29 cells 
however, remain undifferentiated under normal culture conditions unless they 
are treated with drugs including colchicine, nocodazole and taxol287. Both cell 
lines were obtained from Dr Sahira Khalaf at the Blizard Institute, Whitechapel, 
London. HeLa cells are derived from a cervical carcinoma and lack endogenous 
Cx expression. NEB1 and K17 cells are control keratinocyte (skin) cell lines, 
whilst TYLK1 and TYLK2 cells are TOC keratinocyte (skin) cell lines. TYLK1 
and TYLK2 cells are derived from biopsies taken from the skin of a male and 
female TOC patient respectively, from which primary keratinocytes were 
isolated and grown in the presence of a γ-irradiated 3T3 mouse fibroblast 
feeder layer, and were immortalised with HPV16 (E6/E7)252.  HeLa, NEB1, K17, 
TYLK1 and TYLK2 cells were obtained from the Kelsell group.  
2.1.2 Cell culture conditions 
Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 2 mM L-glutamine, 10% foetal bovine serum (FBS) (% v/v), 5,000 U/ml 
penicillin and 5,000 µg/ml streptomycin (complete media) at 37°C in an 
incubator supplemented with 5% CO2. Before passaging cells, the culture 
media was removed and the cells were washed with phosphate buffered saline 
(PBS) to remove serum, which inhibits trypsinisation. The cells were detached 
from the culture flask using 0.05% Trypsin (% w/v) with 0.53 mM  
ethylenediaminotetraacetic acid (EDTA) (Invitrogen). Trypsin detaches cells by 
cleaving proteins responsible for the adherence of cells to the culture flask, 
while EDTA is an ion chelator which enhances the actions of trypsin. 
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Trypsinising cells were incubated at 37ºC until cells had detached. 
Subsequently, the activity of trypsin was inhibited by quenching cells in an equal 
volume of cell culture medium, before centrifugation at 1000 RPM for 5 minutes. 
The supernatant was then removed, and the pellet was resuspended in the 
required volume of complete medium. 
2.1.3 Cryopreservation of cells: generation of cell line stocks 
Cells were trysinised as described in section 2.1.2, centrifuged and the 
supernatant was removed from the pellet. The pellet was resuspended in the 
required volume of 10% DMSO (dimethyl sulphoxide) (% v/v) / 90% FBS (% v/v) 
and aliquoted into cryovials. Cells were frozen slowly at -80ºC for 24 hours 
before transfer to vapour phase liquid nitrogen for long-term storage. To bring 
cells up from frozen, cryovials were incubated on dry ice prior to defrosting in a 
water bath heated to 37ºC. Cells were added to pre-warmed cell culture media 
and centrifuged at 1000 RPM for 5 minutes to remove the DMSO which is toxic 
to cells. The supernatant was removed and the pellet was resuspended in 
complete medium before incubation at 37ºC.  
2.1.4 Transfecting HeLa cells with plasmid constructs 
The plasmid constructs used to transfect HeLa cells are listed in table 2.1. A 
vector map of the pmCherry-N1 vector is shown in figure 2.1. HeLa cells were 
seeded in a 12-well plate at a density of 7.5 × 104 24 hours prior to transfection. 
500 ng/well of plasmid construct and 1.5 µl/well of FuGENE 6 (Roche, Basel, 
Switzerland) transfection reagent were mixed in 50 µl of serum and antibiotic 
free DMEM, and incubated at room temperature for 20 minutes. The 
transfection complex was then added drop-wise to cell culture media prior to 
incubation at 37ºC. Twenty-four hours later, the media was replaced with fresh 
complete media. A further twenty-four hours later, transfected cells were 
processed for bacterial infections and immunofluorescence. The transfection 
efficiency was approximately 50% 48 hours post-transfection.  
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Table 2.1: Plasmid constructs  
 
Plasmid 
Construct 
Description Ref/ Source 
p-(WT)Cx26-
mCherry 
WT Cx26 cDNA was cloned and inserted into the 
EcoRI (GAATTC) and BamHI  (CGATCC) restriction 
sites of the pmCherry-N1 vector (Commercially 
available Clontech, California, USA)  
Dr P. Martin, 
Glasgow 
Caledonia 
University, 
Glasgow, 
Scotland 
p-(R143W)Cx26-
mCherry 
The p.R143W mutation was introduced into the 
(WT)Cx26-mCherry vector construct by site directed 
mutagenesis 
This study 
pmCherry  Vector only: the WT Cx26 insert was removed from 
the (WT)Cx26-mCherry vector construct and the 
EcoRI and BamHI restriction sites were made blunt 
ended and then ligated 
This study 
pGFP Plasmid pFPV25.1 expressing gfpmut3a gene 288 
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(Taken from pmCherry-N1 vector information at 
http://www.clontech.com/xxclt_ibcGetAttachment.jsp?cItemId=44287&minisite=10030&secItmId
=16172) 
2.1.5 siRNA knock down 
ON-TARGET plus SMART pool siRNA directed against human GJB2, human 
ADAM17, human ITGB1 and a non-targeting pool (NTP) siRNA (negative 
control) (all reagents, Thermo Fisher Dharmacon, Colorado, USA) were used 
for siRNA studies. GJB2 was knocked down in HT-29 and Caco-2 cells. 
ADAM17 was knocked down in HT-29, K17, NEB1, TYLK1 and TYLK2 cells. 
ITGB1 was knocked down in K17 and NEB1 cells.    
Figure 2.1: Vector map and multiple cloning site of pmCherry-N1. Vector backbone (a) 
and multiple cloning site (MCS) sequence (b). In the p-(WT)Cx26-mCherry construct the 
Cx26 insert is cloned into the EcoRI and BamHI restriction sites. In the pmCherry construct, 
the Cx26 insert has been removed, and the EcoRI and BamHI restriction sites have been 
made blunt ended and then ligated. In the p-(WT)Cx26-mCherry and p-(R143W)Cx26-
mCherry plasmid constructs, the coding region of Cx26 is upstream of mCherry. The 
expression of mCherry or the Cx26-mCherry fusion protein is under the control of the 
cytomegalovirus (CMV) promoter. The translational efficiency of the plasmid construct is 
enhanced in eukaryotic systems by the Kozak consensus sequence, located immediately 
upstream of the mCherry gene. The vector contains a kanamycin (kan) resistant gene, thus 
meaning that the plasmid can be selected for using LB agar or LB broth containing 
kanamycin.  
 
a) 
b) 
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Cells were seeded in a 12-well plate at a density of 1 × 105 per well 24 hours 
prior to transfection. Serum and antibiotic free DMEM was mixed with siRNA in 
one tube and DharmaFECT I (Thermo Fisher Dharmacon, Colorado, USA) 
transfection reagent in another tube. GJB2 siRNA was used at a final 
concentration of 25 nM/well and ADAM17, ITGB1 and NTP siRNAs were used 
at final concentrations of 100 nM/well.  The two tubes were incubated for 5 
minutes, before mixing the contents of both tubes, and incubating for a further 
20 minutes at room temperature. Subsequently, antibiotic free DMEM was 
added to the transfection complex. The cells were washed with antibiotic free 
DMEM, and then incubated with the transfection complex at 37ºC. Twenty-four 
hours later for GJB2 knockdowns, and forty-eight hours later for ADAM17 and 
ITGB1 knockdowns, cells were processed for bacterial infections, quantitative 
RT-PCR, immunofluorescence and western blotting. 
2.16 Peripheral blood mononuclear cell (PBMC) isolation and culture 
PBMC isolations were performed by Matthew Brooke (Centre for Cutaneous 
Research). PBMCs were isolated from venous blood samples collected from the 
ADAM17 deficient male patient, his mother, the male and female TOC patients 
and two age-matched controls. Heparin was added to the blood samples to 
prevent them from clotting. Equal volumes of blood and PBS were then pipetted 
into a 50 ml tube, and subsequently underlain with 10 ml of Ficoll. The tube was 
then spun at 1600 RPM with the brake off for 30 minutes, to ensure that 
deceleration of the centrifuge did not disrupt the density gradient, meaning that 
components of the blood were found in different layers. The top plasma layer 
was then removed and discarded, before drawing off the lymphocyte layer at 
the density gradient interphase, using a plastic Pasteur pipette. PBMCs were 
then transferred into a 15 ml tube, which was topped up with PBS, and 
underwent two subsequent wash steps in PBS by centrifugation at 1000 RPM 
for 10 minutes. PBMCs (2x105/well of a 96 well plate (BD Biosciences, Franklin 
Lakes, New Jersey, USA)) were then cultured in complete media for 24 hours in 
the presence or absence of 1 ng/ml of lipopolysaccharide (LPS, InvivoGen, San 
Diego, California, USA), 100 ng/ml of phorbol 12-myrisate 13-acetate (PMA, 
Sigma-Aldrich, Dorset, UK), or in anti-CD3-coated-96 well plates (BD 
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Biosciences, Franklin Lakes, New Jersey, USA) with 1 µg/ml of anti-CD28 
antibody (eBioscience, San Diego, California, USA). Concentrations of CXCL5, 
IL-12/23, IL-17-A, IL-17-F, IL-24 and TNFα were measured by ELISA (section 
2.8).  
2.2 DNA and RNA  
2.2.1 DNA quantification 
The concentration and purity of DNA samples were measured using a 
Nanodrop ND-1000 spectrophotometer, which measured the optical density of 
samples. The concentration of the DNA sample was measured by absorbance 
at 260 nm. The purity of the DNA sample was measured by absorbance at 260 
nm and 280 nm. A ratio of greater than 1.8 for 260/280 and 260/230 was 
accepted as pure, as 260/280 ratios below 1.8 may indicate protein 
contamination, while 260/230 ratios below 1.8 many indicate contamination with 
salts or solvents.   
2.2.2 Primer design 
Gene sequences were obtained from NCBI Gene (available from 
http://www.ncbi.nlm.nih.gov/gene). The primer and probe sequences used in 
this study are listed in table 2.2. Primer and probe sequences for normal and 
quantitative RT-PCR were designed using Primer-BLAST (available from 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primers for quantitative RT-
PCR were designed so that they spanned an exon-exon junction, to prevent 
non-coding DNA sequences (introns) within genomic DNA being amplified, 
thereby ensuring accurate quantification of mRNA. Primer sequences for site 
directed mutagenesis were designed using PrimerX (available from 
http://www.bioinformatics.org/primerx/).  Primers were obtained from Sigma 
Aldrich, Dorset, UK.  
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Table 2.2: Primer and probe sequences  
Gene Primer pair and sequence (5’ to 3’) Product 
size 
(bp) 
AT 
(°C) 
Ref/ 
Source 
ADAM17 ADAM17 Forward 
5’-GGTTCCTTTCGTGCTGGCGC-3’ 
ADAM17 Reverse 
5’ AAGCTTCTCGAGTCTCTGGTGGG-3’ 
Probe 
5’-[6FAM]-
CGCGACCTCCGGATGACCCGGGCT-
[BHQ1]-3’ 
 
73 
 
 
 
 
 
60 
 
 
 
Designed 
by 
Matthew 
Brooke  
CSF2 CSF2 Forward 
5’-AGCCCTGGGAGCATGTGAAT-3’ 
CSF2 Reverse 
5’-ACTGTTTCATTCATCTCAGCAGC-3’ 
 
88 60 This 
study 
CSF3 CSF3 Forward 
5’-AGCTTCCTGCTCAAGTGCTTA-3’ 
CSF3 Reverse 
5’-TTGTAGGTGGCACACTCACT-3’ 
 
95 60 This 
study 
CXCL5 CXCL5 Forward 
5’-ACGCAAGGAGTTCATCCCAA-3’ 
CXCL5 Reverse 
5’- 
GTTCTTCAGGGAGGCTACCAC-3’ 
 
96 60 This 
study 
 
DEFB103A 
hBD-3 Forward 
5’-TGGTGCCTGTTCCAGGTCA-3’ 
hBD-3 Reverse 
5’-TGTTCCTCCTTTGGAAGGCA-3’ 
 
109 56 This 
study 
DEFB4A hBD-2 Forward 
5’-AGACTCAGCTCCTGGTGAAGC-3’ 
hBD-2 Reverse 
5’-CAAAAACACCTGGAAGAGGCATCAG-3’ 
 
103 56 This 
study 
GAPDH GAPDH  Forward 
5’- TGGCCCCTCCGGGAAACTGT-3’ 
GAPDH  Reverse 
5’- CCTTGCCCACAGCCTTGGCA-3’ 
Probe 
5’-[HEX]-
CGTGATGGCCGCGGGGCTCTCCA-[BHQ1]-
3’ 
 
92 
 
 
 
 
- 
60 
 
 
 
Designed 
by 
Matthew 
Brooke 
GJB2 Cx26 BF 
5’- 
CCAGGCTGCAAGAACGTGTG-3’  
Cx26 BR 
5’- 
GGGCAATGCGTTAAACTGGC  
-3’ 
 
522 60 289 
Cx26 RT-QPCR Forward 
5’-CCTCCCGACGCAGAGCAAACC-3’ 
Cx26 RT-QPCR Reverse 
5’-GCTGGTGGAGTGTTTGTTCACACC-3’ 
92 
 
 
 
60 
 
 
 
This 
study 
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Probe 
5’-[6FAM]-
GGGGCACGCTGCAGACGATCCTGGGG-
[BHQ1]-3’ 
 
 
 
 
 
 
 
 
CMVF  
5’-CGCAAATGGGCGGTAGGCGTG-3’ 
Mcherry Reverse 
5’- AAGCTGTCCTTCCCCGAG- 3’ 
 
 
 
442 
 
 
 
60 
 
 
This 
study 
and 
Clontech 
p.143W Site Directed Mutagenesis Forward 
5’-
AAGCAGCATCTTCTTCTGGGTCATCTTCG
AAGCC-3' 
p.143W Site Directed Mutagenesis Reverse 
5'-
GGCTTCGAAGATGACCCAGAAGAAGATGC
TGCTTG-3' 
 
- - This 
study 
IL-24 IL-24 Forward 
5’-TGAATGGTGAAGGTGCCTGT-3’ 
IL-24 Reverse 
5’-TCTTGTCCCTCTGGTCCTGT-3’ 
 
99 60 This 
study 
MMP9 MMP9 Forward 
5’-TTCTGCCCGGACCAAGGATA-3’ 
MMP9 Reverse 
5’ACATAGGGTACATGAGCGCC-3’ 
 
109 60 This 
study 
 
2.2.3 Reverse transcriptase polymerase chain reaction (RT-PCR):  normal 
and quantitative 
2.2.3.1 Total RNA extraction from cells 
Total RNA was extracted from cells using the QIAGEN RNeasy mini RNA 
extraction kit (QIAGEN, Crawley, UK) according to the manufacturers’ protocol. 
Briefly, cells were lysed in denaturing buffer, which had 1% (v/v) β-
mercaptoethanol added to it. They were then mixed with 70% (v/v) ethanol, 
which facilitated the binding of RNA to the spin column. The column was then 
incubated with RNAse-free DNAse, which degraded any DNA contamination of 
the RNA sample. RNA was subsequently eluted in 30 µl of RNAse free H2O. 
The concentration and purity of the RNA sample was then quantified using a 
Nanodrop ND-1000 spectrophotometer.  
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2.2.3.2 cDNA synthesis 
cDNA synthesis was performed using the SuperScript® II Reverse Transciptase 
kit (Invitrogen, California, USA) according to the manufacturers’ protocol. 
Briefly, reactions contained 200 ng of total RNA, 0.5 µl of 200 µM random 
hexamers, and 1 µl of 10 mM dNTPs, made up to a 12 µl final volume with 
dH2O. The reactions were incubated at 65ºC for 5 minutes, chilled on ice, and 4 
µl of 5x first strand buffer, 2 µl of 0.1 M DTT and 1 µl of RNase OUT (all 
Invitrogen, California, USA) were added to the reaction. RNase OUT is a 
recombinant ribonuclease inhibitor, which prevents the degradation of RNA. 
Reactions were incubated at 25ºC for 2 minutes and chilled on ice, before 1 µl 
(200 U/µl) of superscript II reverse transcriptase (Invitrogen, California, USA) 
was added. Samples were then incubated at 42ºC for 50 minutes, and then 
70ºC for 15 minutes.  
2.2.3.3 cDNA amplification by normal RT-PCR 
PCR was performed in a 25 µl reaction containing: 200 ng of cDNA, 2.5 µl of 
NH4 Reaction Buffer, 0.75 µl of 50 mM MgCl2, 0.5 µl of dNTP mix (200 nM of 
each dNTP), 0.25 µl of BIOTAQ DNA Polymerase (all BIOLINE, London, UK), 
2.5 µl of 50 µM  of each primer and dH20. Reactions were carried out using a 
DNA engine tetrad PCR system. PCR conditions were: initial denaturation at 
95°C for 1 minute, 35 cycles at 95°C for 15 seconds (denaturation), annealing 
for 15 seconds (temperature dependent on primer pair, see table 2.2) and 72° 
for 30 seconds (extension), followed by final extension at 72°C for 5 minutes.  
2.2.3.4 Agarose gel electrophoresis  
PCR products were analysed on agarose gels. Agarose (Sigma-Aldrich, Dorset, 
UK) was dissolved in 1x TBE  (0.89 M tris base, 0.89 M boric acid, 0.2 M EDTA, 
pH 8.0) in a microwave to give 1-1.3% (w/v) gels. The mixture was cooled, 
before the addition of ethidium bromide to a final concentration of 20 µg/ml. 
Gels were poured into a casting gel tray containing combs, allowed to set, and 
samples were loaded into wells with DNA loading buffer (6x DNA loading buffer: 
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0.25% (v/v) bromophenol blue, 0.25% (v/v) xylene cyanol FF, 30% (v/v) 
glycerol) diluted to 1x in TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0) (alongside 
a 1 kB Plus ladder (Invitrogen, California, USA), which was used to determine 
product size. Gels were run in 1x TBE at 110 V. Bands were visualised on a UV 
transilluminator and photographed.  
2.2.3.5 cDNA amplification by quantitative RT-PCR (qRT-PCR) 
While normal PCR shows the amount of DNA in a sample which has been 
amplified at the end of the PCR reaction, qPCR makes it possible to quantify 
the cycle at which DNA amplification begins. The method relies on the use of 
fluorescent dyes including SYBR Green I, which bind to DNA, or for more 
accurate quantification, fluorescently labeled probes which bind to specific DNA 
sequences. 
GJB2 and ADAM17 QPCRs were carried out using the Rotor-Gene Multiplex 
PCR kit (Qiagen, Crawley, UK). The reaction was carried out in a 25 µl mixture 
containing: 12.5 µl of 2x Rotor-Gene Multiplex PCR Buffer (Qiagen, Crawley, 
UK), 1 µl of 10 µM of each primer, 0.5 µl of 10 µM of GAPDH and ADAM17 
probes, or 0.5 µl of 10 µM of GAPDH and 0.125 µl of 10 µM of Cx26 probes, 
400 ng of cDNA and dH2O.  
CSF2, CSF3, CXCL5, DEFB103A, DEFB4A, IL24 and MMP9 PCRs were 
carried out in two separate reactions, one which quantified the expression of 
GAPDH, and the other which quantified the expression of the gene of interest. 
The GAPDH reaction was carried out as described in the previous paragraph 
using the Rotor-Gene Multiplex PCR kit (Qiagen, Crawley, UK), i.e. in a 25 µl 
mixture containing: 12.5 µl of 2x Rotor-Gene Multiplex PCR Buffer (Qiagen, 
Crawley, UK), 1 µl of 10 µM of each primer, 0.5 µl of 10 µM of GAPDH probe, 
400 ng of cDNA and dH2O. The other reaction was carried out using the 
QuantiTect SYBR Green PCR Kit (Qiagen, Crawley, UK), also in a 25 µl mixture 
containing: 12.5 µl of 2x QuantiTect SYBR Green PCR Master Mix (Qiagen, 
Crawley, UK), 1 µl of 10 µM of each primer, 400 ng of cDNA and dH2O. 
For all qRT-PCRs, PCR conditions were: initial denaturation at 95°C for 10 
minutes, and 45 cycles at 95°C for 45 seconds and 60°C for 50 seconds. 
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Thermal cycling and fluorescent monitoring were performed on a Rotor-Gene Q 
(Qiagen, Crawley, UK). The expression of the gene of interest was calculated 
relative to the expression of the reference gene GAPDH, using the ∆∆CT 
method. The formula used was: Relative expression (RE) = 2^ (-∆∆CT) where: 
• CT = PCR cycle in which the sample fluorescent intensity exceeds that of 
the background 
• ∆CT of sample (siRNA treated sample) = CT target gene  – CT reference 
gene 
• ∆CT of calibrator (NTP siRNA treated sample) = CT target gene – CT 
reference gene 
• ∆∆CT  = ∆CT (sample) – ∆CT (calibrator) 
2.2.4 Illumina™ Gene Expression Profiling  
Gene expression was analysed in four comparisons: 
• Uninfected NTP siRNA treated K17 keratinocytes vs uninfected 
ADAM17 siRNA treated K17 keratinocytes 
• Uninfected NTP siRNA treated TYLK1 keratinocytes vs uninfected 
ADAM17 siRNA treated TYLK1 keratinocytes 
• S. aureus infected NTP siRNA treated K17 keratinocytes vs S. aureus 
infected ADAM17 siRNA treated K17 keratinocytes 
• S. aureus infected NTP siRNA treated TYLK1 keratinocytes vs S. 
aureus infected ADAM17 siRNA treated TYLK1 keratinocytes 
 
Total RNA extracted from cells using the QIAGEN RNeasy mini RNA extraction 
kit (Qiagen, Crawley, UK) was hybridised to Illumina™ Sentrix Human HT12v4 
Expression BeadChips in triplicate by Ms Mimoza Hoti at the Genome Centre, 
Charterhouse Square, London. Each chip contains 47,231 probes and can 
measure the gene expression for twelve samples in parallel. The probes are 
sequences of 50 base pairs in length, which target the 3’ end of genes. 
Hybridisation was detected using fluorescently labeled targets which bind to 
probe sequences, and the strength of the signal generated depended on the 
113 
 
amount of total RNA bound by the probe. Data analysis was subsequently 
performed using Illumina’s BeadStudio™ Data Analysis Software. A list of a 
minimum of 200 differentially expressed genes for each comparison, with diff 
scores of ±22 was compiled and analysed using GeneGo pathway analysis 
software (Thomas Reuters). Information about specific genes of interest was 
obtained using the online GeneCards encyclopedia (http://www.genecards.org). 
Additionally, lists of genes with the 30 most upregulated and downregulated 
genes for each comparison were complied.  
2.2.5 Sequencing 
The pmCherry construct was sequenced using CMVF and Mcherry reverse 
primers (table 2.1).  The p-(R143W)Cx26-mCherry construct was sequenced 
using Cx26 BF and Cx26 BR primers. Direct sequencing of plasmid constructs 
was performed by the cycle sequencing chain termination method. The 
incorporation of fluorescently-labelled dideoxynucleotides into the extending 
chain of nucleotides causes chain termination, and the fluorescent signal is 
detected and converted into a sequence. Constructs were sequenced in forward 
and reverse directions in independent reactions using the BigDye Terminator 
version 3.1. Cycle Sequencing kit (Applied Biosystems, Foster City, Canada). 
The sequencing reaction was carried out in an 11.5 µl mixture containing: 500 
ng of plasmid, 1 µl of 10 µM of primer, 1 µl of BigDye Terminator mix (v 3.1) 
(Applied Biosystems, Foster City, Canada), 3 µl of Better Buffer (Microzone, 
Ottawa, Canada) and dH2O. PCR conditions were 25 cycles of 96°C for 1 
minute (denaturation), 50°C for 15 seconds (annealing), and 60°C for 1 minute 
(extension). 
The sequencing reactions were subsequently transferred to plates. The 
samples were precipitated by the addition of 2 µl of 125 mM EDTA and 30 µl of 
ice-cold 100% (v/v) ethanol, incubation on ice for 10 minutes, and centrifugation 
at 4000 RPM for 20 minutes. Plates were inverted and centrifuged at 250 RPM 
for 30 seconds to remove the supernatant. 130 µl of 70% (v/v) ethanol was 
subsequently added to the samples, which were incubated at room temperature 
for 5 minutes. The samples were then centrifuged at 4000 RPM for 5 minutes, 
and then the supernatant was removed as before. Samples were dried in a 
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heating block at 95ºC for 10 seconds. The following steps were performed by Dr 
Claire Scott. Samples were resuspended in 10 µl of HiDi™ formamide, 
transferred to an ABI plate (both Applied Biosystems, Foster City, Canada,) and 
denatured by incubation at 95ºC for 3 minutes, before loading onto the 
sequencer. 
2.2.5.1 Sequence analysis 
Sequence traces were viewed using Chromas Lite 2.1 software (available from 
http://technelysium.com.au/). The nomenclature for nucleotide positions is given 
by the position from the start of the ATG (methionine) start codon where A=+1. 
The sequence traces were compared to WT sequences obtained from the 
Ensembl Genome browser (available from http://www.ensembl.org/index.html) 
using MultAlin (available from http://multalin.toulouse.inra.fr/multalin/). 
2.3 Plasmid molecular biology  
2.3.1 pmCherry construct generation  
A restriction digest was performed to remove the Cx26 insert from the p-
(WT)Cx26-mCherry plasmid construct, to generate the pmCherry (vector only) 
construct. Restriction enzymes recognise, and cleave specific DNA sequences 
(termed restriction sites) within DNA molecules. The reaction was carried out in 
a 20 µl volume containing: 1 µg of p-(WT)Cx26-mCherry construct, 2 µl of NEB 
buffer, 0.2 µg of bovine serum albumin (BSA), 1 µl of EcoRI and BamHI 
restriction enzymes (all New England Biolabs (NEB), Massachusetts, USA), and 
dH2O, incubated at 37°C for 90 minutes. The digested product was run on a 1% 
(w/v) agarose gel at 100 V, and the vector DNA was excised and purified using 
a MinElute Gel Extraction kit (Qiagen, Crawley, UK).  
In preparation for EcoRI and BamHI restriction site ligation, purified vector DNA 
was made blunt ended using an End-ItTM DNA End-Repair kit (Epicentre 
Biotechnologies, Madison, Wisconsin, USA). Whereas DNA molecules with 
sticky ends have a stretch of unpaired nucleotides at the end of one DNA 
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strand, both DNA strands in a DNA molecule with blunt ends terminate in a 
base pair. The reaction performed made both portions of the vector DNA 
compatible for ligation. The reaction was performed according to the 
manufacturer’s protocol. Briefly, a 40 µl reaction volume containing: 0.5 µg of 
purified DNA, 4 µl of End-Repair Buffer, 4 µl of dNTP mix, 4 µl of ATP (all 
Epicentre Biotechnologies, Madison, Wisconsin, USA), and dH2O, was 
incubated at room temperature for 45 minutes. The reaction was terminated by 
heating at 70°C for 10 minutes.  
The ligation was set up in a 20 µl reaction containing: 12 µl of blunt ended 
vector DNA, 2 µl of ligation buffer, 1 µl of T4 DNA Ligase (400,000 U/ml) (NEB, 
Massachusetts, USA) and dH2O. The reaction was incubated at 16°C overnight 
and heat inactivated at 65°C for 10 minutes. The plasmid was subsequently 
transformed in bacteria, selected for by antibiotic resistance and prepared as 
described in sections 2.3.2 and 2.3.3. Finally, the plasmid was sequenced as 
described in section 2.2.5.  
2.3.2 Transformation of chemically-competent E. coli with plasmid 
constructs 
One vial containing 50 µl of One Shot® TOP10 chemically-competent E. 
coli cells (Invitrogen, Massachusetts, USA) was thawed on ice and then mixed 
with 5 µl of DNA. The transformation mixtures were incubated on ice for 30 
minutes, and then heat shocked at 42°C for 30 seconds to incorporate the DNA 
into cells. They were subsequently incubated on ice for 2 minutes. 250 µl of 
SOC medium (Invitrogen, Massachusetts, USA) prewarmed to 37°C was then 
added to the transformation mixtures, which were then shaken at 225 RPM at 
37°C for 1 hour. Subsequently 50 µl of the transformation mixture was spread 
onto Luria-Bertani (LB) Agar (12-15 g/l agar, 10 g/l tryptone, 5 g/ml yeast extract 
and 10 g/l NaCl) plates containing 50 µg/ml kanamycin, and incubated at 37°C 
overnight.  
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2.3.3 Plasmid constructs DNA extraction from E. coli 
As the plasmid constructs contain a kanamycin resistance gene, bacteria which 
have incorporated them grew on the plate. Single colonies were isolated from 
the plate and grown in LB Broth (10 g/l of tryptone, 5 g/l of yeast extract and 10 
g/l of NaCl) containing 50 µg/ml kanamycin overnight at 37°C in an orbital 
shaker. DNA was subsequently extracted using a QIAprep® Spin MiniPrep kit 
according to the manufacturer’s protocol. 
2.3.4 Site directed mutagenesis: p-(R143W)Cx26-mCherry construct 
generation 
The p.R143W mutation was introduced into the p-(WT)Cx26-mCherry construct 
by site directed mutagenesis using the QuickChange® Site-Directed 
Mutagenesis Kit (Stratagene Agilent, Stockport, Cheshire). Primer sequences 
containing the p.R143W substitution are shown in table 2.1. Primers were 
purified by polyacrylamide gel electrophoresis. PCR was carried out in a 50 µl 
volume containing: 20 ng of double stranded plasmid DNA, 125 ng of each 
primer, 1 µl of dNTPs, 1 µl of PfuTurbo DNA polymerase (2.5 units/µl), 5 µl of 
reaction buffer (all Stratagene Agilent, Stockport, Cheshire) and dH2O. PCR 
conditions were: initial denaturation at 95°C for 30 seconds; and 16 cycles at 
95°C for 30 seconds (denaturation), 55°C for 1 minute (annealing) and 68°C for 
6 minutes (extension). The samples were cooled by incubation on ice for 2 
minutes, before the addition of 1 µl of DpnI restriction enzyme (10 units/µl) 
(Stratagene Agilent, Stockport, Cheshire. Samples were subsequently 
incubated at 37°C for 1 hour to digest parental methylated and hemimethylated 
DNA. Analogous to the pmCherry construct, the p-(R143W)Cx26-mCherry 
construct plasmid was transformed in bacteria, selected for by antibiotic 
resistance and prepared as described in sections 2.3.2 and 2.3.3. Finally the 
plasmid was sequenced as described in section 2.2.5.  
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2.4 Bacteria 
The bacterial strains used in this study are listed in table 2.3. Bacteria were 
grown in LB Broth in an orbital shaker at 37°C, or in serum and antibiotic free 
DMEM statically at 37°C in a 5% CO2 atmosphere.  
Table 2.3: Bacterial strains  
Strain  Description Ref/ Source 
EPEC E69 Wild type EPEC 290 
EPEC E69 ∆escN  EPEC deficient in type III secretion Dr O Marchès, 
Queen Mary, 
University of London 
EPEC JPN15  EPEC which is missing the EAF 
plasmid  
290
 
EPEC JPN15 ∆escN  EPEC which is missing the EAF 
plasmid and deficient in type III 
secretion 
Dr O Marchès, 
Queen Mary, 
University of London 
S. aureus 
Staph. Oxford (NCTC 
6571) 
Wild type S. aureus 291
 
S. flexneri serotype 2a 
(2457T) 
Wild type S. flexneri ATCC 
 
EPEC E69 ∆escN was selected for by kanamycin resistance. In this study, 
EPEC JPN15 and EPEC JPN15 ∆escN were transformed with pGFP 
expression plasmids.  EPEC JPN15 was selected for solely by ampicillin 
resistance, whilst EPEC JPN15 ∆escN was selected for by ampicillin and 
kanamycin resistance. 
2.4.1 Bacterial glycerol stocks 
Isolated bacteria colonies were added to beads in 20% (v/v) glycerol in 
cryovials. The cryovials were inverted, the liquid was removed, and they were 
stored at -80ºC. Samples were streaked onto LB agar (Sigma Aldrich, Dorset, 
UK) plates or used to grow overnight cultures in LB Broth (Sigma Aldrich, 
Dorset, UK) as required. 
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2.4.2 EPEC adherence assays 
Overnight EPEC cultures in LB Broth were diluted 1:50 into serum and antibiotic 
free DMEM, and pre-activated by incubation for 3 hours at 37°C in a 5% CO2 
atmosphere before infection. The media on cells was replaced with serum and 
antibiotic free DMEM, and EPEC was added at a multiplicity of infection (MOI) 
of 120 bacteria per cell, and incubated at 37°C/10% CO2 for 2 hours. Cells were 
then washed three times with PBS. Cells were trypsinised and collected in a 
tube, before lysis with 0.5% (v/v) Trition-X-100 in PBS. Lysates were serially 
diluted in PBS and were plated onto LB agar plates. Bacteria were cultivated 
overnight at 37°C. The number of colonies was counted, and the percentage 
adhesion efficiency relative to the inoculum was quantified.  
For immunofluorescence quantification, cells were fixed in 4% 
paraformaldehyde (PFA) in PBS for 15 minutes after infection.  Cells were 
mounted using Immuno-Mount (Thermo. Scientific, Pittsburgh, PA, USA) 
containing 10 µg/ml of 4’6-diamidino-2-phenylindole (DAPI), and viewed under a 
Leica DM5000 automated epifluorescence microscope (Milton Keynes, UK). 
Images were processed using MetaMorph (Molecular Devices) and ImageJ 
software program (version 1.47, downloaded from website 
http://rsb.info.nih.gov/ij/). In an experiment 50 cells were sampled, where the 
total percentage of cells positive for adhering EPEC was quantified, along with 
the number of bacteria which adhered per cell. Additionally, EPEC infection 
could be quantified by calculating the percentage of cells positive for actin 
pedestal formation.  
For flow cytometry quantification, after infection, cells were trypsinised, 
collected in polystyrene tubes and kept at 4°C until FACS analysis. Samples 
were run on a BD LSRII analyser (Becton Dickinson, New Jersey, USA), where 
20,000 cells were counted, and then analysed using FlowJo software program 
(version 8.77, Treestar, California, USA). EPEC adhesion was quantified by 
calculating the percentage of cells which were GFP positive within the total 
population of cells.  
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2.4.3 S. flexneri invasion assay 
The media on cells was replaced with serum and antibiotic free DMEM. S. 
flexneri was added at an MOI of 100 bacteria per cell. The plate was centrifuged 
at 1000 RPM for ten minutes to bring the cells and bacteria into contact, thereby 
initiating infection. The plate was incubated at 37°C/10% CO2 for 4 hours. Cells 
were washed three times with PBS, and DMEM containing 75 µg/ml of 
gentamycin was added, before incubation at 37°C for 1 hour. Gentamicin 
treatment killed extracellular bacteria, but preserved those which had been 
internalised. Following three washes in PBS, cells were trypsinised and 
collected in a tube before lysis with 0.5% (v/v) Triton X-100 in PBS. Lysates 
were serially diluted in PBS and were plated onto LB agar. Bacteria were grown 
overnight at 37°C. The number of colonies was counted, and the percentage 
invasion efficiency relative to the inoculum was quantified.  
2.4.4 S. aureus infection assay 
Two wells of a 12 well plate were used in each infection assay. The media on 
cells was replaced with serum and antibiotic free DMEM. S. aureus was added 
at an MOI of 200 bacteria per cell. The plate was centrifuged at 1000 RPM for 
ten minutes and incubated at 37°C/10% CO2 for 3 hours. The supernatants 
were removed and the concentrations of CXCL5, IL-6, IL-8, IL-17-A, IL-24 and 
MMP9 were analysed by ELISA (section 2.8). Cells were then washed three 
times with PBS. One well used to determine the cell associated bacteria was 
lysed immediately post infection.  Media containing 75 µg/ml of gentamicin was 
added to the other well, which was used to determine the internalised bacteria. 
The plate was incubated at 37°C for 1 hour and washed three times with PBS.  
Cells were trypsinised, collected in a tube and lysed with 0.5 % (v/v) Triton X-
100 in PBS. Lysates were serially diluted in PBS and were plated onto LB agar. 
Bacteria were grown overnight at 37°C and the number of colonies was 
counted. The number of adhering bacteria was calculated by subtracting the 
internalised bacteria from the cell associated bacteria. The percentage 
adhesion and invasion efficiencies were calculated relative to the inoculum.  
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2.5 Western blotting 
Cells were scraped into 100 µl of PBS, collected in sample buffer (200 mM Tris 
(pH 7.4), 8% (w/v) sodium-dodecyl-sulphate (SDS), 40% (v/v) glycerol, 0.01% 
(w/v) bromophenol blue) and sonicated for 15 seconds. The proteins in a 
volume of lysate were separated by electrophoresis on a 12% (w/v) SDS-
polyacrylamide gel at 12 mA per gel in 1x running buffer (25 mM Tris, 192 mM 
glycine, 0.1% (w/v) SDS).  Each gel cast consisted of a 12% resolving gel (in 5 
ml total volume: 1.6 ml of dH2O, 2.0 ml of 30% acrylamide mix (0.8% (w/v) 
Bisacrylamide, 30% (w/v) Acrylamide) (National Diagnostics, Hull, UK)), 1.3 ml 
of 1.5 M Tris (pH 8.8), 50 µl of 10% (w/v) SDS, 50 µl of 10% (w/v) ammonium 
persulphate, 2 µl of TEMED) and a 5% stacking gel (in 5 ml total volume: 3.4 ml 
of dH2O, 830 µl of 30% acrylamide mix, 630 µl of 1.0 M Tris (pH 6.8), 50 µl of 
10% (w/v) SDS, 50 µl of 10% (w/v) ammonium persulphate, 5 µl of TEMED). 
Lysates were run alongside a rainbow marker (GE Healthcare UK Ltd, 
Buckinghamshire, UK) which was used to determine protein band size.  
Electrophoretic transfer transferred the proteins onto a Hybond C nitrocellulose 
membrane (GE Healthcare UK Ltd, Buckinghamshire, UK). The membrane, 
filter paper and foam pads were pre-soaked in 1x transfer buffer (48 mM Tris, 
30 mM glycine, 0.037% (w/v) SDS, 20% (v/v) methanol). A sandwich was made 
which consisted of two pieces of filter paper with the gel placed on top, the 
membrane on top of the gel, and another two pieces of filter paper on top of the 
membrane. This was placed between foam pads in a transfer cassette in a 
transfer tank. The tank was filled with 1x transfer buffer and the proteins were 
transferred at 300 mA for 2 hours, or at 100 mA overnight.  
The membrane was blocked in 10% (w/v) non-fat milk/1x Tris buffered saline 
(TBS)-Tween 20 (50 mM Tris, pH 7.5, 0.15 M NaCl, 1% (v/v) of Tween-20) for 1 
hour at room temperature, before incubation with primary antibody diluted in 
blocking buffer at 4ºC overnight on a shaker. GAPDH was used as a loading 
control. The membrane was washed three times for 5 minutes in TBS-Tween 
20, and incubated with horseradish peroxidase (HRP) conjugated secondary 
antibody, diluted in TBS-Tween 20, for 1 hour at room temperature on a shaker.  
The membrane was then washed five times for 5 minutes in TBS-Tween 20. 
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20x LumiGlO® Reagent and 20x Peroxide (Cell Signaling Technology®, 
Massachusetts, USA) was used to detect the signal. The membrane was 
exposed to Hyperfilm (GE Healthcare UK Ltd, Buckinghamshire, UK) and 
developed with an automated developer. 
Table 2.4: Antibodies used in immunofluorescence and western blotting 
Antibody 
 
Dilution Product code 
ADAM17, rabbit polyclonal 1/500 WB Abcam (Cambridge, UK) 
ab2051 
Cx26, rabbit polyclonal 1/100 IF (PFA fixation) Invitrogen (Massachusetts, 
USA) 71-0500 
GAPDH, rabbit polyclonal 1/1000 WB Abcam (Cambridge, UK) 
ab9485 
hBD-2, rabbit polyclonal 1/500 WB 
1/50 IF (acetone fixation)  
 
Abcam (Cambridge, UK) 
ab63982 
hBD-3, rabbit polyclonal 1/500 WB Abcam (Cambridge, UK) 
ab19270 
Integrin β1, mouse 
monoclonal 
1/50 IF (acetone fixation) 
1/500 WB 
Abcam (Cambridge, UK) 
ab30388 
MMP9, mouse monoclonal 1/50 IF (PFA fixation) Thermo Scientific Pittsburgh, 
PA, USA) 
MAI-12894 
Alexa-Fluor 488, Goat anti-
rabbit 
1/200 IF 
 
Invitrogen (Massachusetts, 
USA) A11008 
Alexa-Fluor 488, Rabbit anti-
mouse 
Invitrogen (Massachusetts, 
USA) A11059 
Alexa-Fluor 546, Goat anti-
rabbit 
Invitrogen (Massachusetts, 
USA) A11010 
Immunoglobulin conjugated 
to HRP, Rabbit anti-mouse 
1/1000 WB 
Immunoglobulin conjugated 
to HRP, Swine anti-rabbit 
2.6. Immunofluorescence 
Cells were either fixed in 4% (w/v) PFA in PBS for 30 minutes, or 100% (v/v) 
acetone for 10 minutes at -20°C.  PFA fixation results in the formation of 
disulphide intermolecular bridges between free amino groups on the proteins 
expressed within the cell, thus creating a network of cross-linked proteins. On 
the other hand, acetone is an organic solvent which functions to dehydrate the 
cells and remove lipids from them, whilst precipitating proteins on the surface of 
the cells. Although PFA fixation preserves the structure of the cells better than 
methanol or acetone fixation, it requires an additional permeabilisation step to 
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ensure that antibodies can enter the cells and bind to their appropriate antigen. 
Permeabilisation steps were not required if cells were fixed with acetone.   
Cells which had been fixed with PFA were permeabilised in 0.5% (v/v) Triton-X-
100 in PBS for 15 minutes at room temperature. Subsequently all cells were 
blocked with 10% (v/v) goat serum in PBS for 1 hour at room temperature, to 
prevent antibody from binding non-specifically to proteins within the cell. Cells 
were incubated with primary antibodies diluted in 10% (v/v) goat serum, by 
inverting the coverslip onto parafilm with 40 µl of antibody on its surface, for 1 
hour at room temperature, or at 4°C overnight, before washing three times for 5 
minutes with PBS. Cells were incubated for a subsequent hour with secondary 
antibodies diluted in 10% (v/v) goat serum at room temperature, before washing 
five times for 5 minutes with PBS. Cells that were just incubated with secondary 
antibody without the primary antibody were used as a negative control. For 
phalloidin staining, following permeabilisation, cells were incubated with 
AlexaFluor 555 phalloidin (Invitrogen, Massachusetts, USA), diluted 1/100 in 
PBS for 30 minutes at room temperature. Cells were mounted using Immuno-
Mount (Thermo. Scientific, Pittsburgh, PA, USA) containing 10 µg/ml of 4’6-
diamidino-2-phenylindole (DAPI) and viewed under a Leica DM5000 automated 
epifluorescence microscope (Milton Keynes, UK). 
2.7 Immunohistochemistry 
Skin biopsies were obtained from the ADAM17 deficient male patient, the male 
and female TOC patients and healthy age-matched controls. Skin samples were 
cryoembedded and sectioned by a technician in the Pathology core facility, 
Blizard Institute, Whitechapel. Prior to staining, sections were defrosted and left 
to air dry for 30 minutes. The samples were subsequently fixed and stained 
following a protocol analogous to the one described for immunofluorescence in 
section 2.6. 
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2.8 ELISAs 
The concentrations of CXCL5, IL-6, IL-8, IL-17-A, IL-24 and MMP9 in the 
supernatants from uninfected and S. aureus infected keratinocytes were 
measured using a sandwich ELISA technique with specific ELISA kits (R&D 
Systems, Abingdon, UK). CXCL5, IL-17A, IL-24 and MMP9 were also measured 
in the supernatants from K17 and TYLK1 keratinocytes, and in control and TOC 
PBMCs, which had undergone 24 hour stimulations with 100 ng/ml of PMA/ 500 
ng/ml of ionomycin and 1 ng/ml of LPS. Finally, IL-17-A, IL-17-F, IL-12/IL-23 
and IL-22 were measured in PBMCs from the ADAM17 deficient patient and 
control subjects following stimulation with 100 ng/ml of PMA/500 ng/ml of 
ionomycin, or CD3/CD28 activation for 24 hours. This final experiment was also 
carried out in the presence of three inhibitors: two small molecule inhibitors, 
GI254023X which blocks ADAM10 activity, and GW280264X which targets both 
ADAM17 and ADAM10292, and an ADAM17 neutralising antibody293. 
ELISAs were carried out according to manufacturer’s protocols. Briefly, the 
wells of a microtitre plate were coated with capture antibody diluted 1/180 in 
standard reagent diluent (1% (w/v) BSA in PBS), or specific IL-8 reagent diluent 
(0.1% (w/v) BSA, 0.05% (v/v) Tween 20 in TBS), and incubated at 4°C 
overnight. The plate was washed three times by filling the wells with wash buffer 
(0.05% (v/v) Tween 20 in PBS). Remaining protein binding sites within the wells 
which had not been coated with capture antibody were blocked with standard 
reagent diluent or IL-8 blocking solution (1% (w/v) BSA, 0.05% ( w/v) NaN3 in 
PBS) for 1 hour at room temperature. The plate was then washed three times 
with wash buffer, and 100 µl of supernatants were added to each well. Serial 
dilutions of standard antibody were also included. The plate was incubated for 2 
hours at room temperature, and then washed three times with wash buffer. 100 
µl of detection antibody, which had been diluted 1/180 in reagent diluent, was 
added to each well, and the plate was incubated for a further 2 hours at room 
temperature. The plate was washed three times with wash buffer, and then 
incubated with 100 µl of HRP-conjugated streptavidin, diluted 1/200 in reagent 
diluent, which binds to the detection antibody, for 20 minutes at room 
temperature in the dark. The plate was then washed a further three times, and 
100 µl of substrate was added to each well, and the plate was incubated for 20 
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minutes at room temperature in the dark. Cleavage of the substrate by the 
enzyme produces a colour change. The reaction was stopped by the addition of 
50 µl of 1 M H2SO4, and the absorbance of each well was measured at 450 nm 
using a BioTek ELX800 plate reader. 
The standard antibodies were serially diluted so that a standard curve could be 
produced. As the concentration of antibody which produces a particular 
absorbance is known, it is possible to measure the concentration of antibody 
present in the well, thus enabling the concentration of cytokines present in the 
supernatants to be quantified.  
2.9 Statistical analysis 
All statistical analysis was carried out as unpaired two-tailed t tests, and p-
values equal to or less than 5x10-2 were considered as statistically significant. 
Statistically significant results presented as *, **, *** or **** represent p<5x10-2, 
p<5x10-3 p<5x10-4 and p<5x10-5 respectively. 
2.10 Patient material 
The use of patient material was approved by the National Health Services 
research ethics committees, and all participants gave their informed consent.  
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3.1 Introduction 
S. flexneri invasion was quantified by cellular invasion as has been published 
previously45,141,200 and therefore no method optimisation was needed. For this 
study, an initial challenge was being able to accurately quantify EPEC infection. 
Manually counting infected cells as a means to quantify 
infection is less reliable than using an automated counting system. 
Humans may make mistakes over the number of cells which have been 
counted. They may also be biased with regards to which cells to include 
in the analysis. Additionally, manually counting cells is a time 
consuming process so far fewer cells can be counted. In order to quantify EPEC 
infection accurately without any bias, one of the aims 
was to develop an automated counting system. Although some error is 
associated with every system, this should be counteracted by sampling a 
large enough population of cells, hence generating more accurate 
quantification of infection than could be achieved manually. The feasibility of 
using image analysis software and flow cytometry to quantify EPEC infection is 
considered and described in section 3.2. 
3.1.1 Aims 
• Consider the reliability of quantifying EPEC infection by bacterial 
adherence using image analysis software and flow cytometry (method 
2.4.2)   
• Consider the feasibility of quantifying EPEC infection by actin pedestal 
formation using image analysis software 
3.2 Results  
3.2.1 EPEC infection detection by immunofluorescence 
Infection can be detected by bacterial adherence to cells, either by infecting 
cells with EPEC which has been transformed with a green fluorescent protein 
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expression plasmid (pGFP), or by visualising DAPI stained bacterial DNA that is 
associated with cells (figure 3.1 a-c). Infection can also be detected by 
phalloidin staining of actin pedestals formed by the bacteria (figure 3.1 d-f). 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2 EPEC infection quantification by immunofluorescence and image 
processing software 
As discussed in section 3.1.1, one of the aims of this study was to 
quantify EPEC infection using an automated counting system, to enable 
more accurate quantification of infection than would be achieved by 
manual counting. First, the feasibility of quantifying infection by 
immunofluorescence using image analysis software (MetaMorph) was 
investigated. Prior to performing quantification analysis, the clarity 
of all images was improved by application of convolution filters. 
Background noise was removed from images by application of a median 
filter, whilst detail within images was increased by sharpening using a high pass 
Figure 3.1: EPEC infection in HeLa cells. (a, c) Nuclei of cells and bacterial DNA (DAPI 
staining in blue). (b) EPEC (green). (d). Actin (Phalloidin staining in red). (c, f) Merged 
images.  Infection can be detected by bacterial adherence to cells (a-c), either by infecting 
cells with EPEC which has been transformed with a pGFP expression plasmid, or by 
visualising DAPI stained bacterial DNA that is associated with cells. Infection can also be 
detected by actin pedestal formation (d-f). Image magnification 40x. Bars 20µm. 
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filter. This processing was necessary to increase the 
likelihood that the edges of objects of interest would be well defined 
and included in subsequent analysis; artefacts in the 
image would be less well defined and therefore less likely to be included 
in subsequent analysis. 
To understand how application of convolution filters to an image improves its 
subsequent clarity, it is necessary to know the definition of an RGB image, a 
pixel and an 8 bit image, and these definitions are given in section 3.2.2.1. DAPI 
stained nuclei and GFP labelled EPEC were sharpened by application of a high 
pass filter. The way a high pass filter works is depicted in figure 3.2. 
Subsequently the sharpening of nuclei and bacteria is shown in figure 3.3. 
Finally the processing of phalloidin staining is illustrated in figure 3.4. 
3.2.2.1 RGB image, pixel and 8 bit image definitions 
A merged image consists of three channels corresponding to the three primary 
colours of light – red, blue and green. The smallest unit of an image is a picture 
element (pixel), with the whole image being composed of thousands or millions 
of individual pixels arranged in rows and columns. 
A bit, which is a binary digit, is the smallest unit of information on a computer.  A 
binary digit is represented by the numbers one or zero, and the number of bits 
used to represent a pixel in a channel (bits per pixel) determines the number of 
possible brightness levels of the channel. More bits result in more possible 
combinations and therefore more levels.  Each bit has two possible values, so 
every bit added doubles the number of combinations.  For example, 4 bits give 
16 (24) combinations, 5 bits give 32 (25) combinations, and 8 bits give 256 (28) 
combinations. Humans usually represent these combinations of ones and 
zeroes as numbers starting from zero, therefore an 8 bit value would be 
represented by the numbers 0-255 (28-1), giving 256 unique values. 
For image processing, each channel of the merged image was converted to a 
separate greyscale 8 bit image. This meant that the image was composed of 
pixels ranging in value from 0-255, representing the colours black and white 
respectively, with the values in between representing different shades of grey.   
129 
 
3.2.2.2 Image sharpening by application of a high pass filter 
A high pass filter was applied to 8 bit images of DAPI stained nuclei and GFP 
labelled EPEC to increase their detail (figure 3.3). The filter involves centring a 
matrix of values termed a kernel on every pixel of the original image.  The value 
for the corresponding pixel in the new image was calculated from the pixels 
within the kernel.  The filter defines the mathematical function used on these 
pixels.  To illustrate how the process of image sharpening using a high pass 
filter works, DAPI staining has been used as an example (figure 3.2).  A section 
of the original image, highlighted in red (figure 3.2 b) was enlarged (figure 3.2 
c).  Zooming in further (figure 3.2 d), shows the kernel overlaying the values of 
the individual pixels in the original image. The 3x3 kernel (figure 3.2 a) was 
centred on one pixel of the original image (red square, figure 3.2 d). The 
corresponding pixel in the convoluted image (red pixel, figure 3.2 e) was then 
calculated. The pixel values covered by the kernel were multiplied by their 
corresponding kernel values, and then divided by the total of the kernel values 
to give the sharpened pixel values (figure 3.2 e). Figure 3.2 f shows the same 
area as figure 3.9 c after sharpening has occurred, while figure 3.2 g shows the 
final output. Figure 3.3 shows examples of images of cells and bacteria which 
have been sharpened.  
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Figure 3.2: Example of using a high pass filter to sharpen DAPI staining. (a)  3x3 
kernel used in filter. (b) Original image used to demonstrate DAPI sharpening using the 3x3 
kernel (a). The red square (b) is enlarged to show the pixels (c). (d) Pixel values of the 
original image. The pixel values in the convoluted image (e) highlighted in red and green 
are calculated as described. (e) Recalculated pixel values in convoluted image. (f)
Corresponding pixels to (c) post processing. (g) Final output image processed by the high 
pass filter.  
 
a 
b                                                                        c 
131 
 
Figure 3.2: Example of using a high pass filter to sharpen DAPI staining - continued 
d                                                             
 
To calculate the red pixel in the 
processed image, the 3x3 kernel (a) is 
figuratively overlaid on the image.  
The pixel values are then multiplied 
by the corresponding kernel values, 
summed and divided by the total of 
the kernel values i.e.: 
 
((110 * -1) + (113 * -1) + (113 * -1) + 
(107 * -1) + (110 * 9) + (110 * -1) + 
(104 * -1) + (107 * -1) + (110 * -1)) / 1 
= 116 
 
Similarly for the green pixel: 
 
((131 * -1) + (137 * -1) + (146 * -1) + 
(128 * -1) + (134 * 9) + (140 * -1) + 
(125 * -1) + (131 * -1) + (137 * -1)) / 1 
= 131 
e 
f                                                                        g 
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Figure 3.3: Image processing prior to EPEC (E69) adherence quantification. Raw data 
(a-c). (a) Nuclei of cells (DAPI staining in blue). (b) EPEC (green). (c) Merged images.  The 
blue and green channels were converted to 8 bit greyscale images (d, e). The 3x3 pixel 
kernel (figure 3.2 a) was applied to images (d) and (e) to produce sharpened images (f)
and (g). The greyscale images were converted back to RGB images (h, i), and the 
processed images were merged (j). Image magnification 40x. Bars 20µm. 
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3.2.2.3 Phalloidin staining image processing 
A median filter using a 50x50 kernel was first applied to the original image to 
smooth it (figure 3.4 e). Each individual pixel value in the image was replaced 
by the median of the pixels within the kernel.  Background noise was then 
removed from the original phalloidin image, by subtracting the pixel values of 
the median filtered image from the pixel values of the original image (figure 3.4 
f). Finally, the detailed actin staining was sharpened and enhanced in the 
resulting subtracted image, by application of a high pass filter using the 3x3 
kernel in figure 3.2 a (figure 3. g).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Image processing prior to actin pedestal formation quantification. Raw 
data (a-c). (a) Nuclei of cells (DAPI staining in blue). (b) Actin pedestals (phalloidin 
staining in red). (c) Merged images. Actin staining image processing (d-g). Image (b) was 
converted to an 8 bit greyscale image (d). A median filter of 50x50 pixels was applied to 
image (d) to produce the smoothed image (e). Image (e) was subsequently subtracted 
from image (d) to produce image (f).  The 3x3 kernel (figure 3.2 a) was then applied to 
image (f) to produce the sharpened image (g). The greyscale image was converted back 
to an RGB image (i). DAPI stained nuclei were processed analogous to figure 3.3. 
Processed DAPI (h) and phalloidin (i) images were merged (j). Image magnification 40x. 
Bars 20µm.  
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Merge (unprocessed) 
Phalloidin Median filter Subtract 
a b c 
d e f g 
Sharpen 
h i j 
DAPI (processed) Phalloidin 
(processed) 
Merge (processed) 
134 
 
3.2.2.4 Quantifying EPEC E69 adherence 
Once images had been processed by application of convolution filters to 
sharpen their detail and remove background noise, the feasibility of using the 
image processing software (MetaMorph) to quantify infection was investigated.  
In order to quantify bacterial adherence to cells, the aim was to use the software 
to count the number of infected cells within a population of 50 cells. This was 
initially investigated in a population of cells which had been infected with the 
prototype WT EPEC strain, E69. Infected cells were defined as those which 
were positive for adhering bacteria, and uninfected cells as those that were 
negative for adhering bacteria. Cells and bacteria included in the analysis were 
identified by DAPI and GFP staining respectively. Those included in the 
analysis were selected according to their size. The minimum and maximum 
length of cells and bacteria was measured and set as the limit for what was to 
be included in the subsequent analysis. This was necessary as it increased the 
likelihood that the software would accurately identify staining corresponding to 
cells and bacteria, and omit any staining that was an artefact in the image.  A 
threshold was also applied to the images so that only pixels with a value greater 
than the background were included in the analysis, which again helped ensure 
that cells and bacteria were accurately selected, and any non-specific 
background staining was not. 
The ‘Cell Scoring’ tool was used to count the number of infected cells in the 
population of cells (figure 3.5). The first requirement was to ensure that the cells 
and bacteria had been accurately selected for inclusion in the analysis. Cells 
and bacteria which have been selected for inclusion are displayed by 
MetaMorph as red and green respectively (figure 3.5 d, e). MetaMorph displays 
the ‘Cell Scoring’ analysis results as green cells which are positive for adhering 
bacteria and red cells which are negative for adhering bacteria (figure 3.5 f). 
A requirement for using MetaMorph as an automated counter was that it 
produces a maximum error of 10%. To validate the results generated by 
MetaMorph to quantify EPEC adherence to cells, the percentage error between 
the results from MetaMorph and results obtained by manual counting was 
calculated. A population of 50 cells was analysed across 3 independent 
experiments. A population size of 50 was selected as this provided a large 
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enough number of cells for comparison between the two methods, whilst not 
sampling too many cells, and thus avoiding the introduction of human error.  
Bacterial adherence to cells was compared in a population of cells infected with 
WT EPEC and an EPEC mutant, ∆escN. EPEC ∆escN is deficient in type III 
secretion and unable to deliver effectors into the host cell. Manual counting 
identified 60% of cells infected with WT EPEC and 25% of cells infected with 
EPEC ∆escN as positive for adhering bacteria (figure 3.5 g). On the other hand, 
MetaMorph identified 55% of cells infected with WT EPEC and 22% of cells 
infected with EPEC ∆escN as positive for adhering bacteria (figure 3.5 g). The 
increased adherence to cells exhibited by WT EPEC was significant, and arose 
because EPEC ∆escN was unable to inject effectors into the cells, and 
consequently could not adhere intimately to them. Percentage errors of 9% for 
WT EPEC and 10% for EPEC ∆escN were calculated between the results 
obtained by the two methods.  This meant that there was a concordance of 
approximately 90%, and no statistically significant differences between the two 
methods were calculated (figure 3.5 g), demonstrating that MetaMorph could be 
used as an automated counter to quantify adherence to cells.  
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  Figure 3.5:  Quantifying EPEC (E69) adherence by immunofluorescence in HeLa 
cells. (a) Nuclei of cells (DAPI staining in blue). (b) EPEC (green). (c). Merged images. 
Cells and bacteria are selected for analysis based on length and pixel intensity, and those 
included in the analysis are shown in red (d) and green (e) respectively. (f) Selection 
results where cells positive and negative for bacteria are shown in green and red 
respectively. Magnification 40x. Bars 20µm. (g) Results obtained by manual counting and 
MetaMorph for the percentage of cells positive for adhering bacteria (numbers on plot). 
Data represent mean ± the SEM; n=3 Comparison was carried out by using a two-tailed 
unpaired t test where a significantly greater percentage of cells positive for WT EPEC 
compared to EPEC ∆escN was observed (* represents p<5x10-2). No significant 
difference was observed between the results generated by the two methods.   
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3.2.2.5 Quantifying EPEC JPN15 adherence 
One of the limitations of simply quantifying the percentage of cells which are 
positive or negative for adhering bacteria is that it may not give an accurate 
indication of the level of infection. EPEC E69 harbours the EPEC adherence 
factor (EAF) plasmid, which encodes bundle forming pili (BFP), and the bacteria 
undergo localised adherence to cells. BFP are proteinaceous fibrillar organelles 
which extend out of the surface of the bacterium, facilitating the adhesion of the 
bacterium to the host cell, and the recruitment of additional bacteria into micro-
colonies on the cell143,178. Multiple bacteria adhere making it difficult to 
determine the actual number of adhering bacteria per cell. This was dealt with 
by infecting cells with EPEC JPN15. EPEC JPN15 is missing the EAF plasmid 
and does not undergo localised adherence to cells, meaning that individual 
bacteria can be seen adhering per cell. The aim, therefore, was to use 
MetaMorph not only to quantify the percentage of cells positive for adhering 
bacteria, but also to count the number of individual bacteria adhering per cell.  
For this the ‘Granularity’ tool of MetaMorph was used. Similarly to quantifying 
EPEC E69 adherence, cells and bacteria were identified by DAPI and GFP 
respectively, and were selected based on their size and pixel intensity. 
MetaMorph displays cells and bacteria which are included in the analysis as 
green nuclei and white granules respectively (figure 3.6 d). In a population of 50 
cells, manual counting and MetaMorph identified 47% and 50% of cells as 
positive for adhering WT EPEC JPN15, while manual counting and MetaMorph 
identified 26% and 24% of cells as positive for adhering EPEC ∆escN JPN15 
(figure 3.6 e). The difference in adherence between WT EPEC and EPEC 
∆escN was statistically significant and arose because EPEC ∆escN was unable 
to adhere intimately to cells. When the results obtained by MetaMorph were 
validated, concordances of 94% for WT EPEC JPN15 and 92% for EPEC 
∆escN JPN15, and no statistically significant differences between the two 
methods were calculated. This confirmed that MetaMorph could also be used to 
reliably quantify EPEC JPN15 adherence.  
 
  
138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2.6 Quantifying EPEC E69 actin pedestal formation by 
immunofluorescence 
The ‘Granularity’ tool was used to quantify the percentage of cells positive for 
actin pedestal formation (figure 3.7). Cells and actin to be included in the 
analysis were identified by DAPI and phalloidin staining respectively, and were 
also selected based on their size and pixel intensity. As EPEC ∆escN is 
deficient in type III secretion, it is unable to induce actin pedestal formation. One 
of the challenges of using MetaMorph to quantify pedestal formation 
was to ensure that MetaMorph could discriminate between staining of actin 
pedestals and background cellular actin staining. This was tested by using 
MetaMorph to analyse cells that had been infected with both WT EPEC E69 
and EPEC ∆escN E69 (figure 3.7).  
Figure 3.6: Quantifying EPEC JPN15 adherence by immunofluorescence in HeLa 
cells. (a) Nuclei of cells (DAPI staining in blue). (b) EPEC (green). (c)  Merged images. 
Cells and bacteria are selected for analysis based on length and pixel intensity. Nuclei 
included in the analysis are shown in green, whilst bacteria are shown in white (d). 
Magnification 40x. Bars 20µm. (e) Results obtained by manual counting and MetaMorph 
for the percentage of cells positive for adhering bacteria (numbers on plot). Data represent 
mean ± the SEM; n=3. Comparison was carried out by using a two-tailed unpaired t test 
where a significantly greater percentage of cells positive for adhering bacteria was 
observed for WT EPEC compared to EPEC ∆escN infection (***represents p<5x10-4). No 
significant difference was observed between the results generated by the two methods.   
 
a b c 
DAPI EPEC Merge MetaMorph 
d 
e 
139 
 
Of a population of 50 cells that had been infected with WT EPEC, manual 
counting and MetaMorph identified 29% and 32% respectively of cells that were 
positive for actin pedestal formation (figure 3.7 i). MetaMorph quantified 
approximately 4% of cells infected with EPEC ∆escN as positive for actin 
pedestals (figure 3.7 i). These were false positive results and were counted 
because MetaMorph misidentified some background actin staining as actin 
pedestals. Using MetaMorph to quantify the percentage of cells positive for 
actin staining during WT EPEC and EPEC ∆escN infection, revealed a 
significantly greater percentage of cells positive for actin staining during WT 
EPEC infection (figure 3.7 i). When the results obtained by MetaMorph were 
validated, concordances of 94% and 98% for cells infected with WT EPEC and 
EPEC ∆escN respectively, and no statistically significant differences between 
the two methods were calculated. This confirmed that MetaMorph could also 
quantify EPEC infection by actin pedestal formation. 
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3.2.3 Quantifying EPEC E69 adherence by flow cytometry 
Quantifying bacterial adherence by flow cytometry (figure 3.8) was investigated 
as an additional method by which EPEC E69 infection could be quantified in 
HeLa cells infected with WT EPEC E69 and EPEC ∆escN E69 which had been 
transformed with pGFP expression plasmids. An example of the gating used to 
select cells included in the analysis is shown in figure 3.8 a. Cells included in 
the analysis were selected by forward versus side scatter, which selects cells 
based on their size and granularity respectively. Cells were further gated for 
GFP expression into GFP negative and positive populations. An uninfected 
Figure 3.7: Quantifying actin pedestal formation during WT EPEC and EPEC ∆escN 
E69 infection by immunofluorescence in HeLa cells. (a, e) Nuclei of cells (DAPI 
staining in blue). (b, f) Actin (phalloidin staining in red) (c, g) Merged images. Cells and 
actin are selected for analysis based on length and pixel intensity. Nuclei included in the 
analysis are shown in green, whilst actin is shown in white (d, h). Magnification 40x. Bars 
20µm. (i) Results obtained by manual counting and MetaMorph for the percentage of cells 
positive for actin staining (numbers on plot). Data represent mean ± the SEM; n=3. 
Comparison was carried out by using a two-tailed unpaired t test where a significantly 
greater percentage of cells positive for actin staining was observed for WT EPEC 
compared to EPEC ∆escN infection (*** represents p<5x10-4). No significant difference 
was observed between the results generated by the two methods.   
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population of cells provided a negative control to establish where to set the gate 
to discriminate between GFP negative and positive populations for infected 
cells.  
The percentages of GFP negative and positive cells were determined for cells 
infected with WT EPEC and EPEC ∆escN (figure 3.8 b). Within the population 
of cells, 84.5% and 18.6% were GFP positive for WT EPEC and EPEC ∆escN 
infection. This difference was statistically significant. The mean fluorescent 
intensities (MFI) of the GFP negative and GFP positive populations were also 
analysed (figure 3.8 c). The MFIs of GFP negative cells were 445 and 361 for 
WT EPEC and EPEC ∆escN infections, while the MFIs of GFP positive cells 
were 25731 and 2998 for WT EPEC and EPEC ∆escN infections. This 
confirmed that there was increased fluorescence in the GFP positive population. 
To compare the MFI shift for cells infected with WT EPEC and EPEC ∆escN, 
the MFI of the GFP negative population was subtracted from the MFI of the 
GFP positive population (figure 3.8 d). The MFI shifts calculated were 26685 
and 2637.5 for WT EPEC and EPEC ∆escN. This difference was also 
statistically significant. A greater MFI shift suggests increased GFP expression 
by a cell population. Taken together, the flow cytometry results demonstrate 
increased GFP expression by cells infected with WT EPEC compared to EPEC 
∆escN, suggesting that adherence to cells by WT EPEC was greater than 
EPEC ∆escN.  
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Figure 3.8: Quantifying EPEC E69 adherence by flow cytometry in HeLa cells. (a) 
Example of the gating used to select cells included in the analysis. Cells were selected by 
forward (FSC-A) versus side scatter (SSC-A), and then further gated into GFP (FITC-A) 
negative and positive populations. The percentage of cells within the GFP negative and 
positive populations (b), the mean fluorescent intensities (MFIs) of the GFP negative and 
positive populations (c), and the MFI shift between the GFP negative and positive 
populations (d) were quantified, and are represented by the numbers on the plot. Data 
represent mean ± the SEM; n=2. Unpaired two-tailed t tests revealed a significantly 
greater percentage of GFP positive cells for cells infected with WT EPEC compared to 
EPEC ∆escN (b), and a significantly increased MFI shift in GFP expression for cells 
infected with WT EPEC compared to EPEC ∆escN (d) (* and ** represents p<5x10-2 and 
p<5x10-3 respectively).   
 
a 
FSC-A 
SS
C-
A 
Ce
lls
 
FITC-A 
b 
d 
c 
143 
 
3.3 Discussion 
The results described in this chapter have demonstrated that it is possible to 
use an automated counter to quantify EPEC infection. For immunofluorescence 
quantification, there was a minimum concordance of approximately 90%, and 
no statistically significant difference between the results obtained by manual 
counting and those obtained by image processing software, for both bacterial 
adherence to cells and actin pedestal formation. MetaMorph could discriminate, 
to a statistically significant degree, between actin pedestals and background 
actin staining. It is therefore possible to use MetaMorph to batch process large 
numbers of images and accurately quantify infection, without the introduction of 
human error or bias. A much larger sample of cells can be analysed by 
MetaMorph than by manual counting, which will improve the reliability of the 
results generated.  By immunofluorescence it was possible to quantify both the 
percentage of cells which were positive for adhering bacteria, and the number 
of bacteria that adhered per cell, meaning that the infection level of individual 
cells could be established. 
In published studies, actin pedestal formation has traditionally been the more 
widely used method to quantify EPEC infection. Intimate adherence to intestinal 
epithelial cells has been thought to be mediated by actin pedestals resulting 
from bacterial induced actin polymerisation. More recently, however, in vitro 
observations have demonstrated that some strains have failed to induce actin 
polymerisation, yet  were still able to form attaching and effacing lesions on 
cells294.  In light of this, in this study EPEC infection will be quantified by 
bacterial adherence to cells. This will aim to ensure that all infected cells are 
identified; quantifying actin pedestals alone could possibly miss some infected 
cells, if any such cells had adhering bacteria and no visible pedestals.   
Flow cytometry was explored as a second method by which EPEC adherence 
could be quantified. The flow cytometry results depicted in figure 3.8 support the 
immunofluorescence results in figure 3.5, where adherence to cells was 
significantly greater by WT EPEC than EPEC ∆escN. One of the limitations of 
using flow cytometry, however, is that infection can only be quantified as the 
percentage of cells within a population that are positive for adhering bacteria. It 
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is not possible to count the number of bacteria which adhere per cell, and so 
provides no information on the infection level of individual cells.  
In this study EPEC infection has therefore been quantified by 
immunofluorescence rather than flow cytometry. The methods described in 
section 3.2 have been used to quantify how EPEC infection is affected by 
changes in Cx26 and ADAM17 expression. These results are presented in 
chapters 4 and 5.  
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Effect of Cx26 Expression on 
Gastrointestinal  
Bacterial Infection  
Chapter  4 – Effect of C x26 Expressio n on Gastro intestinal B act erial  Infection   
 
 
  
146 
 
4.1 Introduction 
Recessive mutations in Cx26 cause non syndromic hearing loss (NSHL).  As 
described in section 1.1.16, there are specific mutations which cause the 
majority of Cx26 NSHL in certain geographic locations and ethnic groups. Such 
mutations include c.35delG in European populations114,115, c.235delG in 
Japanese populations116 and p.143W in African95 populations.  It has been 
hypothesised that these mutations may confer a heterozygote advantage to 
carriers45,118-120. For example, heterozygote carriers of the p.R143W120 and 
c.35delG118 mutations have a significantly thicker epidermis than WT Cx26 
homozygotes, which could provide improved protection against bacterial 
infection. Furthermore, HeLa cells expressing p.R143W are significantly less 
susceptible to cellular invasion by S. flexneri than HeLa cells expressing WT 
Cx2645, suggesting that being a carrier of p.R143W may result in decreased 
susceptibility to gastrointestinal bacterial infection.  
4.1.1 Aims 
• Consider whether a loss of functional Cx26 expression improves 
resistance to infection with gastrointestinal bacteria  
• Investigate the effect of expressing Cx26 NSHL mutations in transfected 
HeLa cells on bacterial infection  
• Compare EPEC adherence (method 2.4.2) and S. flexneri invasion 
(method 2.4.3), as a positive control, in HeLa cells expressing WT-Cx26 
and p.R143W-Cx26 
• Confirm the sequences of plasmid constructs (method: 2.2.5) and their 
localisation in transfected HeLa cells (methods 2.1.4 and 2.6) prior to 
performing infection studies 
• Investigate how EPEC adherence and S. flexneri invasion were affected 
by Cx26 siRNA treatment (method 2.1.5) in intestinal epithelial Caco-2 
and HT-29 cells 
• Confirm Cx26 expression by qRT-PCR (method 2.2.3.5) and 
immunofluorescence (method 2.6) in intestinal cells prior to performing 
infection studies  
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4.2 Results 
4.2.1 Cx26 expression in intestinal HT-29 and Caco-2 cells 
To validate models of the intestinal environment which could be used to study 
how enteric bacterial infection was affected by Cx26 expression, Cx26 mRNA 
and protein expression were analysed in intestinal HT-29 and Caco-2 cells by 
qRT-PCR and immunofluorescence. The cell lines are obtained from two 
different patients; HT-29 cells and Caco-2 cells are derived from well 
differentiated and moderately differentiated adenocarcinomas respectively. 
They provide two independent intestinal models, and therefore differences exist 
between the two cell lines. For example, Caco-2 cells spontaneously express 
differentiation markers and form polarised monolayers with microvilli and tight 
junctions upon reaching confluence286. HT-29 cells however, remain 
undifferentiated under normal culture conditions unless they are treated with 
drugs including colchicine, nocodazole and taxol287.  In this study, any 
differences in results obtained in HT-29 and Caco-2 cells could result from 
different characteristics, for example in terms of cell structure and gene 
expression between the two cell lines. Both cell lines expressed Cx26 mRNA, 
but expression was greater in HT-29 cells (figure 4.1). QRT-PCR revealed that 
Cx26 mRNA was detected at a lower cycle threshold number in HT-29 cells 
(green population) compared to Caco-2 cells (blue population, figure 4.1 b). 
When Cx26 mRNA expression was normalised to GAPDH, an expression ratio 
of 1:0.24 for HT-29 cells: Caco-2 cells was calculated (figure 4.1 c).   
 
 
 
 
 
 
 
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cx26 protein expression was analysed by immunofluorescence in Caco-2 and 
HT-29 cells. To confirm the specificity of any staining detected in intestinal cells, 
the antibody specificity was first investigated in HeLa cells (figure 4.2).  HeLa 
cells do not express endogenous Cx proteins, making them ideal for use in 
transfection studies. HeLa cells transfected with p-(WT)Cx26-EGFP and p-
(WT)Cx31-EGFP were stained with Cx26 antibody. Colocalisation could be 
detected between transfected GFP-tagged Cx26 protein and Cx26 antibody 
staining in p-(WT)Cx26-EGFP transfected HeLa cells (figure 4.2 a-h), 
confirming that the antibody specifically detected Cx26 protein. The antibody 
recognised GJ plaques composed of Cx26 between HeLa cells transfected with 
p-(WT)Cx26-EGFP (figure 3.2 e-h). Additionally, as staining HeLa cells 
Figure 4.1: Cx26 mRNA 
expression in intestinal cells by 
qRT-PCR. (a) GAPDH and (b) 
Cx26 mRNA levels in HT-29 (blue) 
and Caco-2 (green) cells. Note that 
Cx26 mRNA expression is greater 
in HT-29 cells as the green 
population of cells crosses the 
cycle threshold (CT) at an earlier 
cycle number (b).  (c) Cx26 mRNA 
expression was quantified relative 
to GAPDH in HT-29 and Caco-2 
cells (numbers on plot). Data 
represent mean ∆∆CT value ± the 
SEM; n=3.  
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transfected with p-(WT)Cx31-EGFP did not result in colocalisation between 
transfected GFP-tagged Cx31 protein and the Cx26 antibody, this showed that 
the antibody did not cross react with Cx31. Cx26 protein expression was 
detected in HT-29 (figure 4.3 a-c) and Caco-2 cells (figure 4.3 g-i), and the 
antibody could specifically detect GJ plaques composed of Cx26. Furthermore, 
as published previously67, Cx26 protein could be detected at low levels in the 
basal layer of the epidermis of normal skin (figure 4.3 m-o). Taken together, 
these results have shown that both HT-29 and Caco-2 cells express Cx26 and 
form Cx26 GJ dependent plaques. These two lines can thus be used as models 
of the intestinal environment to study how gastrointestinal infection is affected 
by Cx26 expression. 
 
Figure 4.2: Specificity of Cx26 antibody in transfected HeLa cells. (a-h) HeLa cells 
transfected with (WT)Cx26-EGFP. (i-l) HeLa cells transfected with (WT)Cx31-EGFP).  (a, 
e, i) Nuclei of cells (DAPI staining in blue). (b, f, j) Transfected protein (green).  (c, g, k)  
Cx26 antibody staining (red). (d, h, l) Merged images.  Note the colocalisation of Cx26 
antibody staining with Cx26 transfeced protein (d, h) compared to the absence of any 
colocalisation of Cx26 antibody with Cx31 transfection protein (l,) confirming that the Cx26 
antibody recognised Cx26 protein, but did not cross react with Cx31 protein. Note the 
staining of Cx26 aggregates characteristic of GJ plaques in the extracellular space 
between (WT)Cx26-EGFP transfected HeLa cells (white arrows in g, h). Image 
magnification 40x. Bars 20µm. 
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Figure 4.3: Cx26 protein expression in intestinal cells and the epidermis. (a-c) HT-29 
cells. (g-i) Caco-2 cells. (m-o) Frozen skin sections. (a, d, g, j, m, p) Nuclei of cells (DAPI 
staining in blue). (b, h, n),  Cx26 (red). (d, k, o) Negative control: unstained cells and tissue 
section. (c, f, i, l, o, r) Merged images. Note the localisation of Cx26 aggregates 
characteristic of GJ plaques in the extracellular space between cells (white arrows in b, c, h, 
i), and Cx26 expression restriction to the basal epidermal layer of frozen skin sections (n, 
o).  Image magnification 40x. Bars 20µm. 
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4.2.2 p-(WT)Cx26-mCherry, p-(R143W)Cx26-mCherry and pmCherry 
constructs 
Infection studies were performed using EPEC which had been transformed with 
a pGFP expression plasmid. To quantify infection in transfected HeLa cells, 
Cx26 expressing constructs had to be labelled with a different colour reporter 
tag. Therefore, the constructs used in these studies were tagged with mCherry 
protein. A p-(WT)Cx26-mCherry construct was obtained from Dr P. Martin. As 
an empty vector plasmid construct was not available, a restriction digest was 
performed in this study to remove the Cx26 insert from the p-(WT)Cx26-
mCherry construct. This created a negative control pmCherry construct, which 
was used for mock transfecting cells. To investigate the effect of Cx26 NSHL 
mutations on bacterial infections, site directed mutagenesis was performed to 
introduce the p.143W mutation into the p-(WT)Cx26-mCherry construct. Prior to 
performing infection studies, the sequences of pmCherry and p-(R143W)Cx26-
mCherry, and the localisation of p-(WT)Cx26-mCherry, p-(R143W)Cx26-
mCherry and pmCherry  were verified in transfected in HeLa cells. 
4.2.2.1 Sequencing of pmCherry and p-(R143W)Cx26-mCherry constructs 
Analysis of the pmCherry construct sequence confirmed removal of the Cx26 
insert and ligation of the EcoRI and BamHI restriction sites (black rectangle, 
figure 4.4 a).  This was also shown by alignment with the known pmCherry-N1 
vector sequence (pink rectangle, figure 4.4 b). The sequences (black arrows, 
figure 4.4 c, d) and the alignment between the p-(WT)Cx26-mCherry and p-
(R143W)Cx26-mCherry constructs sequences (black arrow, figure 4.4 e), 
revealed a thymine for cytosine substitution in the (R143W)Cx26-mCherry 
construct, confirming introduction of the p.R143W mutation.  
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Figure 4.4: Sequencing of pmCherry and p-(R143W)Cx26-mCherry constructs. (a) 
pmCherry sequence confirming removal of Cx26 insert and ligation of EcoRI and BamHI 
restriction sites (black rectangle). (b) Sequence alignment between the known pmCherry-N1 
vector sequence (top line) and the pmCherry construct (bottom line). EcoRI (pink rectangle) 
and BamHI (green rectangle) restriction sites. (c) p-(WT)Cx26-mCherry, (d) p-
(R143W)Cx26-mCherry sequences. (e) Sequence alignment between p-(WT)Cx26-mCherry 
(top line) and p-(R143W)Cx26-mCherry (bottom line). Note the thymine for cytosine 
substitution (black arrows), confirming introduction of the p.R143W mutation by site directed 
mutagenesis. 
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4.2.2.2 Localisation of constructs in transfected HeLa cells 
The localisation of the three constructs in transfected HeLa cells was visualised 
by epifluorescence microscopy (figure 4.5). Protein aggregates were observed 
in the extracellular space between cells transfected with (WT)Cx26-mCherry 
(white arrows, figure 4.5 b, c), which are indicative of GJ plaques.  Such protein 
aggregates were absent in cells transfected with (R143W)Cx26-mCherry, and in 
contrast a perinuclear localisation of Cx26 protein was visualised (figure 4.5 d-
f). Vector only transfected cells exhibited diffuse cytoplasmic staining of 
mCherry protein (figure 4.5 g-i). 
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4.2.3 Effect of Cx26 expression on gastrointestinal bacterial infection 
4.2.3.1 S. flexneri invasion and EPEC adherence in p-(R143W)Cx26-
mCherry expressing HeLa cells 
To determine how Cx26 expression affected gastrointestinal bacterial infection, 
S. flexneri and EPEC infection were first analysed in HeLa cells transfected with 
Figure 4.5: Localisation of plasmid constructs in transfected HeLa cells. (a-c) 
(WT)Cx26-mCherry. (d-f) (R143W)Cx26-mCherry. (g-i) mCherry (vector only). (a, d, g) 
Nuclei of cells (DAPI staining in blue).  (b, e, h) Transfected protein (red). (c, f, I) Merged 
images. Note the localisation of (WT)Cx26 aggregates characteristic of gap junction plaques 
in the extracellular space between cells (white arrows, in b, c), compared with perinuclear 
staining observed with (R143W)Cx26 (e, f), and the cytoplasmic staining observed in vector 
only transfected cells (h, i). Image magnification 40x. Bars 40µm. 
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p-(WT)Cx26-mCherry and p-(R143W)Cx26-mCherry, and in HeLa cells mock 
transfected with pmCherry. S. flexneri invasion efficiencies were 5.74%, 4.07% 
and 3.69% in HeLa cells transfected with p-(WT)Cx26-mCherry, p-
(R143W)Cx26-mCherry and pmCherry respectively (figure 4.6). This work 
initially confirmed previous findings45,141,200; S. flexneri invasion was significantly  
increased in HeLa cells transfected with p-(WT)Cx26-mCherry compared to 
mock transfected (mCherry) HeLa cells, and HeLa cells transfected with p-
(R143W)Cx26-mCherry (figure 4.6). Although the difference between 5.74% 
and 4.07% is small, it is possible that this has significant implications for 
infection level, since very small numbers of bacteria are sufficient to establish 
disease127.  
 
 
 
 
 
 
 
To investigate how Cx26 expression affects WT EPEC (E69) infection, the total 
percentage of transfected cells positive for adhering bacteria was quantified 
using DAPI stained bacterial DNA (figure 4.7). 83% and 58% of HeLa cells 
expressing p-(WT)Cx26-mCherry and pmCherry respectively were positive for 
adhering EPEC (figure 4.7 g). Although bacterial adherence was increased by 
the expression of p-(WT)Cx26-mCherry, the difference was not significant.  
It was hypothesised that any effect which WT Cx26 had on EPEC infection level 
may be more subtle, for example by altering the number of bacteria which 
adhered per transfected cell. This may not have been observed by quantifying 
the total percentage of transfected cells positive for adhering bacteria.  This 
experiment was therefore repeated using EPEC JPN15, which had been 
transformed with a pGFP expression plasmid. Unlike EPEC E69, EPEC JPN15 
does not form microcolonies on cells, so fewer EPEC JPN15 (figure 4.8) 
Figure 4.6: S. flexneri 
invasion efficiency in 
transfected HeLa cells. 
Data represent mean 
percentage invasion 
efficiency (numbers on plot) 
± the SEM; n=3. Comparison 
was carried out by using 
unpaired, two-tailed t-tests, 
where significant differences 
were observed between 
(WT)Cx26 and 
(R143W)Cx26, and 
(WT)Cx26 and mCherry (* 
represents p<5x10-2). 
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adhered per cell compared to EPEC E69 (figure 4.7). Subsequently the number 
of adhering EPEC JPN15 per cell was also determined (figure 4.8).  HeLa cells 
transfected with p-(R143W)Cx26-mCherry were included to consider how EPEC 
adherence was affected by a non-functional deafness associated Cx26 
mutation. 80.00%, 34.00% and 42.67% of HeLa cells expressing p-(WT)Cx26-
mCherry, p-(R143W)Cx26-mCherry and pmCherry respectively were positive 
for adhering EPEC JPN15. EPEC JPN15 adherence was significantly increased 
by the expression of p-(WT)Cx26-mCherry compared to pmCherry or p-
(R143W)Cx26-mCherry (figure 4.8 m). There was no significant difference in 
EPEC adherence to cells expressing p-(R143W)Cx26-mCherry compared to 
pmCherry (figure 4.8 m). Furthermore, the number of bacteria which adhered 
per transfected cell was greatest when p-(WT)Cx26-mCherry was expressed 
(figure 4.8 n). This suggested that Cx26 expression could affect the 
susceptibility of individual cells to EPEC infection.  
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Figure 4.7: Wild type EPEC (E69) adherence to transfected HeLa cells. Adherence 
was quantified by DAPI stained bacterial DNA by manual couting. (a, d) Nuclei of cells 
and bacterial DNA (white arrows) are stained with DAPI (blue). (b, e) Transfected protein 
(red). (c, f), Merged images. Image magnification 40x. Bars 40µm. (g) Total percentage of 
transfected cells positive for adhering EPEC (numbers on plot). Data represent mean ± 
the SEM; n=3. Comparison was carried out by using an unpaired, two-tailed t-test where 
no significant difference was observed between (WT)Cx26 and mCherry.  
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Figure 4.8: Wild type EPEC (JPN15) adherence to transfected HeLa cells. Adherence 
was quantified by pGFP expression by manual counting. (a, e, i) Nuclei of cells are 
stained with DAPI (blue). (b, f, j) Transfected protein (red). (c, g, k) EPEC (green). (d, h, l) 
Merged images. Image magnification 40x. Bars 40µm. (m) Total percentage of transfected 
cells positive for adhering EPEC (numbers on plot). Data represent mean ± the SEM; n=3. 
Comparison was carried out by using unpaired, two-tailed t-tests; significant differences 
were observed between (WT)Cx26 and mCherry, and (WT)Cx26 and (R143W)Cx26 (** 
and *** represents p<5x10-3 and p<5x10-4 respectively). No significant difference was 
observed between (R143W)Cx26 and mCherry. (n) Number of bacteria that adhered per 
transfected cell. 
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4.2.3.2 EPEC adherence and S. flexneri invasion in intestinal HT-29 and 
Caco-2 cell lines treated with Cx26 siRNA  
Given that EPEC adherence and S. flexneri invasion were enhanced by a gain 
of functional Cx26 expression in transfected HeLa cells, the effect of Cx26 
expression on enteric bacterial infection level was next considered in intestinal 
HT-29 and Caco-2 cells.  Unlike HeLa cells, both of these intestinal cell lines 
express endogenous Cx26, and thus Cx26 expression was manipulated using 
Cx26 specific siRNA. The use of Cx26 siRNA prevents the production of Cx26 
protein, making it possible to replicate in vitro many of the autosomal recessive 
Cx26 NSHL mutations which are termed ‘loss of 
function’, as they produce severely truncated non-functional proteins51.  
Following Cx26 siRNA treatment, Cx26 mRNA expression was quantified 
relative to GAPDH by qRT-PCR. Cx26 mRNA levels were 46.26% and 32.23% 
in HT-29 and Caco-2 cells respectively (figure 4.9 a). Heterozygous carriers of 
Cx26 NSHL mutations have one normal copy and one mutated copy of Cx26, 
so only approximately 50% of the Cx26 protein which they produce is functional.  
In this study therefore, although there was not a total inhibition in production of 
Cx26 mRNA following knock down, the levels observed were more 
representative of carriers of Cx26 NSHL mutations.  
The percentage EPEC adhesion efficiencies were significantly reduced from 
21.46% to 15.68% and from 14.22% to 7.26% in Caco-2 and HT-29 cells 
respectively following Cx26 siRNA treatment (figure 4.9 b). The invasion 
efficiencies of S. flexneri were not significantly different in HT-29 cells treated 
with non-targeting pool (NTP) siRNA (2.64%) and Cx26 siRNA (2.23%) (figure 
4.9 c). Finally, treating cells with Cx26 siRNA significantly reduced S. flexneri 
invasion from 3.08% to 2.01% in Caco-2 cells (figure 4.9 c).  
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Figure 4.9 S. flexneri 
invasion and EPEC 
adherence in intestinal 
cells. (a) Cx26 mRNA 
expression was quantified 
relative to GAPDH by qRT-
PCR in Caco-2 and HT-29 
cells treated with non-
targeting pool (NTP) siRNA 
and Cx26 siRNA (numbers 
on plot). Data represent 
mean ∆∆CT value ± the 
SEM; n=4. (b) EPEC 
adhesion efficiencies and 
(c) S. flexneri invasion 
efficiencies were quantified 
in Caco-2 cells and HT-29 
cells which had been 
treated with NTP siRNA and 
Cx26 siRNA (numbers on 
plots). Data represent mean 
± SEM; n=3. Comparisons 
were carried out by using 
unpaired, two-tailed t-tests. 
A significant reduction in 
EPEC adhesion efficiency 
was observed in both Caco-
2 and HT-29 cells. Although 
a significant reduction in S. 
flexneri invasion efficiency 
was observed in Caco-2 
cells, no significant 
difference was observed in 
HT-29 cells (* represents 
p<5x10-2). 
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4.3 Discussion 
The results in this study provide evidence to support the hypothesis that Cx26 
NSHL mutations, for example p.R143W, may be selected for because they 
confer a protective advantage to the carrier. While S. flexneri invasion is 
enhanced in HeLa cells transfected with WT Cx26, invasion is significantly 
reduced in mock transfected HeLa cells, and HeLa cells expressing the 
p.R143W mutation, as has been previously reported45,141,200. EPEC adherence 
is also significantly increased in HeLa cells expressing WT Cx26 compared to 
mock transfected cells. A loss of functional Cx26 expression associated with the 
p.R143W mutation significantly reduced EPEC adherence to a level which was 
not significantly different to that exhibited by mock transfected cells. 
Furthermore, reducing endogenous Cx26 expression in intestinal cells by Cx26 
specific siRNA, replicated the effects of many Cx26 NSHL mutations, which 
truncate the Cx26 protein and compromise  its function in vitro51. This led to a 
significant reduction in the adhesion and invasion efficiencies of EPEC and S. 
flexneri.  One explanation to account for the selection of Cx26 NSHL mutations 
could therefore be that they provide carriers with improved protection against 
gastrointestinal pathogens including EPEC and S. flexneri. This may be most 
beneficial to carriers of Cx26 NSHL mutations in developing countries, where 
exposure to such pathogens is greater than in developed countries.  
This work could be extended in vitro to consider EPEC and S. flexneri infection 
levels in HeLa cells expressing other Cx26 NSHL mutations including c.35delG, 
c235delC and p.167delT, which are found at high carrier frequencies in 
European, Japanese and Ashkenazi Jewish populations respectively114,116,117. 
Results obtained from experiments performed in cell monolayers, may not 
accurately represent what happens in tissues in vivo, where multiple cell types 
are present. Organotypic cultures grown with Caco-2 or HT-29 cells provide a 
three-dimensional model in which the intestine can be studied in vitro, which 
may mimic what happens in vivo more accurately than cell monolayers. It would 
therefore be interesting to repeat the infection experiments in organotypic 
cultures, and determine whether the results obtained for cultures treated with 
NTP siRNA and Cx26 siRNA replicated the results obtained from cell 
monolayers.   
162 
 
A loss of functional Cx26 expression may result in the host being less 
susceptible to infection with gastrointestinal bacteria. Heterozygous carriers of 
the c.35delG118 and p.R143W120 alleles have a significantly thicker epithelium 
than WT Cx26 homozygotes. Furthermore, keratinocytes expressing the 
p.R143W mutation form a significantly thicker epidermis than keratinocytes 
expressing WT Cx26 in an in vitro organotypic co-culture skin model45. A thicker 
epidermal epithelium may act as a more robust barrier, and in turn, provide 
improved protection against infection. As similar protective properties of the skin 
also exist in the gut epithelium, it is plausible that heterozygous carriers of Cx26 
NSHL mutations have a thicker gut epithelium, and therefore may be better 
protected against infection with gastrointestinal pathogens. The effect of Cx26 
expression on the thickness of the gut epithelium should be investigated in 
future experiments. Any difference in epidermal thickness in organotypic 
cultures grown with Caco-2 or HT-29 cells treated with NTP siRNA and Cx26 
siRNA should be measured. Additionally, the epidermal thickness could be 
measured from gut biopsies taken from homozygotes and heterozygous carriers 
of a range of Cx26 NSHL mutations including p.R143W, c35delG, c235delC 
and p.167delT. 
Cx26 is expressed in the crypts of human colon enterocytes199. After wounding 
rat epidermis in vivo, Cx26 expression is upregulated at the wound site67.  Cx26 
upregulation has been linked to keratinocyte differentiation, proliferation and 
migration into the wound site2,68. Although organotypic cultures with 
keratinocytes expressing WT Cx26 and the p.R143W mutation do not display 
differences in cell proliferation, those expressing p.R143W undergo an 
extended terminal differentiation programme45. Performing scratch migration 
assays also revealed that keratinocytes expressing the p.R143W mutation 
migrate and close the scratch significantly quicker than keratinocytes 
expressing WT Cx2645. As similar protective properties exist between the gut 
and skin epithelium, potentially enterocyte proliferation, differentiation or 
migration could be affected by differential expression of Cx26. This could 
contribute to a thicker gut epithelium, and could also have implications for 
gastrointestinal infections which damage the intestinal epithelium, for example 
S. flexneri. S. flexneri infection is associated with a massive inflammatory 
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response, which in combination with ulceration and bleeding, leads to the 
destruction of the colonic epithelium.  
S. flexneri opens Cx26 hemichannels in transfected HeLa cells releasing ATP 
into the extracellular medium141,200. Prior to invasion, the bacteria are captured 
by filopodial extensions which retract in response to ATP, bringing the bacteria 
into contact with the cell body where invasion takes place141. S. flexneri invasion 
is reduced in HeLa cells expressing the p.143W mutation, and in intestinal cells 
by siRNA against Cx26. Approximately only 50% of the Cx26 protein produced 
by heterozygous carriers of Cx26 NSHL mutations, who have one WT and one 
mutated copy of Cx26, is functional. It is likely that some Cx26 expressed within 
their intestines is non-functional. Therefore, the number of Cx26 hemichannels 
which can be utilised by S. flexneri for invasion might potentially be reduced in 
heterozygous carriers compared to WT Cx26 homozygotes. This could possibly 
explain why they are less susceptible to infection with S. flexneri. Functional 
assays could be performed in future experiments to determine the degree to 
which intestinal hemichannel activity is affected by differential expression of 
Cx26. This could include measuring the level of release of molecules such as 
ATP into the extracellular medium from intestinal HT-29 and Caco-2 cells.  
The effect of Cx26 expression on gastrointestinal bacterial infection remains to 
be investigated in vivo. C. rodentium is used as an in vivo model of human 
EPEC infection201. Unpaired Cx43 hemichannels localise to the apical plasma 
membrane of mouse colonocytes where they facilitate water secretion into the 
intestinal lumen, which contributes to diarrhoea development during C. 
rodentium infection201. Cx43+/- mice that produce less functional Cx43 than WT 
mice, also produce less diarrhoea201, which supports the hypothesis that a loss 
of functional Cx protein reduces infection by enteric bacteria. An aim of future 
work therefore, could be to consider how diarrhoea production during C. 
rodentium infection is affected by changes in Cx26 expression. Although Cx26-/- 
mice are embryonically lethal50, diarrhoea production could be measured in 
Cx26+/- mice, or in mice expressing Cx26 NSHL mutations. Additionally, using 
Cre-lox technology to generate mice where Cx26 is conditionally knocked out in 
the colon could be utilised to investigate whether diarrhoea production is further 
reduced by a complete absence of Cx26. Cre lox technology involves 
tamoxifem inducible Cre recombinase being under the control of an intestinal 
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specific promoter, and the GJB2 gene being flanked by loxP sites. Tamoxifem 
administration activates Cre, leading to the excision of the loxP sites, which in 
turn results in a loss of Cx26 expression from the tissue.  
Cx43 expression has also been linked to Y. enterocolitica infection202. The 
bacteria induced tyrosine phosphorylation of Cx43 in transfected HeLa cells, 
which was thought to trigger hemichannel opening, in turn leading to their 
internalisation202. A reduction in Y. enterocolitica invasion was observed 
following treatment with a hemichannel blocker202, which further supports the 
hypothesis that loss of functional Cx expression reduces infection with 
gastrointestinal bacteria. Additionally, Cx43 has also been linked to Salmonella. 
Tumour cells display reduced levels of GJIC and interestingly, treating them 
with Salmonella stimulated dye transfer between cells295. This indicated the 
presence of functional GJs, which occurred concomitantly with increased Cx43 
expression295.  Combined administration of Salmonella and the chemotherapy 
agent cisplatin reduced tumour growth by 73%, whereas cisplatin alone did not 
significantly affect tumour growth295. While this discovery is promising for cancer 
therapy, it also provides another example of gastrointestinal bacteria modifying 
GJIC, and therefore could potentially have implications for the treatment of 
enteric bacterial infections. In future experiments this work could also be 
extended to consider how Cx26 expression affects infection with other enteric 
bacteria including Shigella, Yersinia, Salmonella, Listeria and Campylobacter in 
vivo. The production of diarrhoea could be measured in living mice. In addition, 
the disease burden could be measured by sacrificing the mouse and 
determining the number of bacteria that are recovered from the colon. It would 
be interesting to confirm whether reductions in diarrhoea production and 
disease burden correlate with a loss of functional Cx26 expression. Cx26 may 
represent a potential, new therapeutic target for gastrointestinal bacterial 
infection. Loss of functional expression of both Cx26 and Cx43 has been 
associated with reduced enteric bacterial infection. However, since Cx43 is the 
most widely expressed Cx protein17, targeting Cx43 may result in more adverse 
effects systemically than Cx26, and therefore of the two, Cx26  may  represent 
the more attractive target.  
During EPEC infection, the structure and function of tight junctions (TJ) and 
adherens junctions (AJ) is manipulated, which contributes to the production of 
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diarrhoea. Although a loss of functional Cx26 expression has been shown to 
reduce bacterial infection and result in a thicker epidermal barrier, other studies 
have also suggested that functional Cx26 has a role in maintaining the integrity 
of the epithelial barrier. Cx26 has been shown to colocalise with the TJ proteins 
occludin and ZO-1 in T84 colonic epithelial cells296, and the AJ proteins α-
catenin and E-cadherin in hepatocytes297. These interactions have been 
postulated to facilitate GJ, TJ and AJ formation. In a more recent study, 
chemically disrupting Caco-2 cell monolayers stably expressing Cx26 resulted 
in significantly decreased paracellular permeability and increased transepithelial 
resistance compared to mock transfected cells298. Expression of the TJ protein 
claudin 4 was also significantly increased in Caco-2 cells stably expressing 
Cx26298. The authors suggested that Cx26 mediated GJIC may therefore 
improve barrier maintenance in Caco-2 cells298. In future experiments it would 
be interesting to investigate whether differential expression of Cx26 affected the 
structure and function of the intestinal barrier during EPEC infection. 
Experiments could be carried out in intestinal HT-29 and Caco-2 cells in the 
presence and absence of Cx26 specific siRNA, and in HeLa cells transfected 
with various Cx26 NSHL mutants. Parameters measured could include the 
localisation of various TJ and AJ proteins, the transepithelial resistance and the 
paracellular permeability across the intestinal barrier. If these parameters were 
not significantly different in either uninfected or infected cells with differential 
expression of Cx26, the reduced infection associated with a loss of functional 
Cx26 would probably be unrelated to the maintenance of the intestinal barrier. If 
these parameters were significantly altered, any effect would probably be Cx26 
rather than EPEC dependent, since infection is reduced by a loss of functional 
Cx26 expression. The localisation of TJ and AJ proteins could also be 
visualised by two photon microscopy in mice with differential expression of 
Cx26 during C. rodentium infection.  
Although these results support others studies, which suggest that a loss of 
functional Cx expression could improve resistance to gastrointestinal infection, 
Cx expression has also been linked to the induction of immune responses. 
Infecting A431 cells (derived from a vulva epidermal carcinoma) with S. flexneri, 
leads to the activation of NF-ĸB and the MAP kinases JNK, p38 and ERK, and 
the production of IL-8 in both infected, and non-infected bystander cells157. IL-8 
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production by bystander cells is significantly reduced by siRNA against Cx43, or 
by treatment with the GJ blocker 18β-glycyrrhetinic acid157. This suggests that 
activation of proinflammatory signalling cascades is transferred from infected 
cells to uninfected neighbouring cells via GJs, in turn amplifying the host 
immune response during bacterial infection157. Shigella injects effectors 
including OspF and OspG, which dampen the host immune response129,160, 
during the later stages of infection. During the earlier stages of infection, 
however, Shigella induces a massive inflammatory response, of which IL-8 in 
particular plays an important role, because it stimulates neutrophil recruitment 
into the intestine. This damages the epithelial surface allowing more bacteria to 
cross the intestinal barrier, and gain access to the basolateral pole of epithelial 
cells where invasion takes place. Thus, propagation of the immune response 
via GJs could potentially be less beneficial to the host initially, when a strong 
inflammatory response helps the bacteria establish an infection. During the later 
stages of infection, when the bacteria try to suppress inflammation, a strong 
inflammatory response may be more beneficial to the host, and may contribute 
to the elimination of infection.  
Although Cx43 was linked to the induction of immune responses during S. 
flexneri infection in vitro, it would be interesting to determine if the immune 
response was affected by differential expression of either Cx26 or Cx43 during 
S. flexneri infection of mice in vivo. If mice were infected with bacteria labelled 
with a fluorescent reporter tag, two photon microscopy could be employed to 
determine whether activation of immune cascades was solely in infected cells, 
or whether it also propagated to uninfected cells. Immune signalling cascade 
activation could be determined by nuclear localisation of NF-ĸB and 
phosphorylation of the MAP kinases JNK, p38 and ERK. The transcription of 
inflammatory molecules could also be followed if their promoters controlled the 
expression of the fluorescent luciferase reporter gene299. Any effect of 
differential expression of Cx26 or Cx43 on immune cell recruitment into the 
intestine could also be followed. If propagation of the immune response via GJs 
occurred, the potential implications for the host in terms of infection level could 
be determined by sacrificing mice at different infection time points and 
quantifying the number of bacteria recovered from the intestine. 
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Peptidoglycan derived from gram positive bacteria has also been shown to 
activate the innate immune response, in a process dependent on Cx 
expression. Stimulating endothelial cells with S. epidermidis has been shown to 
induce Cx43 hemichannel opening, which in turn stimulates TLR2 and IL-6 
gene transcription; IL-6 and TLR2 expression is abolished by treatment with 
hemichannel blockers300,301. In a subsequent study, IL-6 mRNA production was 
also observed 6 hours post stimulation with S. aureus in HaCaT keratinocytes 
which had been transfected with WT Cx26301. Interestingly, in this study, 
expression of IL-6 mRNA was significantly greater in HaCaT cells which had 
been transfected with keratosis-ichthyosis-deafness (KID) syndrome mutations, 
but was significantly reduced by blocking hemichannel activity301. Many KID 
patients are prone to infection with gram positive bacteria301. Although KID 
mutations and Cx26 NSHL mutations both prevent the formation of functional 
GJs, KID mutations may be associated with increased S. aureus infection, 
whereas Cx26 NSHL mutations have been linked to reduced infection by 
gastrointestinal bacteria. A simple explanation for this could be that different 
types of bacteria use different methods to set up an infection in the host. 
However, Cx26 NSHL mutations and KID mutations also behave differently. S. 
flexneri triggers Cx26 hemichannel opening to facilitate invasion and 
dissemination141,200. Therefore, rather than trafficking to the cell surface, if a 
NSHL mutation such as p.R143W accumulates in the cytoplasm, it follows that 
infection would be reduced. KID mutants, however, traffic to the cell surface 
where they induce aberrant hemichannel activity51,19. The hemichannels may 
be open for longer durations than WT Cx26 hemichannels, as evidenced by 
their significantly increased release of ATP into the extracellular medium301. Y. 
enterocolitica also induces Cx hemichannel opening favouring bacterial 
uptake202. It is potentially possible that S. aureus internalisation could be 
enhanced by open hemichannels, and if Cx26 hemichannels formed from KID 
mutants were open for longer durations, could suggest why KID patients are 
prone to infection.  
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4.4. Conclusion 
This chapter has demonstrated that a loss of functional Cx26 expression 
significantly reduces the adherence and invasion of EPEC and S. flexneri in 
vitro. The results provide support for the hypothesis that Cx26 NSHL mutations 
may be selected for because they confer a protective advantage to the carrier. 
Cx26 may represent an alternative therapeutic target for the treatment of 
gastrointestinal infection. The discovery that cystic fibrosis transmembrane 
conductance regulator (CFTR) genetic mutations, responsible for cystic fibrosis, 
confer an advantage to carriers exposed to secretory diarrhoea agents such as 
cholera, has already led to the development of several CFTR inhibitors for 
antidiarrheal therapy. The development of Cx26 inhibitors in the future would 
therefore also hopefully improve treatment for enteric bacteria, which are 
becoming increasingly resistant to multiple antibiotics. 
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5.1 Introduction 
ADAM17 acts as a sheddase enzyme cleaving various membrane-bound 
precursor proteins from the surfaces of cells203. This releases the soluble, 
extracellular portions of the proteins into the bloodstream which subsequently 
participate in a wide range of biological processes. ADAM17 was the first ADAM 
protein to be implicated in ectodomain shedding, following its identification as 
the TNFα converting enzyme (TACE), which sheds a biologically active form of 
TNFα203,205,206. ADAM17 also facilitates proinflammatory cytokine signalling by 
shedding receptors including the IL-6R209,224,226,227, and is thus an important 
stimulator of the immune response. ADAM17 sheds ligands of the epidermal 
growth factor (EGF) receptor including amphiregulin230, making it an important 
upstream regulator of the EGFR signalling pathway. This is important for 
maintenance of the epidermal238 and intestinal243 barriers in mice. These 
combined activities of ADAM17 suggest that it may play an important role in 
providing protection during bacterial infection. Loss of function mutations in 
ADAM17 have been linked to a recessively inherited neonatal onset 
inflammatory skin and bowel disease in two siblings239. The syndrome was 
associated with recurrent skin infections with S. aureus, and chronic diarrhoea 
which was worsened by gastrointestinal infection239. This is consistent with a 
role for ADAM17 providing protection during infection. 
ADAM17 has recently been linked to a major regulator of its activity, inactive 
rhomboid protein iRhom2. iRhom2 transports pro-ADAM17 from its site of 
synthesis in the ER, to the Golgi apparatus where it matures256,258,259.  Gain of 
function mutations in RHBDF2, make iRhom2 overactive, and have recently 
been identified as the cause of the skin condition tylosis with oesophageal 
cancer (TOC)248,252. Two studies provide evidence suggesting that iRhom2 
plays a role in the regulation of the ADAM17 dependent immune 
response256,258. In the first study, TNFα secretion was significantly reduced in 
macrophages from iRhom2-/- mice compared to WT mice256, whilst in the 
second study, iRhom2-/- mice were more susceptible to infection with L. 
monocytogenes than WT mice258. These results are consistent with impaired 
trafficking of ADAM17 to the cell surface, which in turn compromises the 
induction of immune responses required to clear bacterial infection. 
 d 
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In a paper being prepared for publication, experiments performed by Matthew 
Brooke (Centre for Cutaneous Research) using two immortalised keratinocyte 
cell lines deriving from biopsies taken from TOC patients, have shown that TOC 
keratinocytes have increased ADAM17 activity compared to control 
keratinocytes. Immunofluorescence demonstrated increased ADAM17 
expression at the plasma membrane, whilst western blotting revealed increased 
mature ADAM17 protein expression and cleaved pro-domain in TOC 
keratinocytes. Secretion of cytokines including TNFα, IL-6 and IL-8, and growth 
factors including amphiregulin and HB-EGF was also increased in TOC 
keratinocytes. These observations provide support for the hypothesis that 
overactive iRhom2 in TOC keratinocytes leads to increased trafficking of 
ADAM17 to the cell surface. Since these results strongly suggest that ADAM17 
activity is increased in TOC keratinocytes, and other studies have demonstrated 
a protective effect for ADAM17 during bacterial infection, it follows that infection 
levels may be reduced in TOC keratinocytes. 
5.1.1 Aims 
• Investigative how infection with the gastrointestinal pathogens EPEC 
(method 2.42) and S. flexneri (method 2.43) was affected by loss of 
functional ADAM17 expression 
• Consider how a loss of functional ADAM17 expression affected S. 
aureus adhesion and invasion (method 2.44) in keratinocyte skin cell 
lines. Since attempts made to immortalise keratinocytes from the 
ADAM17 deficient patient were unsuccessful, this was replicated by 
studying how infection was affected by treating keratinocytes with siRNA 
against ADAM17 (method 2.15) 
• Confirm ADAM17 knock down at the mRNA and protein level by qRT-
PCR (method 2.2.3) and western blotting (method 2.5) 
• Consider how S. aureus infection is affected by increased ADAM17 
activity; infection will be compared in control and TOC keratinocytes 
• Assuming that ADAM17 is shown to protect against bacterial infection, its 
method of action will be explored in subsequent experiments: 
o Investigate whether the secretion of proinflammatory cytokines is 
affected by changes in ADAM17 expression in S. aureus infected 
keratinocytes by ELISA (method 2.8) 
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o Investigate whether ADAM17 affects α5β1 integrin mediated S. 
aureus invasion 
o Investigate whether the secretion of the antimicrobial peptides, 
human beta defensins 2 and 3, is affected by changes in ADAM17 
activity 
o Carry out gene expression profiling to identify other downstream 
targets of ADAM17 in control and TOC keratinocytes, in the 
prescence and absence of ADAM17 siRNA (method 2.24). 
Following their identification, additional experiments including 
qRT-PCRs, western blotting, immunohistochemistry and ELISAs 
(methods 2.23, 2.5, 2.7 and 2.8) will be performed to further 
investigate whether they are affected by changes in ADAM17 
expression 
5.2 Results 
5.2.1 ADAM17 knock down evaluation 
To study how bacterial infection was affected by a loss of ADAM17 expression, 
cells were treated with siRNA against ADAM17. To confirm that any difference 
in infection was due to differential expression of ADAM17, the knock down 
efficiency was first evaluated at the mRNA level by qRT-PCR (figure 5.1 a). This 
was carried out in HT-29 intestinal epithelial cells, in NEB1 and K17 control 
keratinocyte skin cells, and in TYLK1 and TYLK2 TOC keratinocyte skin cells. 
Quantifying ADAM17 mRNA relative to GAPDH 48 hours post knock down, 
revealed that ADAM17 levels were reduced by approximately 70% in HT-29 
cells, 75% in NEB1 cells, 80% in K17 cells, 13% in TYLK1 cells and 10% in 
TYLK2 cells (figure 5.1 a). 
ADAM17 protein expression was analysed by western blotting in HT-29 cells 
(figure 5.1 b) and keratinocytes (figure 5.1 c) which had been treated with a 
non-targeting pool (NTP) siRNA and ADAM17 siRNA. Two bands at 
approximately 100 kDa and 125 kDa corresponding to ADAM17 expression 
could be detected in cells which had been treated with NTP siRNA (HT-29 cells, 
figure 5.1 b, TOC and control keratinocytes, figure 5.1 c). ADAM17 is 
synthesised as a pro-protein, and cleavage of its pro-domain generates mature 
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ADAM17. Therefore, the band at 125 kDa represents pro-ADAM17, whilst the 
band at 100 kDa represents mature ADAM17 which has undergone pro-domain 
removal.  Analysis of cells treated with ADAM17 siRNA revealed an absence of 
the two bands (HT-29 cells, figure 5.1 b, and TOC and control keratinocytes, 
figure 5.1 c). Together with the qRT-PCR data, these results demonstrate that 
the knock down of ADAM17 was efficient at the mRNA and protein level in all 
five cell types.  
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Figure 5.1: ADAM17 
knock down 
evaluation. ADAM17 
expression in HT-29 
cells, control (NEB1 
and K17) and TOC 
(TYLK1 and TYLK2) 
keratinocytes treated 
with NTP siRNA and 
ADAM17 siRNA. (a) 
Relative expression of 
ADAM17 mRNA 
normalised to GAPDH 
(numbers on plot) 
quantified by qRT-
PCR. Data represent 
mean ∆∆CT value ± 
SEM; n=3. (b) 
ADAM17 protein 
expression in HT-29 
cells. (c) ADAM17 
protein expression in 
TOC (TYLK1 and 
TYLK2) and control 
(NEB1 and K17) 
keratinocytes. Bands 
at approximately 125 
kDa and 100 kDa 
represent full length 
and mature ADAM17 
expression in cells 
treated with NTP 
siRNA, which are 
absent in cells treated 
with siRNA to 
ADAM17, confirming 
knock down at protein 
level (b, c). GAPDH is 
used as a loading 
control (b, c).  
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Figure 5.2: S. flexneri invasion 
efficiency in HT-29 cells and NEB1 
cells treated with NTP siRNA and 
ADAM17 siRNA. Data represent 
mean percentage invasion efficiency 
(numbers on plot) ± the SEM; n=3. 
Comparisons were carried out by 
using unpaired, two-tailed t-tests, 
where significant differences were 
observed between NTP siRNA and 
ADAM17 siRNA treated HT-29 and 
NEB1 cells (* represents p<5x10-2).   
5.2.2 S. flexneri invasion and EPEC adherence in intestinal HT-29 cells and 
control NEB1 keratinocytes treated with ADAM17 siRNA 
To consider how bacterial infection was affected by ADAM17 expression, the 
effect of knocking down ADAM17 on bacterial infection was first investigated. 
EPEC and S. flexneri were initially used as models of infection, as they were the 
two pathogens which had been worked with previously. Treating HT-29 cells 
with ADAM17 siRNA resulted in increased bacterial infection. Treating cells with 
ADAM17 siRNA led to a significant increase in the invasion efficiency of S. 
flexneri from 2.40% to 4.13% (figure 5.2). In a population of HT-29 cells infected 
with EPEC, 45.56% and 65.74% of cells treated with NTP siRNA and ADAM17 
siRNA respectively, were positive for adhering bacteria and this difference was 
statistically significant (figure 5.3).  The number of bacteria that adhered per cell 
was also greater following treatment with ADAM17 siRNA, suggesting that the 
infection level of individual cells was higher following knock down (figure 5.3 h).  
This suggests that ADAM17 provides protection against gastrointestinal 
pathogens in HT-29 cells. 
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Figure 5.3: Wild type EPEC (JPN15) adherence to HT-29 cells treated with NTP 
siRNA and ADAM17 siRNA. Adherence was quantified by pGFP expression by manual 
counting. NTP siRNA (a-c) and ADAM17 siRNA (d-f). (a, d) Nuclei of cells and bacterial 
DNA (DAPI staining in blue). (b, e) EPEC (green). (c, f) Merged images. Image 
magnification 40x. Bars 20µm. (g) Total percentage of cells positive for adhering EPEC 
(numbers on plot). Data represent mean ± the SEM; n=3. Comparison was carried out by 
using an unpaired, two-tailed t-test, where a significant difference was observed between 
HT-29 cells treated with NTP siRNA and ADAM17 siRNA (**** represents p<5x10-5). (h) 
Number of bacteria that adhered per cell. 
g 
h 
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Next, in order to be relevant to the study of skin disease, EPEC and S. flexneri 
infection assays were repeated in NEB1 keratinocytes treated with NTP siRNA 
and ADAM17 siRNA. In further support of the HT-29 cell infection results, 
treating NEB1 cells with ADAM17 siRNA resulted in a significant increase in the 
invasion efficiency of S. flexneri from 2.80% to 7.26% (figure 5.2), a significant 
increase in the total percentage of cells positive for adhering EPEC from 
50.00% to 76.67% (figure 5.4 g), and an increase in the number of EPEC which 
adhered per cell (figure 5.4 h). The consistency of the infection assay results in 
the two different cell lines strongly suggests that ADAM17 expression reduces 
infection by gastrointestinal pathogens.  
  
EPEC 
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Figure 5.4: Wild type EPEC (JPN15) adherence to NEB1 cells treated with NTP 
siRNA and ADAM17 siRNA. Adherence was quantified by pGFP expression by manual 
counting. (a-c) NTP siRNA. (d-f) ADAM17 siRNA. (a, d) Nuclei of cells and bacterial DNA 
(DAPI staining in blue). (b, e) EPEC (green). (c, f) Merged images. Image magnification 
40x. Bars 20µm. (g) Total percentage of cells positive for adhering EPEC (numbers on 
plot). Data represent mean ± the SEM; n=3. Comparison was carried out by using an 
unpaired, two-tailed t-test, where a significant difference was observed between NEB1 
cells treated with NTP siRNA and ADAM17 siRNA (** represents p<5x10-3). (h) Number of 
bacteria that adhered per cell. 
g 
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5.2.3 Effect of ADAM17 expression on S. aureus infection in control and 
TOC keratinocytes 
S. aureus was considered a more relevant model of infection for studying how 
ADAM17 expression affects bacterial infection in the skin.  S. aureus can persist 
as an extracellular pathogen adhering to components of the plasma membrane 
and extracellular matrix (ECM), or as an intracellular pathogen following 
invasion into specific cell types. Therefore, both the adhesion and invasion 
efficiencies were quantified to measure S. aureus infection.  Bacterial 
adherence was measured by subtracting the internalised bacteria from the cell-
associated bacteria. For more accurate quantification of infection, two control 
and two TOC keratinocyte cell lines were analysed. NEB1 and K17 control 
keratinocytes, and TYLK1 and TYLK2 TOC keratinocytes were pooled for 
subsequent statistical analysis.  
As expected, knocking down ADAM17 in control keratinocytes resulted in 
significantly increased S. aureus adhesion and invasion efficiencies from 21.2% 
to 70.0% (figure 5.5 a, b) and from 2.6% to 5.5% (figure 5.5 c, d) respectively. 
This suggested a requirement for ADAM17 in providing protection against S. 
aureus infection. It therefore follows that increased ADAM17 activity may be 
associated with reduced S. aureus infection. To investigate how infection was 
affected by increased ADAM17 activity, infection levels were compared in 
control keratinocytes and TOC keratinocytes. The adhesion efficiencies of 
control and TOC keratinocytes were 21.2% and 13.2% (figure 5.5 b), while the 
invasion efficiencies were 2.6% and 1.3% (figure 5.5 d). As these results 
demonstrate that increased ADAM17 activity associated with TOC keratinocytes 
significantly reduces S. aureus infection, this provides additional support for the 
hypothesis that ADAM17 is required for protection during S. aureus infection. 
This was further demonstrated by knocking down ADAM17 in TOC 
keratinocytes. As expected, treatment with ADAM17 siRNA led to significant 
increases in bacterial adhesion and invasion efficiencies to 44.8% and 3.8% 
respectively (figure 5.5 c, d).  
  
180 
 
 
 
a 
b 
c 
d 
Figure 5.5: Effect of ADAM17 expression on S. aureus infection in keratinocytes. S. 
aureus adhesion (a, b) and invasion (c, d) efficiencies (numbers on plots) in control 
(NEB1 and K17) and TOC (TYLK1 and TYLK2 keratinocytes treated with NTP siRNA and 
ADAM17 siRNA. (a, c) Results from individual cell lines. (b, d) Control and TOC 
keratinocyte results are pooled for statistical analysis. Data represent mean ± the SEM; a, 
c n=3; b, d n=6.  Comparisons were carried out by using unpaired, two-tailed t tests; 
where significant differences were observed between control NTP siRNA and control 
ADAM17 siRNA, control NTP siRNA and TOC NTP siRNA, and TOC NTP siRNA and 
ADAM17 siRNA for adhesion (b) and invasion (d) efficiencies (**, *** and **** represents 
p<5x10-3, p<5x10-4 and p<5x10-5 respectively).  
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In summary, this set of experiments strongly suggests that ADAM17 is required 
to reduce S. aureus skin infection. Loss of functional ADAM17 in control 
keratinocytes leads to increased infection, whilst increased ADAM17 activity in 
TOC cells decreases infection. Furthermore, the protective effect conferred by 
increased ADAM17 in TOC cells is lost following ADAM17 knock down, when a 
significant increase in infection is observed. The next set of experiments carried 
out therefore investigated the mechanisms of ADAM17 mediated protection 
during bacterial infection.  
5.2.4 Effect of ADAM17 expression on the secretion of proinflammatory 
cytokines IL-6 and IL-8 
ADAM17 drives inflammatory responses, first and foremost by cleaving TNFα. 
TNFα expression coordinates early immune responses, by stimulating the 
expression of other proinflammatory cytokines including IL-1β and IL-6, and by 
the induction of adhesion molecules and chemokines which recruit leukocytes 
to the site of infection302. IL-8 is a potent neutrophil recruiter. As discussed in 
section 1.2.13, neutrophils are the first innate immune cells recruited to the site 
of infection, and once recruited, they use multiple mechanisms to kill invading 
pathogens269. 
Although IL-6 and IL-8 are not shed by ADAM17, they are produced in response 
to TNFα signalling, so their production is affected by changes in ADAM17 
expression. As mentioned in section 5.1, experiments performed by Matthew 
Brooke (Centre for Cutaneous Research) confirmed that IL-6 and IL-8 secretion 
was increased in TOC keratinocytes compared to control keratinocytes 
following stimulation with LPS and PMA/ionomycin, but significantly reduced in 
both cell types following treatment with ADAM17 siRNA. The increased 
secretion of proinflammatory cytokines by TOC keratinocytes could therefore 
represent one way by which ADAM17 acts to reduce infection. The next set of 
experiments carried out considers IL-6 and IL-8 production during S. aureus 
infection in control and TOC keratinocytes, in the presence and absence of 
ADAM17 siRNA. It was hypothesised that their production would be linked to 
changes in ADAM17 expression.  
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In uninfected cells, IL-6 and IL-8 secretion was dependent on ADAM17 
expression. Knocking down ADAM17 in control keratinocytes significantly 
reduced IL-6 production from 106.85 pg/ml to 46.03 pg/ml (figure 5.6 a, b), and 
IL-8 secretion from 326.98 pg/ml to 220.69 pg/ml (figure 5.6 c, d). Secretion was 
significantly greater in TOC keratinocytes, which produced 211.03 pg/ml of IL-6 
(figure 5.6 a, b) and 611.44 pg/ml of IL-8 (figure 5.6 c, d). In addition, siRNA 
against ADAM17 in uninfected TOC keratinocytes significantly reduced IL-6 
production to 41.22 pg/ml (figure 5.6 a, b), and IL-8 production to 209.78 pg/ml 
(figure 5.6 c, d). 
S. aureus infection increased IL-6 and IL-8 secretion above the basal level 
produced in uninfected cells. Control keratinocytes displayed significantly 
reduced IL-6 production from 172.33 pg/ml to 91.92 pg/ml (figure 5.6 a, b), and 
IL-8 secretion from 473.89 pg/ml to 310.69 pg/ml (figure 5.6 c, d) after treatment 
with siRNA against ADAM17. Increased ADAM17 activity in TOC keratinocytes 
correlated with significantly increased cytokine production; they produced 
211.03 pg/ml of IL-6 (figure 5.6 a, b) and 834.35 pg/ml of IL-8 (figure 5.6 c, d) 
respectively. Finally, knocking down ADAM17 in infected TOC keratinocytes 
significantly decreased IL-6 secretion to 116.75 pg/ml (figure 5.6 a, b), and IL-8 
production to 352.70 pg/ml (figure 5.6 c, d). 
In summary, this set of experiments has demonstrated that the production of IL-
6 and IL-8 in uninfected keratinocytes and during S. aureus infection is 
dependent on ADAM17 expression. On the one hand, a loss of functional 
ADAM17 expression in both control and TOC keratinocytes is accompanied by 
a decreased secretion of IL-6 and IL-8. On the other hand, TOC keratinocytes 
with increased ADAM17 activity, display reduced infection, occurring 
concomitantly with increased IL-6 and IL-8 secretion. These results may 
therefore indicate one way that ADAM17 acts to provide protection during skin 
infection with S. aureus.  
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Figure 5.6: Secretion of IL-6 and IL-8 in keratinocytes. IL-6 (a, b) and IL-8 (c, d) 
secretion in control (NEB1 and K17) and TOC (TYLK1 and TYLK2 keratinocytes treated 
with NTP siRNA and ADAM17 siRNA. (a, c) Results from individual cell lines. (b, d) 
Control and TOC keratinocyte results are pooled for statistical analysis. Data represent 
mean ± the SEM; a, c n=3; b, d n=6.  Comparisons were carried out by using unpaired, 
two-tailed t tests. For IL-6 (b) and IL-8 (d), significant differences were observed between 
uninfected and infected, control NTP siRNA and control ADAM17 siRNA, control NTP 
siRNA and TOC NTP siRNA, and TOC NTP siRNA and ADAM17 siRNA  (**** represents 
p<5x10-5).  
 
b 
c 
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 5.2.5 Effect of ADAM17 expression on α5β1 integrin mediated S. aureus 
invasion 
Cellular invasion by S. aureus can be mediated by the interaction of fibronectin-
binding proteins (e.g. FnBPA and FnBPB) expressed on the surface of the 
bacterium with the host cell α5β1 integrin ECM component264. In addition, 
ADAM17 has been shown to bind to α5β1 integrin through its disintegrin or 
cysteine-rich domains218. As α5β1 integrin has been implicated in S. aureus 
infection and shown to interact with ADAM17, this set of experiments 
investigated whether changes in ADAM17 expression influenced α5β1 integrin 
mediated S. aureus invasion. One hypothesis considered was that ADAM17 
may influence the localisation and availability of α5β1 integrin.   
To initially demonstrate a requirement for α5β1 integrin expression during S. 
aureus infection, β1 integrin was knocked down in control NEB1 and K17 
keratinocytes. As knocking down β1 integrin significantly reduces the 
expression of the α5 subunit303,  any differences in infection were assumed to 
result from an impaired interaction with both the α5 and β1 subunits. Knock 
down of β1 integrin was confirmed by western blotting and 
immunofluorescence. The antibody against β1 integrin produced heavy 
background staining, which made it difficult to detect expression by western 
blotting (figure 5.7).  However, a faint band could be detected at 130 kDa in 
NEB1 (figure 5.7 a) and K17 cells (figure 5.7 b) which had been treated with 
NTP siRNA. The same band was absent in cells which had been treated with 
siRNA against β1 integrin. The expression of β1 integrin was detected by 
immunofluorescence at the plasma membrane in K17 (figure 5.8 a-c) and NEB1 
(figure 5.8 g-i) cell monolayers treated with NTP siRNA. This staining was 
absent in K17 (figure 5.8 d-f) and NEB1 (figure 5.8 j-l) cell monolayers treated 
with β1 integrin siRNA. Together, the western blotting and immunofluorescence 
results demonstrate that the knock down of β1 integrin protein was successful.   
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Figure 5.7: Western blotting for β1 integrin protein in keratinocytes treated with 
NTP siRNA and β1 integrin siRNA. (a) NEB1 cells. (b) K17 cells. The band at 130 kDa 
corresponds to β1 integrin expression in cells treated with NTP siRNA. It is absent in 
cells treated with siRNA against β1 integrin, confirming a reduction in β1 integrin protein 
following knock down. GAPDH is used as a loading control. 
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Figure 5.8: Immunofluorescence for β1 integrin expression in keratinocytes treated 
with NTP siRNA and β1 integrin siRNA. K17 (a-c) and NEB1 (g-i) cells treated with NTP 
siRNA and K17 (d-f) and NEB1 cells (j-l) treated with β1 integrin siRNA. Negative control: 
cells which have not been stained with β1 integrin antibody. (a, d, g, j, m) Nuclei of cells 
(DAPI staining in blue). (b, e, h, k) β1 integrin (green). (n) Unstained cells (negative control). 
(c, f, i, l, o) Merged images. Note the plasma membrane expression of β1 integrin in cells 
treated with NTP siRNA (b, c, h, i), which is absent in cells treated with β1 integrin siRNA 
(e, f, k, l). Image magnification 40x. Bars 20µm. 
 
187 
 
Treating control keratinocytes with β1 integrin siRNA significantly reduced S. 
aureus infection (figure 5.9).  The adhesion efficiencies of S. aureus decreased 
from 38.8% to 20.3% in NEB1 keratinocytes, and from 69.2% to 22.5% in K17 
keratinocytes following knock down (figure 5.9 a). Treatment with β1 integrin 
siRNA also reduced the bacterial invasion efficiencies from 4.0% to 2.2% in 
NEB keratinocytes, and from 4.7% to 2.0% in K17 keratinocytes (figure 5.9 b). 
Together, these results confirmed a requirement for α5β1 integrin during S. 
aureus infection in control keratinocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
In preliminary experiments, the effect of ADAM17 expression on β1 integrin 
localisation was also investigated by staining frozen normal, TOC and ADAM17 
deficient human skin sections (figure 5.10). An identical expression pattern of 
β1 integrin restricted to the basal epidermal layers was detected in all three 
specimens (figure 5.10). As changes in ADAM17 expression did not affect the 
localisation of β1 integrin protein, it suggests that the protective effect of 
ADAM17 during S. aureus infection was not mediated through α5β1 integrin.  
 
Figure 5.9: Effect of β1 
integrin expression on S. 
aureus infection in 
keratinocytes. S. aureus 
adhesion (a) and invasion (b) 
efficiencies (numbers on plot) in 
NEB1 and K17 keratinocytes 
treated with NTP siRNA and β1 
integrin siRNA. Data represent 
mean ± the SEM); n=3. 
Comparisons were carried out 
by using unpaired, two-tailed t 
tests, where significant 
differences were observed 
between NEB1 NTP siRNA and 
NEB1 β1 integrin siRNA, and 
K17 NTP siRNA and K17 β1 
integrin siRNA for adhesion and 
invasion efficiencies (*, ** and 
*** represents p<5x10-2, p<5x10-
3
 and p<5x10-4 respectively).  
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5.2.6 Effect of ADAM17 expression on hBD-2 and hBD-3 expression 
In humans, the defensin family of peptides, which consists of α- and β-
defensins, plays an important role in innate immunity. Defensins are expressed 
within neutrophil granules and many different tissue types including the skin304. 
Defensins exhibit antimicrobial activity towards bacteria. They may act to inhibit 
bacterial growth, or lyse bacterial membranes to directly kill them. Defensins are 
also chemotactic and recruit immune cells to the site of infection304. 
Candida albicans is a polymorphic yeast which colonises epithelial surfaces 
within the body as a commensal organism305. However, C. albicans also causes 
Figure 5.10: Effect of ADAM17 expression on β1 integrin expression in skin. β1 
integrin expression in frozen normal (a-c), ADAM17 LOF (d-f) and TOC (g-i) skin 
sections. Negative control: normal skin section which has not been stained with β1 
integrin antibody (j-l). (a, d, e, i) Nuclei of cells (DAPI staining in blue). (b, e, g) β1 integrin 
(green). (k) Unstained cells. (c, f, i, l) Merged images. Note that the expression of β1 
integrin is identical in normal (a-c), ADAM17 LOF (d-f) and TOC (g-i) skin, and is 
restricted to the epidermal basal layer.  Image magnification 20x. Bars 20µm. 
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invasive disease including candida oesophagitis, which is associated with 
upregulation of human β-defensins (hBDs) 2 and 3305. Recently, C. albicans has 
been shown to induce hBD-2 expression through IL-1β signalling, whilst hBD-3 
was induced in response to signalling through the EGFR305. ADAM17 is an 
upstream regulator of EGFR signalling, and as expected, treatment with 
ADAM17 specific siRNA significantly reduced hBD-3 expression305. Although 
treatment with siRNA against ADAM17 did not affect hBD-2 expression in this 
study305, hBD-2 expression is induced by proinflammatory cytokines, including 
IL-1β, whose expression can be driven by TNFα.  It therefore follows that hBD-2 
expression could be affected by changes in ADAM17 expression. This set of 
experiments investigated the effects of ADAM17 activity on hBD-2 and hBD-3 
expression. Expression was analysed in the presence and absence of ADAM17 
siRNA to consider how it was affected by a loss of functional ADAM17 activity. 
To investigate whether their expression was affected by increased ADAM17 
activity, expression levels were compared in control (K17) and TOC (TYLK1) 
keratinocytes.  
5.2.6.1 Semi quantitative RT-PCR for hBD-2 and hBD-3 mRNA expression  
Initially, semi quantitative RT-PCRs for hBD-2 and hBD-3 were performed in 
uninfected and S. aureus infected control (K17) and TOC (TYLK1) 
keratinocytes. As a positive control, RT-PCRs for GAPDH were also performed. 
If the mRNA expression of hBD-2 and hBD-3 was affected by changes in 
ADAM17 expression, it would follow that hBD-2 and hBD-3 cDNA amplification 
would occur at a lower cycle in TOC keratinocytes than control keratinocytes. At 
cycle 27, GAPDH was expressed in all of the samples, but neither hBD-2, nor 
hBD-3 were expressed (figure 5.11 a). At cycle 28, hBD-3 was detected in all 
samples (figure 5.11 b). As the bands were of similar intensities, it suggested 
that changes in ADAM17 expression did not affect hBD-3 expression in control 
and TOC keratinocytes (figure 5.11 b). However, at cycle 28 for hBD-2 
expression, two brighter bands of greater intensity could be detected in both 
uninfected and S. aureus infected TOC keratinocytes (figure 5.11 b).  As a 
preliminary result, this suggested that increased ADAM17 expression in TOC 
keratinocytes was associated with upregulation of hBD-2 mRNA expression. 
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5.2.6.2 qRT-PCR and western blotting for hBD-2 and hBD-3 expression 
QRT-PCRs were performed to quantify any ADAM17-dependent effect on hBD-
2 (figure 5.12 a, b) and hBD-3 (figure 5.12 c, d) mRNA expression. The 
expression of mRNA was compared in control keratinocytes treated with NTP 
siRNA and ADAM17 siRNA (red bars), in control keratinocytes and TOC 
keratinocytes treated with NTP siRNA (green bars), and in TOC keratinocytes 
treated with NTP siRNA and ADAM17 siRNA (blue bars).  These comparisons 
were carried out in uninfected (hBD-2 figure 5.12 a, hBD-3, figure 5.12 c) and S. 
aureus infected (hBD-2 figure 5.12 b, hBD-3 figure 5.12 d) keratinocytes. As 
each comparison performed revealed that there were no significant differences 
in hBD-2 or hBD-3 mRNA expression, this suggested that neither hBD-2, nor 
hBD-3 mRNA expression were affected by changes in ADAM17 expression. 
This finding was later supported by gene expression array data carried out in 
1) Uninfected control (K17) 
2) S. aureus infected control (K17) 
3) Uninfected TOC (TYLK1) 
4) S. aureus infected TOC (TYLK1) 
       GAPDH               hBD-2                               hBD-3 
1        2         3         4         1          2        3        4         1        2        3         4  
         GAPDH                      hBD-2                               hBD-3 
1        2         3        4         1         2        3        4           1        2        3         4  
Figure 5.11: Semi-quantitative RT-PCR for the effect of ADAM17 on hBD-2 and hBD-3 
mRNA expression. GAPDH, hBD-2 and hBD-3 expression in uninfected and S. aureus 
infected control (K17) and TOC (TYLK1) keratinocytes at cycles 27 (a) and 28 (b). Although 
GAPDH expression is detected, neither hBD-2 nor hBD-3 is expressed at cycle 27 (a). At 
cycle 28 (b), no difference in hBD-3 expression was observed. Note the bands of brighter 
intensity (3 and 4) for hBD-2 expression, suggesting increased hBD-2 expression in TOC 
keratinocytes at cycle 28.  
 a 
b 
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section 5.2.7, which confirmed that hBD-2 and hBD-3 were not differentially 
expressed, in either uninfected or infected control, or TOC keratinocytes, 
treated with ADAM17 siRNA compared to NTP siRNA.  
b 
c 
d 
Figure 5.12: qRT-PCR for the effect of ADAM17 on hBD-2 and hBD-3 mRNA 
expression. Relative expression of hBD-2 (a, b) and hBD-3 (c, d) mRNA normalised to 
GAPDH (numbers on plot) in control (K17) and TOC (TYLK1) keratinocytes treated with 
NTP siRNA and ADAM17 siRNA. (a, c) Uninfected cells. (b, d) Infected cells. Data 
represent mean ∆∆CT value ± SEM; n=3. Comparisons were carried out by using 
unpaired, two-tailed t tests where no significant differences were observed between 
control NTP siRNA and control ADAM17 siRNA (red bars), control NTP siRNA and TOC 
NTP siRNA (blue bars), and TOC NTP siRNA and TOC ADAM17 siRNA (green bars), for 
hBD-2 or hBD-3 expression, in uninfected or infected cells.  
 a 
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Western blotting also provided further evidence that changes in ADAM17 
expression do not affect hBD-2 or hBD-3 protein expression (figure 5.13).  
Bands of identical intensities of 7 kDa corresponding to hBD-2, and 5 kDa 
corresponding to hBD-3, were detected in uninfected, and S. aureus infected 
control, and TOC keratinocytes, treated with NTP siRNA, and siRNA against 
ADAM17. The bands corresponding to hBD-3 are of weaker intensity than the 
bands corresponding to hBD-2, which could suggest that control and TOC 
keratinocytes express more hBD-2 than hBD-3 protein (figure 5.13).  Taken 
together, the results depicted in figures 5.12 and 5.13 strongly suggest that the 
expression of hBD-2 and hBD-3 is not affected at the mRNA or protein level by 
changes in ADAM17 expression. 
It is important to remember, however, that the results in figures 5.12 and 5.13 
show mRNA and protein results from cell lines which grow in monolayers. In the 
skin, along with keratinocytes, neutrophils, macrophages, monocytes, mast 
cells and sebocytes also produce hBD-2 and hBD-3306,307. Consequently, 
analysis of monolayers which contain one cell type may not give an accurate 
representation of hBD-2 and hBD-3 expression in tissue. Therefore, their 
expression was also analysed by immunofluorescence in control, ADAM17 
deficient and TOC frozen skin sections.  Although the antibody against hBD-3 
did not detect any staining in the skin sections, identical expression of hBD-2 
restricted to the epidermal layer was detected in all three specimens (figure 
5.14).  In summary, the expression of hBD-2 and hBD-3 does not appear to be 
affected by ADAM17 expression. Therefore, it probably does not represent a 
mechanism by which ADAM17 provides protection during S. aureus infection.  
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Figure 5.13: Western blotting for the effect of ADAM17 on hBD-2 and hBD-3 
expression.  hBD-2 and hBD-3 protein expression in uninfected, and S. aureus infected 
control (K17), and TOC (TYLK1) keratinocytes, treated with NTP siRNA, and ADAM17 
siRNA. Bands of identical intensity at 7 kDa corresponding to hBD-2, and at 5 kDa 
corresponding to hBD-3, are expressed by all of the samples, suggesting that ADAM17 
expression does not affect hBD-2 or hBD-3 protein expression. GAPDH is used as a 
loading control.  
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5.2.7 Illumina™ gene expression profiling analysis 
The results in this chapter have suggested that one mechanism used by 
ADAM17 to provide protection during infection is the induction of 
proinflammatory cytokine secretion. A gene expression array was then 
performed as an attempt to identify other downstream targets of ADAM17. 
Since microarray experiments can measure the transcriptional activity of 
thousands of genes in a sample simultaneously, it makes it possible to identifty 
numerous genes whose expression may be affected by changes in ADAM17 
expression in a single experiment. While most molecular biology techniques 
Figure 5.14: Effect of ADAM17 expression on hBD-2 expression in skin. hBD-2 
expression in frozen normal (a-c), ADAM17 LOF (d-f) and TOC (g-i) skin sections. 
Negative control: normal skin section which has not been stained with hBD-2 antibody (j-
l). (a, d, e, i) Nuclei of cells (DAPI staining in blue). (b, e, g) hBD-2 (green). (k) Unstained 
cells. (c, f, i, l) Merged images. Note that the expression of hBD-2 is identical in normal (a-
c), ADAM17 LOF (d-f) and TOC (g-i) skin, and is restricted to the epidermal basal layer.  
Image magnification 20x. Bars 20µm. 
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only permit the strudy of a small number of genes in the sample, carrying out 
the microarray should make it possible to identify novel targets of ADAM17.  
Gene expression profiling was carried out on RNA extracted from uninfected 
and S. aureus infected control (K17) and TOC (TYLK1) keratinocytes, which 
had been treated with NTP siRNA and ADAM17 specific siRNA. To ensure that 
the identification of genes expressed within a sample was accurate, the 
detection p value was analysed. This value shows whether or not the 
fluorescent intensity of a given probe was significantly higher than the 
background, which was defined by negative control probes.  The data set was 
filtered to include only genes which had a detection p value of less than 1x10-2. 
A detection p value equal to 1x10-2 means that there is a 1% false positive 
detection rate. The fold changes and diff scores of gene expression between 
the control and comparison groups were analysed to identify differentially 
expressed genes for four comparisons: 
1. Uninfected K17 NTP siRNA vs K17 ADAM17 siRNA 
2. Uninfected TYLK1 NTP siRNA vs TYLK1 ADAM17 siRNA 
3. S. aureus infected K17 NTP siRNA vs K17 ADAM17 siRNA 
4. S. aureus infected TYLK1 NTP siRNA vs TYLK1 ADAM17 siRNA 
5.2.7.1 Fold change analysis and IL-24 expression  
Lists detailing the 30 most up and downregulated genes for each comparison 
were compiled, which can be viewed in the appendix. Genes that were 
differentially expressed in at least two comparisons were of particular interest, 
since the differential expression was more likely to result from changes in 
ADAM17 expression than by chance. Most results of genes that were 
differentially expressed in two comparisons were obtained from comparisons 
performed on the same cell type. As gene expression may be affected by 
knocking down ADAM17 in one cell type but not the other, this suggests that 
differences in gene expression exist between the two cell lines. ADAM17 was 
downregulated in the four comparisons, which provided a positive control 
confirming that the microarray had worked. A significant find from this analysis 
was that IL-24 was the most consistently downregulated gene across all of the 
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four comparisons. This strongly suggested that IL-24 gene expression was 
affected by changes in ADAM17 expression in both cell lines. IL-24 has recently 
been shown to be protective during bacterial infection in mice. For example, in 
mouse models of Mycobacterium tuberculosis (TB)308 and Salmonella309, IL-24 
stimulates IL-12 and interferon (IFN) γ production by neutrophils, which 
activates cytotoxic CD8+ T cells and leads to the killing of infected cells. In 
summary, gene expression profiling has identified IL-24 as a potential 
downstream target of ADAM17. Since IL-24 has been shown to be protective 
during bacterial infection, it follows that production of IL-24 may represent a 
protective mechanism of ADAM17.  
5.2.7.2 Diff score selection and Genego pathway analysis 
RNA hybridised to Illumina™ Sentrix Human HT12v4 Expression BeadChips is 
fluorescently labelled. The fluorescent intensity of each probe corresponds to 
the level of gene expression within the RNA sample. The diff score is a 
measurement based on the fluorescent intensity difference between the control 
group and the comparison group. It is a transformation of the detection p value, 
and positive and negative diff scores represent genes which are up and 
downregulated in the comparison group compared to the control group. 
According to the manufacturers’, a p value of 1x10-4 transforms into a diff score 
of ±65, and represents the most up and downregulated genes in the 
comparison group compared to the control group. Detection p values of 1x10-3 
and 1x10-2 transform into diff scores of ±33 and ±22, and represent less 
differentially expressed genes between the control and comparison groups.   
Lists of differentially expressed genes generated for each of the four 
comparisons were imported into the pathway analysis MetaCore program from 
Genego. The program contains information drawn from the literature on 
signalling pathways, biological processes and diseases that specific proteins 
are involved in. Diagrams of signalling pathways illustrate interactions of 
specific proteins within the pathway. Based on the gene lists imported into the 
program, signalling pathways containing the greatest number of differentially 
expressed genes for each comparison were identified.  
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The pathway analysis software required lists of a minimum of 200 differentially 
expressed genes in the comparisons. This helped identify all of the signalling 
pathways that may have been affected by changes in ADAM17 expression. 
Initially genes with diff scores ±65 were considered to generate lists of 
differentially expressed genes. If this filtering process did not select enough 
genes, the filtering conditions were broadened to include genes with diff scores 
of ±33 or ±22.  Table 5.1 details the selection criteria used for each comparison, 
the number of genes that were selected for further analysis, and the number of 
genes that were up and downregulated for each comparison.  
Table 5.1 Selection criteria used to identify differentially expressed genes 
Comparison Selection criteria Number of 
genes 
selected 
Number of genes 
upregulated and 
downregulated 
 
Uninfected K17 NTP 
siRNA vs uninfected K17 
ADAM17 siRNA 
Diff score ±22 322 Upregulated: 181 
Downregulated: 141 
Uninfected TYLK1 NTP 
siRNA vs uninfected 
TYLK1 ADAM17 siRNA 
Diff score ± 33 241 Upregulated: 85 
Downregulated: 156 
S. aureus infected K17 
NTP siRNA vs S. aureus 
infected K17 ADAM17 
siRNA 
Diff score ±22 437 Upregulated: 265 
Downregulated:172 
S. aureus infected TYLK1 
NTP siRNA vs S. aureus 
infected TYLK1 ADAM17 
siRNA 
Diff score ±22 318 Upregulated:131 
Downregulated:187 
 
No comparisons have been carried out between K17 and TYLK1 cells. 
Selecting genes with diff scores ±65 would have included approximately 3,000 
genes in the comparison. Even when this list was further processed to only 
include those genes which also had detection p values of less than 1x10-5, more 
than 1,200 genes were still selected. The massive difference in gene 
expression probably occurs by chance since K17 and TYLK1 keratinocytes are 
two different cell lines. Thus, any pathways containing differentially expressed 
genes identified by the software, would probably result from chance, rather than 
from differences in ADAM17 expression.  
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5.2.7.3 IL-17 signalling pathway 
Colony stimulating factors (CSF) 2 and 3, chemokine (C-X-C motif) ligand  
(CXCL) 5, and matrix metalloprotease (MMP) 9 are components of the IL-17 
signalling pathway that were differentially expressed between control and 
comparison groups (figure 5.15). Recently this pathway has been implicated 
during defence against S. aureus infection262. The IL-17 family is composed of 
six members (IL-17 A-F)310. IL-17-A and F are produced by several cell types 
within the skin including natural killer (NK) cells, T helper (Th) 17 cells and γδ T 
cells. Th17 cells also produce IL-22, and are induced by cytokines including IL-6 
and IL-23 produced by dendritic cells, IL-1β produced by macrophages, and IL-
21 produced by activated T cells. Consequently, these cytokines are also 
important components in the IL-17 signalling pathway. IL-17 and IL-22 signalling 
leads to the production of antimicrobial factors including hBD-2 and hBD-3, 
chemotactic factors including IL-8, CXCL1, CXCL2 and CXCL5, and the 
granulopoiesis factors CSF2 and CSF3. CXCL5 (ENA-78) (GeneCard 
database: GC04M074851) is produced concomitantly with IL-8, and is 
responsible for neutrophil recruitment to the site of infection. The gene 
expression array showed that CXCL5 was downregulated in uninfected and S. 
aureus infected K17 cells, treated with ADAM17 siRNA compared to NTP 
siRNA (figure 5.15). Additionally, fold change analysis revealed that CXCL5 was 
within the 30 most downregulated genes in both comparisons (appendix). CSF2 
(GM-CSF) (GeneCard database: GC05P131409) and CSF3 (G-CSF) 
(GeneCard database: GC17P038171) control the production, differentiation and 
function of macrophages and granulocytes. CSF2 and CSF3 downregulation 
was also observed in uninfected K17 cells treated with ADAM17 siRNA 
compared to NTP siRNA.  
MMP9 exhibited reduced expression in uninfected K17 cells treated with 
ADAM17 siRNA compared to NTP siRNA. MMP9 expression was also reduced 
in both uninfected, and S. aureus infected, TYLK1 cells treated with ADAM17 
siRNA compared to NTP siRNA. MMP9 is induced by stimuli including EGF and 
TNFα311, and therefore could be a downstream target of ADAM17. Consistently, 
ADAM17 has been shown to induce MMP9 expression in lung epithelial cells312.  
According to GeneGo, MMP9 is a downstream target of the EGFR signalling 
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pathway, suggesting that it may be involved in maintenance of the epidermal 
barrier. MMP9 also cleaves IL-8 to a more potent form313, illustrating a role for 
MMP9 in the immune response. Finally, MMP9 induction by proinflammatory 
cytokines during Mycobacterium tuberculosis infection in mice, suggests that it 
may play a protective role during bacterial infection314.  
With the exception of a downregulation of IL-1β following siRNA against 
ADAM17 in uninfected K17 and TYLK1 cells, the expression of cytokine mRNA 
involved in Th17 cell induction, namely IL-6 and IL-23, was not affected by 
changes in ADAM17 expression. Additionally, IL-17-A, IL-17-F and IL-22 mRNA 
was not affected by knocking down ADAM17. This could suggest that ADAM17 
expression may affect existing IL-17 signalling cascades, rather than affecting 
new Th17 cell generation. 
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Figure 5.15: IL-17 signalling pathway. Th17 cells are important producers of members 
of the IL-17 family of cytokines including IL-17-A and IL-17-F, and additionally produce IL-
22. The yellow rectangle highlights the induction of Th17 cells by cytokines including IL-6 
and IL-23 produced by dendritic cells, IL-1β produced by macrophages, and IL-21 
produced by activated T cells. The black rectangles highlight particular components of 
interest of the IL-17 pathway that may be linked to changes in ADAM17 expression. IL-17 
signalling increases the mRNA levels of MMP9, granulopoiesis factors G-CSF (CSF3) and 
GM-CSF (CSF2), and chemotactic factors ENA-78 (CXCL5), IL-8 and GCP2 (CXCL6). 
Four comparisons were carried out: 1) uninfected K17 NTP siRNA vs ADAM17 siRNA; 2) 
uninfected TYLK1 NTP siRNA vs ADAM17 siRNA; 3) infected K17 NTP siRNA vs 
ADAM17 siRNA; 4) infected TYLK1 NTP siRNA vs ADAM17 siRNA. Within the black 
rectangles, blue bars dictate which comparison(s) the differentially expressed gene(s) 
was/were downregulated in.  
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5.2.7.4 Differentially expressed genes summary 
Based on the results from the fold change, and diff score selection and pathway 
analysis, five genes were selected for follow up work. These were CSF2, CSF3, 
CXCL5, IL-24 and MMP9. Based on their diff score, table 5.2 summarises which 
of the comparisons the genes were differentially expressed in. The fold changes 
of these genes along with ADAM17 are shown in figure 5.16. 
Table 5.2: Differential expression of genes based on diff score 
 Uninfected K17 
NTP siRNA vs 
ADAM17 siRNA 
Uninfected 
TYLK1 NTP 
siRNA vs 
ADAM17 siRNA 
Infected K17 
NTP siRNA vs 
ADAM17 siRNA 
Infected TYLk1 
NTP siRNA vs 
ADAM17 siRNA 
CSF2 Yes No No No 
CSF3 Yes No No No 
CXCL5 Yes No Yes No 
IL-24 Yes Yes Yes Yes 
MMP9 No Yes Yes Yes 
 
 
.  
 
 
 
 
 
 
5.2.8 Validation of gene expression array hits by qRT-PCR 
The expression of CSF2, CSF3, CXCL5, IL-24 and MMP9 was validated at the 
mRNA level by qRT-PCR in uninfected, and S. aureus infected, K17 and TYLK1 
cells for each of the four comparisons (figure 5.17). Both uninfected and S. 
Figure 5.16: Fold change of gene expression array hits. Fold change of ADAM17, 
CSF2, CSF3, CXCL5, IL-24 and MMP9 in K17 and TYLK1 keratinocytes treated with 
ADAM17 siRNA. Fold change expressed as the ratio of the log e of the mean signal 
strength (n=3) for cells treated with NTP siRNA and ADAM17 siRNA.  
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aureus infected K17 and TYLK1 keratinocytes treated with siRNA against 
ADAM17, displayed reductions in the mRNA level of each of the five genes. The 
level of reduction ranged from approximately 30-80% depending on the gene 
and the comparison (figure 5.17). By qRT-PCR, IL-24 and MMP9 were the two 
most consistently downregulated genes across the four comparisons (figure 
5.17). These results provide support for the gene expression array data, and 
suggest that ADAM17 may induce the transcription of IL-24 and certain 
components of the IL-17 signalling pathway, thus making them potential 
downstream targets of ADAM17. 
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Figure 5.17: 
Gene 
expression 
array hits 
validation by 
qRT-PCR. 
Relative 
expression of 
CSF2 (a), 
CSF3 (b), 
CXCL5 (c), IL-
24 (d) and 
MMP9 (e) 
mRNA 
normalised to 
GAPDH 
(numbers on 
plot) in 
uninfected, 
and infected, 
control (K17), 
and TOC 
(TYLK1) 
keratinocytes, 
treated with 
NTP siRNA, 
and ADAM17 
siRNA. Data 
represent 
mean ∆∆CT 
value ± SEM; 
n=3.  
Uninfected 
K17 NTP 
siRNA vs 
ADAM17 
siRNA (yellow 
bars), 
uninfected 
TYLK1 NTP 
siRNA vs 
ADAM17 
siRNA (blue 
bars), infected 
K17 NTP 
siRNA vs 
ADAM17 
siRNA (red 
bars), infected 
TYLK1 NTP 
siRNA vs 
ADAM17 
siRNA (green 
bars).  
a 
b 
c 
d 
e 
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5.2.9 MMP9 protein expression by immunofluorescence 
MMP9 degrades the ECM components collagen IV and V (GeneCard database: 
GC20P044637) and is involved in ECM remodelling. ECM remodelling occurs 
during physiological processes including cell proliferation, cell adhesion, cell 
migration and wound healing, and during some disease processes including 
metastasis (GeneGo). It is known that MMP9 is induced by EGFR signalling, 
and in mice, ADAM17 mediated regulation of EGFR signallling is required for 
epidermal barrier maintenance238. One hypothesis considered for the protective 
role of ADAM17 was that ADAM17 induces MMP9 expression. This in turn 
could participate in ECM remodelling, and contribute to cell proliferation and 
migration, which may be important for the structure and function of the 
epidermal barrier. 
MMP9 is secreted as an inactive proprotein of 92 kDa. Following cleavage by 
the extracellular proteinase plasmin311, an active protein of 84 kDa is generated. 
MMP9 expression was analysed in normal, ADAM17 deficient and TOC frozen 
skin sections by immunofluorescence (figure 5.18). Although results from the 
expression array and qRT-PCR suggested that MMP9 mRNA expression was 
affected by changes in ADAM17 expression, immunofluorescence revealed 
identical MMP9 expression in the three specimens. MMP9 was expressed 
throughout the epidermis, and particularly by epidermal appendages including 
sweat glands and hair follicles (figure 5.18). The antibody used for 
immunofluorescence recognised full length MMP9, and could explain why no 
differences in MMP9 were detected between the three samples. If ADAM17 
expression does not lead to existing MMP9 protein degradation, and if MMP9 
transcription occurs more quickly than translation, then the total amount of 
MMP9 protein expression could potentially be the same between all samples. 
. 
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5.2.10 MMP9, CXCL5, IL-24 and IL-17-A secretion by ELISA 
Since MMP9 is activated extracellularly, secretion was investigated in both S. 
aureus infected, and PMA/ ionomycin stimulated, control and TOC 
keratinocytes, in the presence and absence of ADAM17 siRNA. Ionomycin is an 
ionophore, which increases the intracellular concentration of Ca2+, whilst PMA is 
a direct activator of Protein kinase C (PKC). When used together to stimulate 
cells, PKC activation is synergistically enhanced315, which in turn increases 
cytokine secretion. MMP9 secretion was significantly reduced in unstimulated 
control (K17) keratinocytes from 89.75 pg/ml to 29.70 pg/ml, and in S. aureus 
infected K17 keratinocytes from 151.07 pg/ml to 65.85 pg/ml (figure 5.19 a) 
Figure 5.18: Effect of ADAM17 expression on MMP9 expression in skin.  MMP9 
expression in frozen normal (a-c), ADAM17 LOF (d-f) and TOC (g-i) skin sections. Negative 
control: normal skin section which has not been stained with the MMP9 antibody (j-l). (a, d, 
e, i) Nuclei of cells (DAPI staining in blue). (b, e, g) MMP9 (green). (k) Unstained cells. (c, f, 
i, l) Merged images. Note that the expression of MMP9 is identical in normal (a-c), ADAM17 
LOF (d-f) and TOC (g-i) skin, and is expressed throughout the epidermis, and in particular 
by epidermal appendages including sweat glands and hair follicles. Image magnification 
20x. Bars 20µm.  
d 
g 
j 
b 
e 
c 
f 
h i 
k l 
a 
DAPI (normal) 
DAPI (ADAM17 LOF) 
DAPI (TOC) 
DAPI (control) 
MMP9 (normal) 
MMP9 (ADAM17 LOF) 
MMP9 (TOC) 
-ve (control) 
Merge (normal) 
Merge (TOC) 
Merge (ADAM17 LOF) 
Merge (control) 
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following treatment with ADAM17 siRNA. Increased ADAM17 activity correlated 
with significantly increased MMP9 secretion. MMP9 production was 346.15 
pg/ml by uninfected TOC (TYLK1) keratinocytes, and 526.19 pg/ml by S. aureus 
infected TYLK1 cells (figure 5.19 a). Finally, MMP9 secretion was significantly 
reduced to 235.75 pg/ml and 271.54 pg/ml  in unstimulated, and S. aureus 
infected TYLK1 cells when ADAM17 was knocked down (figure 5.19 a), 
reinforcing that MMP9 secretion is affected by changes in ADAM17 expression. 
Interestingly, K17 and TYLK1 keratinocytes appeared to be unresponsive to 
stimulation with PMA/ionomycin since they did not produce any MMP9 following 
stimulation (figure 5.19 a). 
Although the gene expression array did not identify IL-17-A mRNA as being 
affected by changes in ADAM17 expression, it is an important component of the 
IL-17 signaling pathway, so when ELISAs were performed on array follow up 
hits CXCL5 and IL-24, IL-17-A was also included for analysis. A maximum 
production of 26 pg/ml of CXCL5 (figure 5.19 b) and 9 pg/ml of IL-17A (figure 
5.20 a) by keratinocytes was detected following infection with S. aureus, or 
stimulation with PMA/ionomycin. As these values were very low, it suggested 
that under normal circumstances, keratinocytes do not secrete IL-17A (figure 
5.20 a) or CXCL5 (figure 5.19 b).  
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Measurements ranging from approximately 20-110 pg/ml of IL-24 were 
observed in S. aureus infected and PMA/ionomycin stimulated keratinocytes 
(figure 5.20 c). S. aureus infected K17 and TYLK1 keratinocytes, treated with 
either NTP siRNA or ADAM17 siRNA, produced nearly identical amounts of IL-
24 (figure 5.20 c). Following stimulation with PMA/ionmycin, TYLK1 
keratinocytes produced more IL-24 than K17 keratinocytes. However, no 
significant differences were observed in IL-24 production in K17 cells treated 
with NTP siRNA and ADAM17 siRNA, or between TYLK1 keratinocytes treated 
with NTP siRNA and ADAM17 siRNA (figure 5.20). Thus, the method of 
a 
b 
c 
Figure 5.19: MMP9 and CXCL5 secretion in keratinocytes and PBMCs. MMP9 (a) and 
CXCL5 (b) secretion in keratinocytes treated with NTP siRNA and ADAM17 siRNA, and 
CXCL5 secretion in PBMCs (c). Results from unstimulated, S. aureus infected/LPS (1 
ng/ml) stimulated, and PMA (100 ng/ml)/ ionomycin (I) (500 ng/ml) stimulated cells. Data 
represent mean ± the SEM; a, b n=3; c n=2. Comparisons were carried out by using 
unpaired, two-tailed t tests. For MMP9, (a) significant differences were observed between 
unstimulated and infected K17 NTP siRNA and ADAM17 siRNA, K17 NTP siRNA and 
TYLK1 NTP siRNA, and TYLK1 NTP siRNA and ADAM17 siRNA. For CXCL5 (c) 
significant differences were observed between LPS and PMA/I stimulated control and 
TOC PBMCs (**, *** and **** represents p<5x10-3, p<5x10-4 and p<5x10-5).   
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stimulation used may influence the amount of IL-24 produced by K17 and 
TYLK1 keratinocytes, but any effect is likely to occur independently of ADAM17.  
Western blotting was also performed to determine whether there was any 
difference in CXCL5, IL-24 and MMP9 protein expression in K17 and TYLK1 
cells treated, with NTP siRNA and ADAM17 siRNA. However, all available 
antibodies produced heavy background staining, which made it impossible to 
detect bands of 12 kDa, 24 kDa, or 92 kDa corresponding to CXCL5, IL-24, or 
immature MMP9 respectively. Thus, in this study it was not possible to conclude 
whether CXCL5, lL-24 or MMP9 protein levels were affected by differential 
expression of ADAM17.  
Next, the production of CXCL5, IL-17-A and IL-24 was measured in PBMCs 
isolated from control and TOC subjects (figures 5.19 c, 5.20 b and 5.20 d). 
PBMCs comprise immune cells including T and B lymphocytes, NK cells, 
monocytes and dendritic cells. PBMCs are likely to produce greater amounts of 
CXCL5 and IL-17-A than keratinocytes, which secrete little or none. IL-24 
secetion is probably also greater in PBMCs than keratinocytes. Therefore, as it 
should be possible to measure increased volumes of cytokines in PBMCs, this 
should enable the role of ADAM17 in their production to be further investigated. 
Due to limited volumes of the control and TOC patients’ PBMCs, MMP9 
secretion was not investigated. While the results for keratinocyte secretion of 
MMP9 strongly suggest that MMP9 secretion is affected by changes in 
ADAM17 expression (figure 5.19 a), the results obtained for keratinocyte 
secretion of CXCL5, IL-17-A, and IL-24 (figures 5.19 b, 5.20 a and 5.20 c) do 
not give any real indication as to whether they are affected by ADAM17 activity. 
Therefore, because of limited sample availability, this was the rationale behind 
measuring PBMC secretion of CXCL5, IL-17-A and IL-24, and not MMP9. LPS 
stimulation of PBMCs caused a greater increase in CXCL5 (figure 5.19 c) and 
IL-24 (figure 5.20 d) than PMA/ionomycin stimulation. No significant difference 
in IL-24 secretion by control or TOC PBMCs was observed (figure 5.20 d).  This 
suggests that although a loss of functional ADAM17 expression reduces IL-24 
mRNA levels in keratinocytes, increased ADAM17 expression in PBMCs does 
not affect IL-24 secretion. It is possible that PBMCs may have a maximum 
volume of IL-24 that they secrete. If this level had been reached in control 
PBMCs, then increased ADAM17 activity might not allow for greater IL-24 
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production by TOC PBMCs. This could potentially explain why production of IL-
24 was not significantly different in control and TOC PBMCs.  CXCL5 secretion 
however, was significantly increased in TOC PBMCs compared to control 
PBMCs following stimulation with LPS and PMA/ionomycin. In response to LPS 
and PMA/ionomycin stimulation, TOC PBMCs secreted 1049 pg/ml and 333 
pg/ml respectively of CXCL5 (figure 5.19 c). However, control PBMCs only 
produced 194 pg/ml and 235 pg/ml of CXCL5 following stimulation with LPS 
and PMA/ionomycin respectively (figure 5.19 c). Although IL-17-A production 
was not observed in PBMCs following stimulation with LPS, stimulation with 
PMA/ionomycin led to control PBMCs producing 149 pg/ml of IL-17-A, while 
TOC PBMCs released a significantly greater volume of 450 pg/ml of IL-17-A 
(figure 5.20 b). Taken together, these results provide support for changes in 
ADAM17 expression affecting secreted components of the IL-17 signaling 
pathway.  
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5.2.11 Secretion of IL-17 related cytokines in control and ADAM17 
deficient PBMCs 
The experiments described in sections 5.2.7-10 suggest that the IL-17 signalling 
pathway may be a downstream target of ADAM17. To investigate this further, 
Figure 5.20: IL-17-A and IL-24 secretion in keratinocytes and PBMCs.  IL-17-A (a, b) 
and IL-24 (c, d) secretion in keratinocytes treated with NTP siRNA and ADAM17 siRNA 
(a, c), and control and TOC PBMCs (b, d). Results from unstimulated, S. aureus 
infected/LPS (1 ng/ml) stimulated, and PMA (100 ng/ml)/ ionomycin (I) (500 ng/ml) 
stimulated cells. Data represent mean ± the SEM; a, c n=3; b, d n=2.  Comparisons were 
carried out using by unpaired, two-tailed t tests. For IL-17-A (b), no significant differences 
were observed between PMA/I stimulated control and TOC PBMCs (*** represents 
p<5x10-4). For IL-24, no significant differences were observed in keratinocytes (c) or 
PBMCs (d).  
 
a 
b 
c 
d 
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the secretion of the Th17 inducing cytokine IL-23, and the Th17 cytokines IL-17-
A, IL-17-F and IL-22 were measured in PBMCs from the ADAM17 deficient 
patient, his mother and control subjects. As the mutation which truncates the 
ADAM17 protein is recessive239, cytokine production by the mother should be 
similar to control subjects. IL-23 is a member of the IL-12 family of cytokines. IL-
23 is composed of two subunits, p19 and p40. The p19 subunit is only 
expressed by IL-23, but the p40 subunit is also expressed by IL-12316. IL-23 
was detected using an ELISA kit which recognised the common IL-12/IL-23 p40 
subunit. Cytokine production was investigated in PBMCs stimulated with 
PMA/ionomycin, and CD3/CD28, which activates T cells. In T cells, CD3 is 
required for signal transduction following ligand binding to the αβ or γδ receptor, 
whilst CD28 provides co-stimulatory signals required for T cell activation317.  In 
these experiments TNFα secretion was measured as a positive control. 
To further investigate how IL-17 cytokine secretion was affected by changes in 
ADAM17 expression, these experiments were also carried out in the presence 
of three inhibitors: two small molecule inhibitors; GI254023X which blocks 
ADAM10 activity, GW280264X which targets both ADAM17 and ADAM10292, 
and an ADAM17 neutralising antibody293.  ADAM10 and ADAM17 are both 
implicated in the shedding of the IL-6R, CX3CL1 and CXCL16292. Constitutive 
and inducible shedding of these molecules is thought to be mediated by 
ADAM10 and ADAM17 respectively292. Whilst GI254023X potently blocked the 
constitutive release of the IL-6R, CX3CL1 and CXCL16, it had no effect on the 
PMA-induced shedding, which was only blocked by GW280264X292. This was in 
line with GI254023X solely blocking ADAM10 activity, and GW280264X 
targeting both ADAM17 and ADAM10292. The ADAM17 neutralising antibody293, 
which was the third inhibitor used in this study, has been shown to bind to both 
the TACE ectodomain and the isolated catalytic domain293. This led to an 
inhibition of the ADAM17 dependent shedding of TNF-α, HB-EGF, TGF-α and 
amphiregulin293. In this study, the ability of the neutralising antibody to block 
ADAM17 activity was first tested in K17 and TYLK1 keratinocytes by measuring 
amphiregulin secretion (figure 5.21). Treating K17 cells with 100 nM of 
neutralising antibody for 4 hours only reduced amphiregulin secretion by 8%. 
However, ADAM17 activity was significantly reduced in K17 cells treated with 
200 nM of neutralising antibody for 4 hours, and in TYLK1 cells treated with 
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either 100 nM or 200 nM of neutralising antibody, for either 4 or 24 hours. This 
was shown by decreases in amphiregulin secretion which ranged from 
approximately 30%-60 (figure 5.21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.11.1 TNFα secretion 
Although there was variability in TNFα secretion between the mother and two 
control samples following stimulation with PMA/ionomycin or CD3/CD28, all 
produced more TNFα than the ADAM17 deficient patient, as expected (figure 
5.22 a). The efficacy of the three inhibitors was varied. As the two small 
molecule inhibitors GI254023X and GW280264X were dissolved in DMSO, 
measuring TNFα secretion by stimulated keratinocytes in the presence of 
DMSO alone was used as a positive control. However, rather than producing 
similar results to PMA/ionomycin or CD3/CD28 stimulated cells in the absence 
of any inhibitors, TNFα secretion was reduced in the presence of DMSO alone, 
Figure 5.21: Effect of ADAM17 neutralising antibody on amphiregulin secretion in 
keratinocytes. Amphiregulin secretion in K17 (a) and TYLK1 keratinocytes (b), treated 
with 100 nM or 200 nM of ADAM17 neutralising antibody for 4 or 24 hours. Data represent 
mean ± the SEM; n=2.  Comparisons were carried out by using unpaired, two-tailed t 
tests. For K17 keratinocytes (a), significant differences were observed between 0 nM and 
200 nM for 4 hours; 0 nM and 100 nM for 24 hours; and 0 nM and 200 nM for 24 hours. 
For TYLK1 keratinocytes (b), significant differences were observed between 0 nM and 
100 nM for 4 hours; 0 nM and 200 nM for 4 hours; 0 nM and 100 nM for 24 hours; and 0 
nM and 200 nM for 24 hours (*, **,*** and **** represents p<5x10-2, p<5x10-3, p<5x10-4 
and p<5x10-5 respectively).  
 
a 
b 
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suggesting that DMSO interfered with pathways affecting TNFα production. 
Consistently, DMSO has been shown to reduce TNFα production following 
stimulation in rat Kuppfer cells318, and in mouse macrophages319,320, and has 
also reduced TNFα induced MMP9 production by human keratinocytes321. 
GW280264X blocks ADAM10 and ADAM17 activity292, and consequently 
abolished TNFα secretion following stimulation with either PMA/ionomycin or 
CD3/CD28. While TNFα secretion was reduced in cells treated with GI254023X 
compared to untreated PMA/ionomycin or CD3/CD28 stimulated cells, it was 
not significantly different to TNFα production in PMA/ionomycin or CD3/CD28 
stimulated cells treated with DMSO. This suggests that the GI254023X inhibitor 
had little effect on TNFα secretion, which is consistent with it blocking ADAM10 
rather than ADAM17292. The ADAM17 neutralising antibody activity is best 
displayed in CD3/CD28 stimulated PBMCs. The IgG1 antibody is used as an 
isotype control, meaning that it is the same immunoglobulin class, and raised in 
the same species as the ADAM17 neutralising antibody. It therefore confirms 
that results obtained by the neutralising antibody are specific, and result from an 
inhibition of ADAM17. TNFα production by CD3/CD28 stimulated PBMCs 
treated with the neutralising antibody is reduced compared to untreated 
CD3/CD28 stimulated PBMCs. Out of all of the three inhibitors, the neutralising 
antibody has least effect on TNFα secretion. While treating PMA/ionomycin 
stimulated PBMCs with the neutralising antibody leads to a small decrease in 
TNFα secretion, little difference is observed in TNFα production between 
PMA/ionomycin stimulated PBMCs treated with the neutralising antibody and 
the isotype control antibody. This experiment has therefore not worked well 
enough to draw any conclusions from and should be repeated in the future.   
5.2.11.2 IL-17 related cytokine production 
IL-17 related cytokine production by PBMCs was not affected by changes in 
ADAM17 expression. Although IL-17-F and IL-22 production were not detected 
in PBMCs, no differences in IL-17-A or IL-12/IL-23 production in control and 
ADAM17 deficient PBMCs were observed (figure 5.22 b, c). Likewise, their 
secretion was not affected by any of the three inhibitors.  The data from ELISAs 
performed on control and ADAM17 deficient PBMCs (figure 5.22 b, c) contrast 
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the results from ELISAs performed on control and TOC PMBCs (figures 5.19 c, 
5.20 b). Rather than suggesting that IL-17 related cytokine production is 
affected by changes in ADAM17 expression, these results suggest that their 
secretion may occur independently of ADAM17 activity. This will be discussed 
in detail in section 5.3. 
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Figure 5.22: TNFα, IL-17-A and IL-12/IL-23 secretion in PBMCs. TNFα (a), IL-17-A (b) 
and IL-12/IL-23 (c) secretion in PBMCs from the ADAM17 LOF patient, mother and two 
controls, following stimulation with PMA/Ionomycin and activation of CD3/CD28. 
Experiments were carried out in the presence of three inhibitors: two small molecule 
inhibitors, GW280264X (GW) which blocks ADAM10 and ADAM17, and GI254023X (GI) 
which blocks ADAM10, and a neutralising antibody against ADAM17 (αA17). DMSO and 
IgG1 provided controls for the small molecule inhibitors and αADAM17 respectively. Data 
represent mean ± the SEM; n=2. 
 
a 
b 
c 
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5.3 Discussion 
The results in this chapter strongly suggest that ADAM17 acts to provide 
protection during cutaneous S. aureus skin infection. ADAM17 deficiency is 
associated with recurrent Staphylococcal skin infections in a patient suffering 
from an inflammatory skin and bowel syndrome239. While attempts made to 
immortalise keratinocytes from this patient were unsuccessful, using siRNA 
against ADAM17 provided a way to study the loss of functional ADAM17 
expression in vitro. Knocking down ADAM17 in control keratinocytes resulted in 
significantly increased S. aureus adhesion and invasion. Furthermore, ADAM17 
is probably also important during gastrointestinal bacterial infection, as treating 
intestinal cells with siRNA against ADAM17 increased EPEC adhesion and S. 
flexneri invasion. 
Immortalised keratinocytes from TOC patients carrying the gain of function 
mutation p.ILe136Thr in iRhom2252, were utilised to study the effects of 
increased ADAM17 activity. iRhom2 has recently been shown to transport pro-
ADAM17 from the ER to its site of maturation in the Golgi apparatus, and is thus 
a key regulator of ADAM17 activity. Macrophages from iRhom2-/- mice exhibit 
abrogated secretion of TNFα secretion compared to WT mice256,258. 
Experiments performed by Matthew Brooke (Centre for Cutaneous Research) 
demonstrate increased ADAM17 activity in TOC keratinocytes compared to 
control keratinocytes, with elevated expression of mature ADAM17 at the 
plasma membrane, together with enhanced release of ADAM17 dependent 
cytokines and growth factors. Increased ADAM17 activity in TOC keratinocytes 
correlates with reductions in S. aureus infection, which is consistent with a 
hypothesis that ADAM17 is required for protection during bacterial infection.  
Furthermore, treating TOC keratinocytes with siRNA against ADAM17 abolishes 
this protective effect, leading to increases in infection.  
One limitation of these experiments is they were only performed in one cell type 
grown in a monolayer. In addition to epithelial cells, S. aureus invades other 
non-professional phagocytes including endothelial cells and fibroblasts, as well 
as professional phagocytes including neutrophils, monocytes and 
macrophages260,265 . For future experiments it would be interesting to consider 
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how infection is affected by changes in ADAM17 expression in other cell types. 
It remains to be investigated how S. aureus is affected by changes in ADAM17 
expression in vivo. Although ADAM17-/- mice exhibit perinatal lethality203, mice 
in which ADAM17 is conditionally knocked out in keratinocytes (ADAM17-/-) 
have been descibed238.  If a transgenic mouse model of TOC, carrying either  
the p.Ile186Thr or p.Pro189Leu mutations were available, it would be interesting 
to investigate if there were differences in S. aureus infection in such mice 
compared to WT mice and ADAM17-/- mice.  
 Perhaps the most obvious way ADAM17 acts to provide protection during 
bacterial infection is by stimulating an immune response. ADAM17 drives 
inflammatory responses, first and foremost by its cleavage of TNFα. TNFα 
expression coordinates early immune responses, by stimulating expression of 
other proinflammatory cytokines including IL-1β and IL-6, and by induction of 
chemokines and adhesion molecules, which recruit leukocytes to the site of 
infection302. Proinflammatory cytokine expression also enhances bacterial killing 
by upregulating phagocytosis, antimicrobial peptide and proteinase production, 
lysosomal production of reactive oxygen species, degranulation, and by 
production of neutrophil extracellular traps322. In this study, the production of IL-
6 and IL-8 in S. aureus infected keratinocytes was shown to be ADAM17 
dependent, with production being significantly greater in TOC keratinocytes 
compared to control keratinocytes, and being significantly reduced following 
treatment with ADAM17 siRNA. This supports observations made by Matthew 
Brooke (Centre for Cutaenous Research), where proinflammatory cytokine 
secretion was linked to changes in ADAM17 expression. Furthermore, as the 
elevated secretion of IL-6 and IL-8 is indicative of an enhanced inflammatory 
response in TOC keratinocytes, and correlates with a reduction in S. aureus 
infection, this could represent one way ADAM17 acts to provide protection 
during bacterial infection. It would be interesting to investigate whether other 
components of the immune response are affected by changes in ADAM17 
expression. The effect of manipulating ADAM17 expression in a neutrophil or 
macrophage cell line on bacterial killing could be investigated by a number of 
different methods. The level of phagocytosis could be measured by quantifying 
the number of internalised bacteria. Production of proteinases including 
cathepsin D and elastase, which degrade bacterial proteins and components262, 
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could be measured by immunofluorescence and western blotting. 
Immunofluorescence could also be used to investigate lysosomal production of 
reactive oxygen species (ROS). Dyes including aminophenylfluorescein (AFP) 
become fluorescent in the presence of ROS. Neutrophil degranulation could 
also be measured in vitro by quantifying the release of components including 
myeloperoxidase323. For example, 3,3',5,5'-tetramethylbenzidine is a substrate 
of myeloperoxidase, and an interaction between the two molecules produces a 
quantifiable colour change323. Finally, recruitment of immune cells to the site of 
infection could be measured in vivo by two photon microscopy. Immune cells 
could be labelled according to cell surface marker expression, for example 
neutrophils by L-selectin, or macrophages or dendritic cells with CD11 
(http://www.biolegend.com/cell_markers).  
Upstream regulation of EGFR signalling by ADAM17, which sheds EGFR 
ligands including amphiregulin, TGF-α and HB-EGF230, may represent a second 
way in which ADAM17 acts to provide protection during bacterial infection. In 
mice EGFR signalling maintains the epidermal barrier238. It drives the terminal 
differentiation of keratinocytes as they migrate through the suprabasal layers to 
the epidermal surface. It also activates transglutaminases (TGM) 1 and 3, which 
initiate cornified envelope formation, by cross linking structural components of 
keratinocytes. Mice with a conditional knock out of ADAM17 in keratinocytes 
(ADAM17-/-) have a defective epidermal barrier resulting from defects in 
keratinocyte terminal differentiation, and reduced TGM activity, preventing 
cornified envelope formation238. Blaydon et al252 suggested that EGFR 
signalling is increased in TOC keratinocytes compared to control keratinocytes. 
In the absence of EGF within the culture media, control keratinocytes exhibited 
very low levels of proliferation and migration, whilst TOC keratinocytes 
displayed increased proliferative and migratory potentials. Consistent with 
increased EGFR signalling, experiments performed by Matthew Brooke (centre 
for Cutaenous Research) demonstrated that the shedding of ADAM17 
dependent growth factors is increased in TOC keratinocytes. As keratinocyte 
wound healing relies on cell proliferation and migration, increased EGFR 
signalling in TOC keratinocytes could lead to keratinocyte hyperproliferation324.  
Additionally, a recent study in rats has shown that ADAM17 mRNA is 
upregulated in the epidermis and dermis following wound healing325, providing 
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further evidence that ADAM17 is likely to be important for epidermal barrier 
maintenance. MMP9 is a downstream target of the EGFR pathway, whose 
expression was shown to be affected at the mRNA and secretion level by 
changes in ADAM17 expression in this study. As already mentioned, MMP9 
plays a role in ECM remodelling which occurs during processes including cell 
growth, cell migration and wound healing. Matthew Brooke (Centre for 
Cutaenous Research) has also shown by immunofluorescence that frozen TOC 
keratinocytes have increased TGM1 activity, which is likely to enhance the 
cornification process. In combination with keratinocyte hyperproliferation and 
MMP9 induced ECM remodelling, increased TGM1 activity could potentially 
contribute to a thicker epidermal barrier and provide improved protection 
against invading pathogens in TOC cells.   
In the ADAM17-/- mice, the defective epidermal barrier was shown by increased 
transepithelial water loss (TWL)252. If a mouse model of TOC was available, it 
would be interesting to measure how TWL compared to WT mice, to determine 
whether there is any effect of increased ADAM17 activity on epidermal barrier 
function in vivo. It would also be interesting to visualise how TGM1 and terminal 
differentiation marker expression is affected by increased ADAM17 activity in 
vivo. Finally, measuring the epidermal thickness of organotypic cultures grown 
with control and TOC keratinocytes, in the presence and absence of ADAM17 
siRNA, could provide an insight into whether epidermal thickness is affected by 
changes in ADAM17 expression.  
The gene expression array and qRT-PCR data first suggested that the IL-17 
signalling pathway may be affected by ADAM17 expression, with siRNA against 
ADAM17 leading to decreases in CSF2, CSF3, CXCL5 and MMP9 mRNA 
levels. Keratinocyte secretion of MMP9 appeared to correlate with ADAM17 
expression, but other ELISA data suggested that IL-17-A secretion might occur 
independently of ADAM17 activity. Keratinocytes do not produce IL-17-A, but 
there was no significant difference in secretion between PBMCs from control 
subjects and PBMCs from the ADAM17 deficient patient. Furthermore, reducing 
ADAM17 activity with various inhibitors had no effect on the secretion of IL-17-A 
or the Th17 inducing cytokines IL-12/IL-23, providing further evidence that it 
may be ADAM17 independent.  TOC PBMCs produced significantly more IL-17-
A and CXCL5 than control PBMCs. This could potentially result from increased 
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endogenous expression of IL-17-A and CXCL5, in turn leading to increases in 
their secretion following stimulation with PMA/ionomycin. 
Two different skin conditions with a similar clinical presentation have been 
shown to have different levels of ADAM17 expression and IL-17 signalling 
compared to healthy controls. At one end of the spectrum, ADAM17 expression 
is increased in psoriasis, with psoriatic lesions displaying elevated levels of 
ADAM17 mRNA compared to control skin225. Psoriasis is a chronic skin disease 
which presents with inflamed lesions covered by scaly patches of dead skin. It 
is associated with dysregulated inflammation, keratinocyte hyperproliferation 
and abnormal keratinocyte terminal differentiation225. The IL-17 signalling 
pathway is also overactive in psoriatic patients, and increased levels of IL-17-A, 
IL-17-C and IL-17-F have been observed in psoriatic lesions326. Interestingly, at 
the other end of the spectrum, the impaired function of ADAM17 causes an 
inflammatory skin disease which has a similar clinical presentation to 
psoriasis239. A recent study in mice has shown that conditionally knocking out 
ADAM17 in the epidermis of mice leads to atopic dermatitis1. Interestingly, 
these mice also have increased IL-17 signalling1. They display chronic 
inflammation with Th17 and IL-17-A producing γδ T cell infiltration, along with 
increased production of IL-17-A, IL-22, and two Th17 cell inducing cytokines, IL-
1β and IL-231. So these are two different skin conditions with a similar 
phenotype, with very different levels of ADAM17 expression, yet they share the 
common feature of elevated IL-17 signalling. This could suggest that rather than 
being directly regulated by ADAM17, the IL-17 signalling pathway may be 
activated by an unknown upstream factor. If IL-17 pathway activation is the 
common factor responsible for the chronic inflammation in both diseases, they 
may share a common event which induces IL-17 signalling cascades.  ADAM17 
may therefore not have a role in the IL-17 signalling pathway, and could explain 
why PBMCs from the ADAM17 deficient patient produce similar levels of IL-17-
A to PBMCs from control subjects. An aim of future work, therefore should be to 
identify any common upstream factor that may lead to IL-17 signalling in both 
diseases. 
When ADAM17 was knocked out in the epidermis of mice, the mRNA 
expression of IL-17 related cytokines increased1, yet  in this study, 
keratinocytes 48 hours post knock down displayed no differences in the mRNA 
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expression of Th17 inducing cytokines, IL-17-A/F or IL-22, but reduced 
expression of the downstream components CXCL5, MMP9, CSF2 and CSF3 . 
These differences in results could arise for a variety of reasons. Firstly, 
differential gene expression may exist between humans and mice. Secondly, 
mRNA expression is measured in cell monolayers in human keratinocytes, 
whilst its expression is measured within the epidermis in mice. Other cell types 
exist within the epidermis, and therefore the mRNA level measured includes 
cells other than just keratinocytes. Thirdly, gene expression may vary 
depending on the time point it is measured at. In human keratinocytes, IL-17 
related cytokine mRNA could potentially have been degraded independently of 
ADAM17, and new mRNA synthesis may not have occurred at the time point 
when expression is measured.  The study in mice does not indicate the time 
point at which gene expression is measured. If mRNA expression were 
measured at a later time point, this could potentially give more time for an 
increase in its synthesis. 
While these results may suggest that the IL-17 signalling pathway is not a direct 
downstream target of ADAM17, and therefore may not be a way ADAM17 acts 
to provide protection during infection, more work is needed to determine this. 
Firstly, as different cell types including NK, Th17 and γδT cells producing IL-17 
reside in the epidermis, it would be interesting to measure mRNA expression of 
different cytokines in the IL-17 pathway in different epidermal cell types. 
Carrying out mRNA expression analysis at different time points post knock 
down, for example, 24, 48, 72 and 96 hours should provide an insight into the 
time point, if any, at which they are affected by ADAM17 activity. Any effect 
could be transient, or occur over a long time period, and could be affected 
directly by ADAM17 activity, or indirectly in response to other signalling 
pathways or cellular processes. The cytokines analysed could include Th17 
inducing cytokines (IL-1β, IL-6, IL-21 and IL-23), IL-17-A, IL-17-F, IL-22 and 
more downstream components (MMP9, CSF2, CSF3 and CXCL5).  Frozen skin 
sections are available from biopsies taken from the ADAM17 deficient patient, 
control and TOC subjects. If RNA were extracted from these samples, qRT-
PCRs could be performed to determine if there is any difference in the total 
RNA level of IL-17 related cytokines in the epidermis of the three specimens. 
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Total RNA could also be measured in PBMCs from control, ADAM17 deficient 
and TOC PBMCs. 
It would also be interesting to measure whether ADAM17 affects IL-17 related 
cytokine protein expression. This could be determined by extracting protein 
from the frozen samples, making lysates and analysing by western blotting. 
Protein expression level and localisation could also be determined by 
immunofluorescence if suitable antibodies were available. Most of the 
components of the IL-17 signalling pathway described in the previous 
paragraphs are secreted, so their expression should also be measured by 
ELISA. PBMCs are significantly greater producers of IL-17 related cytokines 
than keratinocytes. Measuring IL-17-A and IL-12/23 should therefore be 
repeated and include the ADAM17 deficient patient, control and TOC PBMCs in 
the same experiment. The experiment should be extended to include the other 
IL-17 related cytokines described in the previous paragraphs. This should be 
carried out in unstimulated, S. aureus infected and LPS and PMA/ionomycin 
stimulated PBMCs at different time points. Using ADAM17 inhibitors would 
further clarify whether secretion is affected by ADAM17 activity. Additionally, 
whether increased production of IL-17-A and CXCL5 by TOC PBMCs compared 
to control PBMCs is due to differences in ADAM17 activity should be clarified by 
treating TOC PBMCs with ADAM17 inhibitors. If there were no differences in 
their secretion in TOC PBMCs following inhibitor treatment, this would support 
the idea that TOC PBMCs express a higher endogenous level of IL-17A and 
CXCL5 than control PBMCs.  
Finally, flow cytometry and immunofluorescence could be used to investigate 
whether differences exist between the numbers of IL-17 producing cells, namely 
Th17, γδ T cells and NK cells in ADAM17 deficient, control and TOC subjects. 
The number of cells within a population of PBMCs could be analysed by flow 
cytometry by quantifying CD4+/IL-17A+ (Th17), γδ-TCR+327 (γδ) and CD3-
/CD56+328 (NK) cells. Similarly, performing single staining for γδ T cells, and 
double staining for Th17 and NK cells on frozen control, ADAM17 LOF and 
TOC skin specimens, should provide insights as to whether the numbers of IL-
17-A producing cells in the epidermis are affected by different levels of ADAM17 
expression.  
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5.4 Conclusion 
The results in this chapter strongly suggest that ADAM17 provides protection 
during cutaneous bacterial skin infection in vitro. ADAM17 mediated protection 
probably results in part from its roles in the induction of immune responses and 
in the maintenance of the epidermal barrier.  This study suggests that ADAM17 
probably does not influence α5β1 integrin mediated S. aureus invasion, or affect 
the expression of the antimicrobial peptides hBD-2 or hBD-3. Finally, research 
over recent years has demonstrated the importance of the IL-17 signalling 
pathway during S. aureus infection. However, whether ADAM17 targets the IL-
17 signalling pathway as a way to provide protection during bacterial infection 
remains to be investigated.  
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This study began with investigating how gastrointestinal bacterial infection was 
affected by a loss of functional Cx26 expression. Within certain geographic 
locations and ethnic groups, high carrier frequencies of specific recessive 
mutations account for the majority of Cx26 related non-syndromic hearing loss 
(NSHL), for example c.35delG and p.R143W in Europe114,115 and Ghana 
respectively95.  The common occurrence of specific mutations in different 
populations is possibly due to geographic isolation. Given that mutations have 
remained in populations for thousands of years, however, suggests that they 
may provide a heterozygous advantage to carriers. Heterozygote carriers of the 
NSHL mutations c.35delG and p.R143W alleles were previously shown to have 
a thicker epidermis than wild type (WT) Cx26 homozygotes118,120, and cells 
expressing the p.143W mutant were also significantly less susceptible to 
invasion by S. flexneri than cells expressing WT Cx2645. This study investigated 
how infection by the attaching and effacing pathogen EPEC was affected by 
expression of the p.143W mutation. Subsequently, EPEC and S. flexneri 
infection were measured in intestinal cells treated with Cx26 siRNA.  
 
S. flexneri infection was quantified using cellular invasion as has been 
published previously45,141,200, so no method optimisation was needed. In this 
study however, an automated system was developed to quantify EPEC infection 
by bacterial adherence and actin pedestal formation. This made it possible to 
quantify infection within a large population of cells, and without the introduction 
of human error or bias. In addition to solely quantifying the total percentage of 
infected cells within a given population, it was also possible to measure the 
infection level of individual cells. By measuring the adhesion of individual 
bacteria to cells, more subtle effects of differential expression of Cx26 on 
infection could be determined. The methods described in chapter 3 could also 
be applied to quantify infection of different types of bacteria that are 
fluorescently labelled by immunofluorescence. 
 
The in vitro results presented in chapter 4 demonstrate that a loss of functional 
Cx26 expression provides improved protection against gastrointestinal bacterial 
pathogens. EPEC adherence was significantly reduced by expression of a Cx26 
NSHL mutation. Additionally, when endogenous Cx26 expression was reduced 
by siRNA in intestinal cells, S. flexneri invasion and EPEC adherence were 
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significantly decreased. Therefore, although inheriting two Cx26 recessive 
mutations causes deafness in homozygous individuals, such mutations may 
remain in the population if they are beneficial to heterozygous carriers. If 
heterozygotes were less susceptible to gastrointestinal bacterial infection, this 
could potentially explain the high carrier frequencies of specific Cx26 NSHL 
mutations. 
 
Bacterial infection was also hypothesised to be affected by differential 
expression of a second host protein, ADAM17. Since ADAM17 sheds the 
proinflammatory cytokine TNFα203,205,206 and ligands of the EGFR230, it plays 
important roles in the stimulation of immune responses and in the maintenance 
of the epidermal barrier. These combined activities suggest that ADAM17 may 
provide protection during bacterial infection. Consistently, a loss of functional 
ADAM17 expression led to recurrent Staphyloccocal skin infections in a patient 
with an inflammatory skin and bowel syndrome239. The results described in 
chapter 5 show that a loss of functional ADAM17 expression was associated 
with significantly increased S. aureus infection in vitro.  Furthermore, iRhom2 is 
required for ADAM17 maturation256,258,259, and TOC keratinocytes which have 
increased iRhom2 and ADAM17 activity, also have significantly reduced S. 
aureus infection. These findings strongly suggest that ADAM17 is required for 
protection during skin infection. Experiments performed in this study and by 
Matthew Brooke (Centre for Cutaneous Research), have shown that shedding 
of proinflammatory cytokines and growth factors positively correlates with 
ADAM17 activity. Increased ADAM17 in TOC keratinocytes may contribute to 
reduced infection by production of an enhanced inflammatory response and 
stronger epidermal barrier. In this chapter, gene expression profiling was also 
carried out. This identified the IL-17 signalling pathway, which is important 
during S. aureus infection, as a potential downstream target of ADAM17. 
However, whether or not ADAM17 activates the IL-17 signalling pathway during 
bacterial infection remains to be investigated. 
 
Cx26 and ADAM17 may represent two potential alternative therapeutic targets 
for treatment of bacterial infections.  Some patients with bacterial infections may 
benefit from a reduction in functional Cx26 expression, whilst others may benefit 
from a stimulation of ADAM17 activity. This may be beneficial for bacterial 
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infections which may be difficult to treat with current therapies, in part because 
of the development of resistance to multiple antibiotics. The next major step for 
considering the role of either protein during bacterial infection probably involves 
investigating the infection of a broader range of bacterial pathogens in an in vivo 
setting.  
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Figure A2: Control probe 
hybridisation. Hybridisation of 
control probes to all samples is 
high, suggesting that there are no 
problems with the quality of the 
RNA samples.  
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Figure A1: RNA integrity. (a) Control. (b) Example of RNA sample (all samples 
produced identical traces). The total RNA sample was composed of over 80% ribosomal 
RNA compared to approximately 1-3% mRNA, so ribosomoal RNA was used to check 
the quality of the RNA. Peaks 1, 2 and 3 correspond to small RNA (non-coding RNA 
that is not translated into protein), 18S RNA (small eukaryotic cytoplasmic ribosomal 
unit), and 28S RNA (large eukaryotic nuclear ribosomal unit) respectively. An RNA 
integrity number (RIN) is assigned to the sample, and level 10 represents RNA which 
was completely intact.  
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Figure A3: Number of genes detected on the gene expression array. The detection p 
values were set at either 0.01 (blue) or 0.05 (red). Values below the defined p value indicate 
that gene expression was detected. The detection score represents the confidence that a 
given gene is expressed above the background defined by negative probes.  
Figure A4: Scatter plot example of gene expression between two comparisons. Black 
dots represent genes whose expression is similar between samples, whilst blue dots 
represent genes whose expression is different between samples. Scatter plots provide an 
overall indication of sample similarity, but do not identify differences in expression of 
individual genes.  
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Figure A5: Dendrogram representing differential expression of probes within the 
eight samples.   
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Table A1: 30 most up and downregulated genes: uninfected K17 NTP siRNA vs ADAM17 
siRNA 
Upregulated 
genes 
Gene Fold change 
 
 
1 LOC100129882 1.125804643 
2 CD55 1.068279631 
3 KPRP 1.060597687 
4 DAAM1 1.054105982 
5 CYP1B1 1.052573291 
6 PATE3 1.048643718 
7 CXCL10 1.046565766 
8 LCE2D 1.046314122 
9 PHACTR3 1.044932632 
10 NMI 1.044587262 
11 ZC3HAV1 1.043712682 
12 LCE2C 1.042311106 
13 WEE1 1.041983602 
14 LPAR2 1.041348699 
15 MAFB 1.041103853 
16 CCNE2 1.040913707 
17 MX1 1.040365147 
18 LCE2B 1.038941527 
19 AMMECR1 1.03817924 
20 SNORD13 1.037917934 
21 CTDSP2 1.036914947 
22 NIPAL1 1.036906988 
23 ASPRV1 1.03689018 
24 AMMECR1 1.036183063 
25 KLF4 1.036046925 
26 IGFBP3 1.035447888 
27 NDNL2 1.034913972 
28 OAS1 1.034802892 
29 OAS2 1.034385387 
30 RRM2 1.034357772 
 
  
Downregulated 
genes 
 
Gene Fold change 
-30 LOC387934 -1.038959385 
-29 HOXA10 -1.039004043 
-28 LOC441481 -1.039610035 
-27 CXCL2 -1.040010231 
-26 HSPA1A -1.040144974 
-25 VIM -1.040150281 
-24 RBM47 -1.040438106 
-23 LOC653438 -1.041793542 
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-22 LOC728285 -1.04217377 
-21 0 -1.042259216 
-20 SH2D5 -1.042278081 
-19 NFKB2 -1.042563088 
-18 LOC650909 -1.042697801 
-17 IL1B -1.042781987 
-16 DKK1 -1.043285303 
-15 ANKRD57 -1.044684813 
-14 ROD1 -1.047893949 
-13 CHMP2B -1.049134702 
-12 SECISBP2 -1.04932171 
-11 NFKB2 -1.051486535 
-10 CXCL5 -1.052734744 
-9 ANKRD46 -1.055014357 
-8 CA12 -1.055379347 
-7 CXCL5 -1.056899052 
-6 IL24 -1.056993167 
-5 TAGLN3 -1.058322808 
-4 TAGLN3 -1.066804581 
-3 OSTM1 -1.075961244 
-2 HSPE1 -1.082000813 
-1 ADAM17 -1.103718766 
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Table A2: 30 most up and downregulated genes: uninfected TYLK1 NTP siRNA vs 
ADAM17 siRNA 
Upregulated  
genes 
 
Gene Fold change 
 
1 CCNE2 1.077591364 
2 LOC650909 1.073346644 
3 SCNN1G 1.06892277 
4 LOC389286 1.059661307 
5 CHRNA5 1.057462568 
6 NINJ1 1.054561969 
7 ID2 1.054159233 
8 ZNF394 1.053429287 
9 TRIM31 1.052151671 
10 TNNI2 1.051546851 
11 KRT15 1.051448176 
12 GCNT3 1.051206828 
13 OXR1 1.050809401 
14 SPRR1A 1.05029158 
15 CYP1B1 1.04941924 
16 LOC643446 1.049040505 
17 LOC148430 1.048528978 
18 LEP 1.048022305 
19 TRIM22 1.047865441 
20 SDCBP2 1.04767403 
21 LOC390530 1.047633341 
22 ST6GALNAC2 1.047594797 
23 RETSAT 1.047239884 
24 PSKH1 1.046935223 
25 LOC202781 1.046398749 
26 KRT4 1.046182595 
27 LOC100133551 1.046015469 
28 LOC283953 1.04582053 
29 ID1 1.045460356 
30 MMP7 1.045395169 
 
  
Downregulated 
genes 
 
Gene Fold change 
-30 VIM -1.047707049 
-29 GMCL1 -1.04907743 
-28 CA12 -1.049134176 
-27 FUT4 -1.049316164 
-26 CDS1 -1.049504629 
-25 NFKB2 -1.049529157 
-24 GMCL1 -1.050117301 
-23 GNB4 -1.050800236 
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-22 DPY19L1 -1.05125417 
-21 KIAA1524 -1.051450845 
-20 ADAMTS1 -1.052006314 
-19 IL1RAP -1.052058277 
-18 TAGLN3 -1.052692632 
-17 DCP2 -1.053126961 
-16 LBR -1.053430827 
-15 PLAU -1.053488821 
-14 VIM -1.054097014 
-13 SECISBP2 -1.055775184 
-12 TSPAN5 -1.056744219 
-11 ANTXR2 -1.058643447 
-10 AGPAT9 -1.06133046 
-9 NLRP3 -1.063569356 
-8 CYP27B1 -1.064562815 
-7 SH2D5 -1.065061685 
-6 CXCL2 -1.066018175 
-5 ANKRD57 -1.066805436 
-4 OSTM1 -1.07041002 
-3 ANKRD46 -1.099538151 
-2 ADAM17 -1.10639641 
-1 IL24 -1.107274036 
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Table A3: 30 most up and downregulated genes: S. aureus infected K17 NTP siRNA vs 
ADAM17 siRNA 
Upregulated 
genes 
 
Gene Fold change 
1 LOC100132761 1.137316133 
2 LOC441763 1.109812343 
3 LOC100134364 1.106725282 
4 LOC100008589 1.101679823 
5 LOC100008589 1.094560072 
6 LOC100132394 1.092860342 
7 LOC389286 1.090583125 
8 LOC100008588 1.08002524 
9 SNORD3D 1.075083213 
10 SNORA12 1.073320417 
11 LOC100132564 1.07323868 
12 SNORD3A 1.073080056 
13 LOC100133565 1.071791974 
14 CXCL10 1.071398081 
15 MYC 1.071055618 
16 LOC100130332 1.070549184 
17 EPR1 1.067160447 
18 IFI6 1.066738708 
19 LOC650909 1.06564464 
20 GFOD2 1.061610251 
21 PRKDC 1.061561892 
22 LOC100129882 1.061187435 
23 SLC25A22 1.061160977 
24 LOC728969 1.059947837 
25 SNORD13 1.056897242 
26 RN7SK 1.05612386 
27 SCAP 1.055206138 
28 MRPS25 1.05514912 
29 ATF5 1.054887828 
30 ARRDC3 1.054184229 
 
  
Downregulated 
genes 
Gene Fold change 
-30 FBLIM1 -1.064143508 
-29 PPDPF -1.064901968 
-28 LOC645979 -1.066535026 
-27 BAT2 -1.066625498 
-26 PKMYT1 -1.067139708 
-25 RPLP1 -1.067699738 
-24 LOC642828 -1.069203204 
-23 CRTC2 -1.070430588 
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-22 CDC42BPB -1.070830601 
-21 JUP -1.071213109 
-20 PKM2 -1.071358059 
-19 PABPC1 -1.074119038 
-18 NPDC1 -1.074155549 
-17 GPR1 -1.075429139 
-16 SERPINE1 -1.07718653 
-15 UBTD1 -1.077204848 
-14 OSTM1 -1.077819078 
-13 YWHAE -1.078345585 
-12 LOC100128485 -1.078953869 
-11 PKM2 -1.079191943 
-10 ANKRD57 -1.079407622 
-9 NFKB2 -1.079755528 
-8 AGRN -1.080157261 
-7 TMEM132A -1.080286359 
-6 LOC644936 -1.085242869 
-5 CXCL5 -1.092714141 
-4 ADAM17 -1.093444959 
-3 LOC100130009 -1.09421618 
-2 SH3BP1 -1.09991806 
-1 IL24 -1.102001538 
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Table A4: 30 most up and downregulated genes: S. aureus infected TYLK1 NTP siRNA vs 
ADAM17 siRNA 
Upregulated 
genes 
 
Gene Fold change  
1 EZH2 1.070358104 
2 KRT4 1.060893423 
3 CCNE2 1.052223195 
4 TSC22D3 1.052029506 
5 DEFB1 1.051162118 
6 RRM2 1.050387712 
7 SAA1 1.047708253 
8 NCCRP1 1.047488427 
9 CYP1B1 1.047448647 
10 SLC1A3 1.047312752 
11 LOC441155 1.047127808 
12 WEE1 1.047072088 
13 TRIM31 1.046495986 
14 MPZL2 1.045718104 
15 CD83 1.045376564 
16 PTPRU 1.044872903 
17 MMP7 1.044700475 
18 SLC15A3 1.044431818 
19 WNT10A 1.043686516 
20 ABHD12 1.043142162 
21 WHAMM 1.042978657 
22 FBXO5 1.042763374 
23 BRP44L 1.042660686 
24 ARID4B 1.042555833 
25 LOC652330 1.042514467 
26 CCNE1 1.042379616 
27 RHOV 1.042230941 
28 CD83 1.0414525 
29 FOXA1 1.041343558 
30 RPL28 1.04129627 
 
  
Downregulated 
genes 
 
Gene Fold change 
-30 LOC100130154 -1.052644147 
-29 EHBP1L1 -1.05341574 
-28 0 -1.053983707 
-27 CXCL2 -1.054129298 
-26 LOC100132425 -1.054236345 
-25 CYP27B1 -1.054284996 
-24 SH2D5 -1.054670561 
-23 C7orf11 -1.054702569 
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-22 CTSC -1.05475049 
-21 DPY19L1 -1.055107191 
-20 FAM73A -1.055275504 
-19 ADAMTS1 -1.055615006 
-18 LAMC2 -1.055833544 
-17 SYAP1 -1.05587409 
-16 IL1RAP -1.057943808 
-15 ANKRD46 -1.058439211 
-14 TNFRSF6B -1.059590787 
-13 TXNL1 -1.059860783 
-12 TNFRSF6B -1.060494823 
-11 FAM116A -1.065151392 
-10 AGPAT9 -1.066113199 
-9 TERC -1.072617247 
-8 VIM -1.072968177 
-7 MMP9 -1.07300177 
-6 VIM -1.076060757 
-5 OSTM1 -1.077422531 
-4 TFPI2 -1.077909652 
-3 IL24 -1.10002384 
-2 ANKRD57 -1.109590277 
-1 ADAM17 -1.121039695 
 
 
 
 
